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Abstract 
The  endothelium  acts  to  maintain  vascular  homeostasis,  including  the  regulation  of 
vascular tone, blood fluidity and coagulation. Endothelial dysfunction, a condition largely 
characterised by reduced NO bioavailability, is an important feature associated with the 
aetiology  of  several  pathophysiological  disorders  including  type  2  diabetes  and 
cardiovascular disease.  
AMPK  is  the  downstream  component  of  a  protein  kinase  cascade  important  in  the 
regulation  of  cellular  and  whole  body  metabolism.  AMPK  has  been  demonstrated  to 
mediate a number of physiological responses in the endothelium, including the stimulation 
of eNOS phosphorylation and NO synthesis; and as such AMPK represents a therapeutic 
target in the dysfunctional endothelium.  
VEGF has been established as the prime angiogenic molecule during development, adult 
physiology and pathology. VEGF stimulates NO production, proposed to be a result of 
phosphorylation  of  Ser-1177  on  eNOS,  a  residue  also  phosphorylated  upon  AMPK 
activation in cultured endothelial cells. The present study, utilising HAEC as a model, 
provides the first demonstration that AMPK is activated by physiological concentrations of 
VEGF; and furthermore, partially mediates VEGF-stimulated phosphorylation of eNOS on 
Ser-1177  and  subsequent  NO  production.  In  addition,  the  present  investigation 
demonstrates that the upstream AMPK kinase CaMKK is responsible for these VEGF-
mediated effects.  
VEGF  is  known  to  increase  intracellular  calcium  levels  in  endothelial  cells  via  the 
generation of DAG and IP3.   DAG increases Ca
2+ influx through a family of non-selective 
cation channels, whereas IP3 promotes the release of Ca
2+ from intracellular stores. High 
potassium-induced depolarisation, which reduces the driving force for Ca
2+ entry through 
non-selective  cation  channels  in  endothelial  cells,  abolished  VEGF-mediated  AMPK 
activation, whereas the IP3 receptor blocker 2-APB was without effect. Exposure of HAEC 
to a DAG mimetic (OAG) also stimulated AMPK, an effect which was sensitive to the 
CaMKK inhibitor STO-609 and high potassium induced depolarization. 
The functional effects of VEGF-stimulated AMPK were also assessed in HAEC. Ablation 
of  AMPK  abrogated  VEGF-stimulated  HAEC  migration  and  proliferation,  two  key 
features  of  the  angiogenic  process.  While  AMPK  was  necessary  for  VEGF-stimulated  
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endothelial cell proliferation direct activation of the kinase was insufficient to induce this 
process. AICAR-stimulated AMPK  activation  has been  demonstrated to  stimulate  fatty 
acid oxidation in endothelial cells. However, exposure of HAEC to VEGF did not alter 
fatty acid oxidation in the present study. 
Together,  the  current  investigation  suggests  that  a  VEGF-Ca
2+-CaMKK-AMPK-eNOS- 
NO  pathway  is  present  in  HAEC,  and  furthermore,  that  AMPK  is  required,  albeit 
insufficient, for the VEGF-stimulated angiogenic response. 
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1  INTRODUCTIONJames A Reihill, 2009    Chapter 1, 24 
1.1 Cellular signalling  
Organisms  exist  in  a  continually  changing  environment  where  they  are  constantly 
bombarded and challenged with stimuli to which they must respond in order to survive. 
Cell signalling is a complex system of communication that enables cells to perceive and 
correctly respond to their microenvironment. In practice a cell detects a signal, such as a 
hormone  or  potentially  damaging  free  radical,  and  activates  a  series  of  enzymes  in  a 
signalling cascade that ultimately determines the appropriate biological outcome.  
Signal transduction networks are formed, in large part, by interacting protein kinases and 
phosphatases, which catalyse protein phosphorylation and dephosphorylation respectively. 
Phosphorylation of proteins or kinases (or their dephosphorylation by phosphatases) can 
provide docking sites for interacting partners or may trigger conformational changes that 
alter the enzymatic activity of a protein and/or its interaction with other proteins or DNA 
(Salazar and Hofer, 2009). These altered enzymatic or interacting properties may transmit 
signals in various ways.  
A simple signalling cascade is  a linear one where  an enzyme regulates the activity of 
another  which  subsequently  activates  another  and  so on.  If  there  is  an  increase in the 
number of activatable enzymes at each step, signal amplification occurs, thus generating a 
robust  response.  Consequently  a  single  activation  event  may  lead  to  the  activation  of 
numerous downstream enzymes. In addition to phosphorylation several post translational 
modifications  are  involved  in  signal  transduction  greatly  enhancing  the  complexity  of 
signalling networks where crosstalk is also a common theme.  
1.1.1  Phosphorylation 
Phosphorylation, (catalysed by protein kinases; discussed in section 1.1.2), is a process 
consisting of the esterification of an amino acid side chain with the terminal γ-phosphate 
group from ATP. A key feature of protein phosphorylation is that it is a readily reversible 
process whereby protein phosphatases catalyse the reverse reaction, hydrolysing the ester 
bond with a resultant release of inorganic phosphate (dephosphorylation). Within a protein, 
phosphorylation can occur on several amino acids. Most kinases act on both serine and 
threonine  (about  98  %  of  the  phosphate  found  on  proteins  is  covalently  linked  to  the 
hydroxyl moiety of these residues), others act on tyrosine, and a number (dual-specificity 
kinases) act on all three (Olsen et al., 2006).  James A Reihill, 2009    Chapter 1, 25 
The addition of a negatively charged phosphate group to an amino acid residue turns a 
non-polar serine, threonine or tyrosine residue into a hydrophilic molecule. This results in 
a major conformational change in the protein which may dramatically alter its function.  
Phosphorylation (or dephosphorylation) is not merely a mechanism to switch the activity 
of a protein on or off, but can have many additional roles including the modulation of its 
intrinsic biological activity, subcellular location, half-life and docking with other proteins 
(Cohen, 2000). Multisite phosphorylation can enable several such effects to operate in the 
same protein and can determine the extent and duration of a response and is the key to 
signal integration allowing different agonists to work synergistically or antagonistically as 
required (Cohen, 2000). It is now known that reversible protein phosphorylation regulates 
almost all aspects of cell life (Manning et al., 2002a; Manning et al., 2002b).  
1.1.2  Protein kinases  
1.1.2.1  An historical perspective 
Protein kinase activity was first observed in 1954 with the discovery of a liver enzyme that 
catalysed  the  phosphorylation  of  casein  (Burnett  and  Kennedy,  1954).  Two  forms  of 
glycogen  phosphorylase  (a  and  b),  the  enzyme  that  catalyses  the  rate  limiting  step  of 
glycogenolysis, had been identified in the late 1930’s. Work by Fischer and Krebs (Fischer 
and  Krebs,  1955;  Krebs  and  Fischer,  1956),  as  well  as  Wosilait  and  Sutherland 
(Sutherland,  Jr.  and  Wosilait,  1955)  demonstrated  that  the  interconversion  of 
phosphorylase  b  to  phosphorylase  a  involved  a  phosphorylation/dephosphorylation 
mechanism. Fischer and Krebs further demonstrated that the b form could be converted to 
the a form in the presence of MgATP and an enzyme they termed phosphorylase kinase 
(Fischer  and  Krebs,  1955;  Krebs  and  Fischer,  1956).  In  the  following  decades  the 
significance of protein kinases in other metabolic pathways and organelles (in addition to 
glycogen metabolism) began to emerge; for review see (Cohen, 2002a). PKA, a kinase 
widely distributed in animal tissues and other organisms (Kuo and Greengard, 1969), was 
shown to activate hormone sensitive lipase (Corbin et al., 1970). This was of particular 
interest  as  the  widespread  distribution  of  PKA  in  animal  tissues  and  other  organisms 
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1.1.2.2  The discovery of AMPK 
With hindsight, the AMPK system was first observed concordantly by two groups more 
than 3 decades ago. Both Beg and co-workers and Carlson and Kim found that soluble 
protein  factors,  in  the presence  of  ATP,  inactivated  two  enzymes involved in liver  fat 
metabolism, HMGR and ACC respectively (Carlson and Kim, 1973; Beg et al., 1973). 
Although  these  factors  were
  correctly  surmised  to  be  protein  kinases,  and  subsequent 
studies revealed the kinases responsible for the action on ACC and HMGR were both 
stimulated by AMP (Yeh et al., 1980; Ferrer et al., 1985), it was not realised that these two 
functions were mediated by the same protein kinase for more than a decade (Carling et al., 
1987). It soon
 became apparent that this was a true multisubstrate protein kinase; and
 thus 
it  was  renamed  AMP-activated  protein  kinase  after  its  allosteric  activator,  AMP,  in 
accordance with the precedent set by PKA (cyclic AMP-dependent protein kinase).  
1.1.2.3  The importance of protein kinases  
It is now known that there are in excess of 500 protein kinase genes in the human genome, 
forming the third most populous gene family (constituting of about 2% of all human genes) 
(Manning et al., 2002b; Caenepeel et al., 2004; Zhu et al., 2000). Furthermore it is thought 
that up to 30 % of all human proteins may be modified by kinase activity (Hubbard and 
Cohen, 1993). Protein kinases regulate the majority of cellular pathways, especially those 
involved in signal transduction (Manning et al., 2002b; Manning et al., 2002a). Defects in 
protein kinase function result in a variety of diseases thus kinases are major targets for 
drug design (Cohen, 2002b). 
1.1.2.4  Mechanisms of substrate specificity 
It  has  been  estimated  that  the  majority  of  human  proteins  might
  be  phosphorylated  at 
multiple sites (giving more than 100 000 potential phosphorylation sites) (Zhang et al., 
2002;  Blom  et  al.,  2004)  Therefore,  to  ensure  signalling  fidelity,  kinases  must  be 
sufficiently specific and act only on a defined subset of cellular targets. This precision of 
specificity is essential for the integrity of signal transduction.  
In general protein kinases exhibit specificities that are often primarily determined by the 
amino acids around the phosphorylation site (Kemp and Pearson, 1991). Early studies on 
PKA  and  phosphorylase  kinase  revealed  that  the  principal  substrate  specificity 
determinants for these kinases were ‘recognition motifs', located in short segments of the 
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1976). The finding that protein kinases phosphorylate short peptide sequences based on 
known  phosphorylation  sites  in  physiological  substrates  led  to  the  consensus  sequence 
model where the kinase recognizes residues directly flanking the site of phosphorylation 
(Pearson and Kemp, 1991). In most cases, the active site of the kinase interacts with four 
amino acids on either side of the phosphorylation site. Sequences that are further away 
from the phosphorylation site can interact with portions of the protein kinase that are just 
outside the active site (Knighton et al., 1991). AMPK substrate specificity based on the 
concensus sequence model is discussed further in section 1.3.1. 
In addition to concensus motifs there are several other control mechanisms, outlined as 
follows, that ensure substrate specificity; reviewed in (Ubersax and Ferrell, Jr., 2007). 1) 
The nature of the active site, such as its depth, charge or hydrophobicity, often enhances its 
binding  preference  for  substrates  with  complementary  characteristics.  2)  Interactions 
between docking motifs on the substrate; often spatially separate from the kinase active 
site and the substrate phosphorylation site, with interaction domains on the kinase (Biondi 
and Nebreda, 2003; Holland and Cooper, 1999), may also act as determinants of substrate 
specificity.  3)  Some  Ser/Thr  kinases  use  binding  partners  containing  docking  domains 
which target the kinase to specific substrates. 4) In addition to direct interactions between 
protein  kinases  and  their  substrates  two  proteins  may  interact  through  intermediate 
adaptors or scaffolds, which recruit both the kinase and the substrate to the same complex 
(Bhattacharyya  et  al.,  2006).  5)  Localization  of  protein  kinases  to  distinct  subcellular 
compartments or structures can promote specificity by limiting the number of substrates to 
which a kinase has access.  
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1.2 AMPK 
1.2.1  A general overview 
The AMPK system is now known to act as an intracellular energy sensor that is conserved 
throughout all eukaryotes (Towler and Hardie, 2007). AMPK is activated in response to an 
increase in the cellular AMP:ATP ratio caused by any metabolic stress that either increases 
ATP  consumption  (eg,  muscle  contraction)  or  compromises  its  production  (e.g., 
deprivation of oxygen or glucose) (Towler  and  Hardie, 2007). The AMPK complex is 
comprised of a catalytic α subunit and regulatory β and γ subunits (Oakhill et al., 2009). 
The β subunit contains a GBD (McBride et al., 2009; Hudson et al., 2003; Polekhina et al., 
2003), whereas the γ subunit is responsible for AMP/ATP sensing (Cheung et al., 2000). 
Activation  of  AMPK  involves  phosphorylation  on  Thr-172  catalysed  by  an  upstream 
kinase. In addition to LKB1 (Hawley et al., 2003), it has been recently demonstrated that in 
a  number  of  tissues  AMPK  may  be  activated  by  an  alternate  Ca
2+-dependent,  AMP 
independent  upstream  kinase,  CaMKK  (Hawley  et  al.,  2005).  Once  activated,  AMPK 
phosphorylates  several  downstream  substrates  resulting  in  the  stimulation  of  ATP-
generating  (catabolic)  pathways  including  glucose  transport,  glycolysis,  and  fatty  acid 
oxidation whilst also inhibiting ATP consuming (anabolic) pathways non-essential to short 
term survival such as fatty acid and cholesterol synthesis (Carling, 2004; Hardie, 2008). In 
addition to the acute effects of AMPK on energy metabolism, activation of AMPK has 
longer term effects, altering both gene (Foretz et al., 1998; Leclerc et al., 1998) and protein 
expression (Winder et al., 2000). Although it may have evolved to respond to metabolic 
stress at the cellular level, AMPK is also regulated by physiological stimuli, independent 
of the energy charge of the cell, including hormones and nutrients. The effect of hormones 
on AMPK, coupled with the role of AMPK in response to muscle contraction, provide 
direct evidence that the kinase plays a part in determining whole body energy metabolism 
(Carling, 2004). 
1.2.2  AMPK subunit structure 
AMPK is a heterotrimeric protein composed of an α subunit, which contains the catalytic 
domain, and non-catalytic regulatory β and γ subunits. The AMPK subunit structure is 
summarised in Figure 1.1. Each AMPK subunit is encoded by two or three distinct genes 
(α1, α2, β1, β2, γ1, γ2, γ3), giving rise to 12 possible heterotrimeric combinations, with 
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the subunits of the AMPK complex have been identified in all eukaryotes for which the 
genome sequences have been completed including vertebrates, invertebrates, plants, fungi 
and protozoa (Hardie  et al., 2003).  Isoforms of AMPK differ in tissue and subcellular 
localisation and may direct different functions (Hardie, 2007).  
1.2.2.1  Alpha subunit 
 The α2 catalytic subunit isoform is the subunit of AMPK predominantly found within 
skeletal and cardiac muscle, whereas, approximately equal distribution of both the α1 and 
α2 isoforms are present in hepatic AMPK. Within pancreatic islet β-cells the α1 isoform 
predominates. In the endothelium both α1 and α2 subunits are expressed (Davis et al., 
2006), with α1 being the dominant isoform (Davis et al., 2006; Zou et al., 2004). The α 
subunit (α1: 550 residues) contains an N-terminal catalytic core (1-312) followed by an 
autoinhibitory  sequence  (Pang  et  al.,  2007)  and  a  C-terminal  sequence  (313-548) 
responsible for autoregulation and binding the βγ subunits (Iseli et al., 2005; Crute et al., 
1998). The α1 and α2 subunit sequence are highly  conserved within the catalytic core 
(α1:1-314/α2: 1-312, 89 % identity) but diverge in their C-terminal sequences (α1:315-
550/α2: 313-552, 60 % identity) (Stapleton et al., 1996). Both α subunits appear to have 
similar substrate specificities (Woods et al., 1996), but the α2 isoform is enriched in the 
nucleus  of  several  cell  types,  including pancreatic  β  cells  (Salt  et  al.,  1998), neurones 
(Turnley et al., 1999) and skeletal muscle (Ai et al., 2002), whereas α1 is predominantly 
cytoplasmic. The α1 isoform has been shown to localise with the apical membrane of 
airway (Hallows et al., 2003) and nasal epithelial cells (Kongsuphol et al., 2009), and the 
plasma membrane in carotid body type 1 cells (Evans et al., 2005). Differences in the 
subcellular  localisation  of  mammalian  α  subunit  isoforms  may  well  depend  on  the 
associated β and γ isoforms.  
1.2.2.2  Beta subunit 
The β subunit acts as a scaffold for the binding of the α and γ subunits (Woods et al 1996), 
and  furthermore  regulates  subcellular  localisation  of  AMPK by targeting  the kinase to 
membranes  via  an N-terminal  myristoyl group  (Warden  2001).  Indeed  3  β subunits in 
Saccharomyces cerevisiae (Sip1, Sip2 and Gal83) direct Snf1 to the vacuole, cytoplasm or 
nucleus respectively (Vincent et al., 2001). Mammalian β1 is a 270 residue protein which 
contains 2 conserved regions, located in the central and C-terminal regions (Jiang and 
Carlson, 1997). The C-terminal region is necessary for a functional αβγ complex, and is 
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central conserved region is recognised to be a glycogen binding domain (GBD) (Hudson et 
al., 2003; Polekhina et al., 2003) which is conserved in the β subunits of all eukaryotic 
species.  
The GBD is classified as an N-isoamylase domain, which is a non-catalytic domain also 
found in enzymes that synthesize or degrade the α1-6 branches in α1-4 linked glucans, 
such as glycogen or starch. Overexpression of αβγ complexes in mammalian cells results 
in the formation of cytoplasmic inclusions containing AMPK associated with glycogen, an 
effect which is not observed when a truncated β subunit lacking the GBD is used (Hudson 
et al 2003). High levels of muscle glycogen have been shown to inhibit AMPK activation 
during exercise in human muscle (Wojtaszewski et al 2003). Furthermore, a recent report 
has demonstrated that glycogen inhibits purified AMPK in cell-free assays, an effect that is 
dependent on binding to the GBD and varies according to the branching content of the 
glycogen (McBride et al., 2009). Oligosaccharides with single α1→6 branch points are 
allosteric inhibitors of AMPK that also inhibit phosphorylation and activation by upstream 
kinases (McBride et al., 2009). Interestingly the GBD may be a regulatory domain that 
allows AMPK to act as a glycogen sensor in vivo thus providing another level whereby 
AMPK regulates overall energy metabolism (McBride and Hardie, 2009). 
1.2.2.3  Gamma subunit 
The three γ subunit isoforms each contain four tandem repeats of a sequence termed a CBS 
motif  (Bateman,  1997),  named  after  the  corresponding  sequences  in  cystathionine  β-
synthase.  CBS  motifs  occurring  in  tandem  pairs  form  a  structure  termed  a  “Bateman 
domain” which is responsible for AMP binding. The importance of the γ subunit for AMP 
binding is highlighted by the  observation that the AMP dependence of a particular AMPK 
complex varies with the γ isoform present (Cheung et al., 2000). Labeling experiments 
using 8-azido-[
32P] AMP have also demonstrated that the γ subunit participates directly in 
the binding of AMP to the AMPK complex (Cheung et al., 2000). Interestingly 3 naturally 
occurring mutations within the CBS domains have been shown to decrease AMPK activity 
by dramatically reducing the AMP activation of the kinase (Daniel and Carling, 2002). The 
Bateman domains antagonistically bind ATP with a lower affinity than AMP (Scott et al., 
2004), consistent with the observation that high concentrations of ATP oppose activation 
of the AMPK complex by AMP (Corton et al., 1995). Thus, AMPK activity is affected by 
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The crystal structure of the regulatory fragment of mammalian AMPKγ1 in complexes 
with AMP and ATP has recently been reported (Xiao et al., 2007). From this work it has 
emerged that there are two sites on the γ domain that readily exchange AMP/ATP, whereas 
a third site contains a tightly bound AMP that is non-exchangeable (Xiao et al., 2007). The 
presence of two exchangeable sites is consistent with binding studies that detected two 
moles of AMP or ATP binding per γ subunit (Scott et al., 2004). The results reported by 
(Xiao et al., 2007) suggest that, at least for mammalian enzyme, AMP binding at this non- 
exchangeable  site  is  not  involved  in  AMP/ATP  sensing.  Binding  of  ATP  to  the 
exchangeable sites was found to elicit little structural rearrangement. Mg.ATP or Mg
2+-
free ATP were found to bind with similar affinity consistent with earlier studies which also 
found the affinity of the protein for ATP was independent of Mg
2+ (Scott et al., 2004). 
Currently  it  remains  uncertain  as  to  how  the  occupancy  state  of  the  AMP/ATP 
exchangeable sites affects allosteric activation of the catalytic domain.  
Interestingly, mutations in the CBS domains of the γ2 subunit (gene symbol PRKAG2) are 
associated  with  Wolff-Parkinson-White  syndrome  (a  syndrome  of  pre-excitation  of  the 
ventricles  of  the  heart)  and  familial  hypertrophic  cardiomyopathy  (Blair  et  al.,  2001; 
Gollob et al., 2001b; Gollob et al., 2001a). An additional inherited disorder associated with 
mutations  in  the  PRKAG2  gene  is  a  severe  cardiac  condition  called  lethal  congenital 
glycogen storage disease of the heart (Arad et al., 2002). This disorder is caused by a 
single  amino  acid  substitution  of  glutamate  for  arginine  at  position  531  (R531Q) 
(Burwinkel et al., 2005).  
1.2.3  Regulation of the AMPK complex by AMP 
AMPK senses changes in the ratio of AMP:ATP by binding both species in a competitive 
manner  (Hardie  et  al.,  1998).  If  the  reaction  catalysed  by  adenylate  cyclase 
(2ADP↔ATP+AMP) is assumed to be at or near equilibrium, the AMP:ATP ratio will 
vary approximately as the square of the ADP:ATP ratio, making the former ratio a much 
more sensitive indicator of reduced cellular energy status (Hardie et al., 1998). Indeed, 
only  a  6-fold  increase  in  nucleotide  concentration  is  required  for  maximal  activity  to 
progress from 10 % to 90 % (Hardie et al., 1999). AMP binding to the γ subunit results in 
allosteric activation of AMPK, and furthermore inhibits the action of protein phosphatases, 
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The degree of allosteric activation by AMP depends on the particular α and γ subunit 
isoforms present in the complex (Hardie et al., 1999). Complexes containing the α2- and 
γ2-isoforms exhibit the greatest degree of activation (almost 5-fold), whereas complexes 
containing the γ3 isoform are only activated <2-fold by AMP (Cheung et al., 2000). As 
AMP stimulation of the kinase is only observed if the intact αβγ complex, and not the 
isolated kinase domain (which lacks the AMP binding site) is used as the substrate, it is 
clear the nucleotides interact with AMPK rather than with the upstream kinase (Hawley et 
al., 2003). Work conducted by Xiao and colleagues would suggest AMPK mainly exists in 
its inactive form in complex with the much more abundant MgATP with only a small 
proportion binding AMP (Xiao et al., 2007). A model proposed by the authors of this study 
suggests that a 2-3 fold increase in the AMP concentration (low µM range) results is a 
similar fold increase in the proportion of AMP bound enzyme in the presence of a much 
higher (mM range) concentration of MgATP (Xiao et al., 2007). 
1.2.4  Phosphorylation of AMPK on Thr-172 
AMPK is activated by phosphorylation at a specific threonine residue (Thr-172) on the α 
subunit, catalysed by an upstream kinase (Hawley et al., 1996). Although AMPK was so 
named as a result of its allosteric activation by AMP, this effect is largely insignificant (up 
to 5-fold) (Carling et al., 1987) in comparison with the effect of Thr-172 phosphorylation 
(>100-fold) (Suter et al., 2006). Phosphorylation of Thr-172 appears to be essential for 
AMPK activity as site directed mutagenesis of Thr-172 to alanine completely abolishes 
kinase activity (Crute et al., 1998; Stein et al., 2000).  
Mass spectrometry studies have shown the α subunit of AMPK is phosphorylated on at 
least 2 other residues, Thr-258 and Ser-485 (Ser491 in α2); however phosphorylation at 
these sites has no effect on AMPK activity (Woods et al., 2003a). Mutagenesis of Thr-258, 
and  Ser-485  to  acidic  residues  to  mimic  phosphorylation  in  the  recombinant  proteins 
indicates that Thr-258 and Ser-485 are not involved in AMPK activation (Woods et al., 
2003b). Transfection of the non-phosphorylatable S485A and T258A mutants in CCL13 
cells subjected to stresses known to activate AMPK further indicate these sites are not 
involved  in  AMPK  activation  (Woods  et  al.,  2003b).  It  may  be  the  case  these 
phosphorylation sites may play a less prominent role in the regulation of AMPK, e.g. in 
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1.2.5  Regulation of AMPK by upstream kinases 
Although it had been apparent that the mechanism of AMPK activation by metabolic stress 
involved  the  action  of  an  AMPKK,  for  many  years  the  molecular  identity  remained 
elusive, despite partial purification of the kinase from rat liver (Hawley et al 1996), and 
many attempts to uncover it by conventional protein purification. This led a number of 
groups  to  focus  on  the  yeast Saccharomyces  cerevisiae system.  In  this  system  genetic 
studies show that the AMPK homologue (the Snf1 complex) is required for the response to 
glucose  starvation  (Hardie  et  al  1998),  while  in  the  moss  Physcomitrella  patens  it  is 
required to allow the plant to survive periods of darkness, the equivalent of carbon source 
starvation  for  a photosynthetic plant  (Thelander  et  al  2004).  Two  groups  subsequently 
reported the identification of three protein kinases encoded in the yeast Saccharomyces 
cerevisiae genome i.e. Elm1, Sak1 (originally called Pak1) and Tos3, that phosphorylated 
the yeast orthologue of the α subunit of AMPK (Snf1) at the equivalent site (Thr-210), and 
provided genetic evidence that these kinases acted upstream of Snf1 in a redundant manner 
in vivo (Hong et al 2003; Sutherland et al 2003). The nearest relatives of Elm1, Sak1 and 
Tos3 in the human genome are CaMKK and the tumour suppressor kinase LKB1. 
1.2.5.1  LKB1 
Historically, interest
 in LKB1 was first aroused in 1998 after it was found
 that germline 
inactivating  mutations  in  this  tumour  suppressing  kinase  causes  the  rare
  Peutz-Jeghers 
syndrome  (Mehenni  et  al.,  1998).  Peutz-Jeghers  is  a  cancer  predisposition  syndrome 
characterized
  by  the  development  of  gastrointestinal  polyps  and  mucocutaneous
 
pigmentation abnormalities.  
1.2.5.1.1  Identification of LKB1 as an AMPKK 
 
Considering  its  intimate  association  with  cancer  development,  it was  of  surprise when 
LKB1 was identified as an AMPK kinase (Hawley et al., 2003; Woods et al., 2003a; Shaw 
et al., 2004). LKB1 exists as a heterotrimeric complex requiring two accessory subunits, 
STRAD and MO25, for activity of the kinase (Boudeau et al., 2003). Recombinant LKB1 
expressed in COS7 cells was  found to  activate AMPK by phosphorylation of Thr-172 
(Woods  et  al.,  2003a).  Homozygous  LKB1  knockout  mice  die  during  embryonic 
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using MEFs demonstrated that LKB1 was necessary and sufficient for activation of AMPK 
by the drugs, AICAR and phenformin (Shaw et al., 2004; Hawley et al., 2003).  
1.2.5.1.2  Importance of LKB1 
It is not clear whether the tumour suppressor effects of LKB1 occur via AMPK, as LKB1 
acts upstream of at least 13 distinct AMPK-related protein kinases (Lizcano et al., 2004). It 
is apparent however that LKB1-mediated activation of AMPK is an important regulatory 
pathway.  Deletion  of  LKB1  in  the  liver  significantly  reduces  total  AMPK  activity 
suggesting LKB1 is the predominant upstream kinase for both AMPK α1 and α2 in this 
tissue. Loss of LKB1 activity in adult mouse liver leads to near complete loss of AMPK 
activity and is associated with hyperglycemia. The hyperglycemia is, in part, due to an 
increase  in  the  transcription  of  gluconeogenic  genes.  Of  particular  significance  is  the 
increased  expression  of  PGC-1α  which  drives  gluconeogenesis.  Reduction  in  PGC-1α 
activity results in normalized blood glucose levels in LKB1-deficient mice. Deficiency of 
LKB1  in  skeletal  muscle  prevents  AMPKα2  activation  and  glucose  uptake  during 
contraction or in response to AICAR or phenformin (Sakamoto et al., 2005). The activity 
of  α1-containing  complexes  is  reduced  but  not  abolished  (Sakamoto  et  al.,  2005). 
Similarly, in heart lacking LKB1, the basal activity of AMPKα2 is vastly reduced and not 
increased by ischemia or anoxia, whereas the activity of AMPKα1 is reduced by a small 
degree  (Sakamoto  et  al.,  2006).  Interestingly,  these  studies  indicate  that  an  alternative 
upstream kinase can activate AMPKα1 in cardiac and skeletal muscle.  
1.2.5.2  The CaMK cascade 
An increase in the intracellular Ca
2+ concentration, often acting through the Ca
2+ receptor 
protein calmodulin (CaM), is a ubiquitous signal that regulates diverse cellular responses. 
The CaMK cascade consists of three related members where CaMKK is the activating 
kinase  for  two  multifunctional  CaM  kinases,  CaMKI  and  CaMKIV  (Soderling,  1999). 
CaMKK  phosphorylates  a  Thr  in  the  T-loop  of  the  catalytic  domain  of  CaMKI  and 
CaMKIV, resulting in a large increase in the catalytic efficiency of each CaMK (Soderling, 
1999). 
CaMKI is broadly distributed in mammal and is mainly cytosolic (Picciotto et al., 1995) 
whereas the two splice variants of CaMKIV are well expressed in neural tissue, T cells and 
testis (Soderling, 1996). CaMKIV is predominantly restricted to the nucleus but also is 
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CaMKK (α and β), which exhibit cytoplasmic and nuclear localisation respectively. High 
levels are found in are brain, testis and spleen, whereas other tissues contain much lower 
levels of CaMKK (Tokumitsu et al., 1995; Kitani et al., 1997; Anderson et al., 1998). 
There are two isoforms of CaMKK, α and β. The binding of Ca
2+/CaM to CaMKKα is 
absolutely required for activation and phosphorylation of target protein kinases (Tokumitsu 
and Soderling, 1996; Selbert et al., 1995; Haribabu et al., 1995), while CaMKKβ activity is 
enhanced but not completely dependent on Ca
2+/CaM, in vitro and in transfected cells 
(Anderson et al., 1998).  
1.2.5.2.1  CaMKK structure and regulation 
CaMKK, as well as CaMKI and CaMKIV, contains an amino-terminal catalytic domain 
and  a  regulatory  domain  (autoinhibitory  and  CaM-binding  segments)  at  its  carboxyl 
terminus (Tokumitsu and Soderling, 1996; Tokumitsu et al., 1997; Matsushita and Nairn, 
1998).  An  interaction  between  the  autoinhibitory  domain  and  the  catalytic  domain 
maintains the kinase in an inactive conformation by preventing binding of protein substrate 
as well as MgATP (Soderling, 1996). Binding of Ca
2+/CaM to the CaM binding domain 
alters the conformation of the overlapping autoinhibitory domain such that it no longer 
interferes with substrate binding resulting in activation of the kinase.   
1.2.5.2.2  Downstream of the CaMK cascade 
In the cytosol members of the CaMK cascade regulate cell survival through the activation 
of  PKB  (Yano  et  al.,  1998),  and  transcription  through  indirect  activation  of  MAPK 
(Soderling, 1999). CaMKIV can also phosphorylate and inactivate type I adenylate kinase, 
thereby deceasing cAMP levels (Wayman et al., 1996). Elevated levels of cAMP can exert 
negative  feedback  by  activating  PKA,  which  phosphorylates  and  inactivates  CaMKK 
(Wayman et al., 1997). There is extensive cross-talk between CaMKK, CaMKIV and other 
signalling cascades, including those that involve the PKA, MAPK and PKB (Soderling, 
1999).  CaMKK  and  CaMKIV  are  also  present  in  the  nucleus  where  they  stimulate 
transcription  through  the  phosphorylation  of  transcription  factors  (Jensen  et  al.,  1991; 
Soderling, 1999). 
1.2.5.2.3  Identification of CaMKK as an AMPK kinase 
Although  LKB1  had  been  identified  as  a  major  AMPKK  a  number  of  observations 
indicated other kinases could activate AMPK in a number of tissues. LKB1
-/- fibroblasts 
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phosphorylation, albeit with reduced responses to known AMPK activators (Hawley et al., 
2005; Shaw et al., 2004).  
CaMKK shows more sequence similarity to Pak1, Tos3 and Elm1 than does LKB1, and in 
1995 it was reported that CaMKK could phosphorylate and activate the AMPK complex in 
cell-free assays (Hawley et al., 1995). However, the major upstream kinase that had been 
purified from rat liver was not calmodulin dependent and as a result CaMKK was ruled out 
as an AMPKK. In hindsight this can be easily explained as in those initial studies AMPK 
kinase was purified from a tissue where LKB1 is the major AMPKK. Three independent 
reports subsequently identified that CaMKK is an upstream kinase for AMPK, that acts in 
a Ca
2+-dependent, AMP-independent manner (Hurley et al., 2005; Hawley et al., 2005; 
Woods et al., 2005).  
1.2.5.3  The mechanism of CaMKK/LKB1-mediated AMPK activation 
In LKB1-deficient HeLa cells activation of AMPK is abolished in response to AICAR or 
other stimuli that increase the AMP:ATP ratio (Hawley  et al., 2003).  However, whilst 
these  observations  demonstrate  that  LKB1  mediates  AMPK  activity  in  response  to  an 
increased AMP:ATP ratio, evidence suggests that AMP does not promote phosphorylation 
of AMPK by recombinant LKB1, nor does it alter LKB1 activity (Woods et al., 2003a; 
Sakamoto et al., 2004). Rather AMP inhibits the dephosphorylation of AMPK by protein 
phosphatases (Figure 1.2) (Sanders et al., 2007a; Suter et al., 2006), and as LKB1 appears 
to be constitutively active (Lizcano et  al., 2004; Sakamoto et al., 2004) this results in 
phosphorylation of AMPK at Thr-172.  
Activation of AMPK in response to increased intracellular Ca
2+ occurs through increased 
CaMKK activity and is independent of adenine nucleotide levels. Once Ca
2+ levels fall 
AMPK is rapidly dephosphorylated (Figure 1.2).  
Recent  studies  using  cultured  endothelial  cells  have  suggested  that  LKB1-mediated 
activation  of  AMPK  occurs  in  response  to  peroxynitrite  (Xie  et  al.,  2006),  whereas 
CaMKK has been reported to mediate the activation of AMPK in response to thrombin 
(Stahmann  et  al.,  2006),  suggesting  both  the  AMP-dependent  and  Ca
2+-dependent 
mechanisms are present in cultured endothelial cells.  James A Reihill, 2009    Chapter 1, 37 
1.2.5.4  Additional AMPKK’s 
Considering that there are 3 upstream kinases for Snf1 in yeast it seems feasible that there 
may be at least three kinases in mammalian cells. Tak1, a member of the MAPK kinase 
kinase family, has recently been proposed as a possible AMPKK in mammals (Momcilovic 
et  al.,  2006).  The  physiological  significance  of  Tak1  and  its  role  in  vivo  however  is 
uncertain  at present.  Further  work  is  necessary  to  further  elucidate  the  role  Tak1,  and 
possibly other kinases, in relation to the regulation of AMPK. 
1.2.6  Pharmacological activators of AMPK 
1.2.6.1  Metformin and phenformin 
Metformin and phenformin are derivatives of guanidine, the active
 ingredient of French 
lilac, used to treat diabetes in medieval
 Europe (Witters, 2001). Currently metformin is 
widely used in both Europe and the US as a treatment for type 2 diabetes (prescribed to 
more than 120 million people worldwide). Phenformin was withdrawn as a treatment as it 
can cause lactic acidosis (Kwong and Brubacher, 1998). These agents were introduced in 
Europe  as  oral  anti-hyperglycemic  agents  during  the  late  1950’s,  even  though  their 
mechanism  of  action  was  uncertain.  Thus,  it  was  of  great  interest  when  it  was 
demonstrated that metformin activates AMPK in intact cells in vivo (Zhou et al., 2001). It 
is likely the therapeutic actions of metformin are primarily on the liver, where it has been 
shown  to  decrease  glucose production  and  increase  fatty  acid  oxidation  in  hepatocytes 
(Zhou  et  al.,  2001).  OCT-1,  which  is  not  expressed  in  many  cultured  cells  but  well 
expressed  in  liver,  facilitates  the  entry  of  metformin  into  tissues  (Wang  et  al.,  2002). 
Indeed  a  liver-specific  LKB1  deletion  in  mouse  liver  results  prevents  the  anti-
hyperglycemic effects of metformin (Shaw et al., 2005). Zhou and co-workers proposed 
that metformin might act by stimulating
 phosphorylation of AMPK by upstream kinase(s) 
or by inhibiting
 dephosphorylation by protein phosphatases (Zhou et al., 2001). However it 
has been reported that metformin does not
 activate of AMPK in cell-free assays by either 
of the two
 upstream kinases found to phosphorylate
 Thr-172 (LKB1 and CaMKK), either 
in the presence or absence of AMP (Hawley et al., 2002). Similarly,
 metformin was found 
to have no effect on inactivation of AMPK by PP2C (Zhou et al., 2001; Hawley et al., 
2002).  
Metformin, phenformin and the TZDs, another group of anti-diabetic agents which are 
discussed in section 1.2.7.2, can act as an
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(Owen  et  al.,  2000;  Brunmair  et  al.,  2004).  Any  metabolic  poison  that  inhibits 
mitochondrial ATP synthesis will raise the AMP:ATP ratio triggering phosphorylation and 
activation of AMPK. It was therefore proposed that these drugs may act as weak poisons 
resulting in a cellular stress which activates AMPK via an increase in the AMP:ATP ratio. 
The cellular AMP:ATP ratio is significantly altered after treatment of cultured cells with 
phenformin (Hawley et al., 2005), and decreases in ATP have been reported in rodent 
hepatocytes treated with metformin (Guigas et al., 2006). Notably, as intestinal epithelial 
cells also express OCT transporters (Koepsell et al., 2007), it seems possible that inhibition 
of  the  respiratory  chain  is  responsible  for  the  adverse  gastrointestinal  side  effects  of 
biguanides, as well as the lactic acidosis that led to the withdrawal of phenformin. Indeed it 
has  been  reported  that  the  lactic  acid  produced  in  animals  treated  with  biguanides  is 
derived from gut (Bailey et al., 1992). 
1.2.6.2  TZDs 
The  TZDs  (thiazolidinediones),  a
  class  of  anti-diabetic  drugs  including  rosiglitazone, 
troglitazone and pioglitazone, improve endothelial function, as
 assessed by endothelium-
dependent vasodilatation in patients
 with type 2 diabetes or insulin resistance (Pistrosch et 
al.,  2004;  Wang  et  al.,  2004;  Natali  et  al.,  2004;  Satoh  et  al.,  2003).  While  the
 
hypoglycemic effects of TZDs are mediated PPARγ-activated genes (Semple et al., 2006), 
evidence suggests that the improvement of
 endothelial function by TZDs is independent of
 
the effect on glycerin (Pistrosch et al., 2004; Satoh et al., 2003). Interestingly, AMPK has 
been identified as an alternative mechanism also modulated upon exposure to TZDs (Fryer 
et  al.,  2002).  A  recent  report  from  our  laboratory  has  demonstrated  that  rosiglitazone 
stimulates  NO  production  in  human  aortic  endothelial  cells  in  an  AMPK-dependent 
manner (Boyle et al., 2008).  
Similar to metformin and phenformin TZDs have been demonstrated act as an
 inhibitor of 
complex 1 of the respiratory chain (Owen et al., 2000; Brunmair et al., 2004), thus an 
increase in the AMP:ATP ratio may be the mechanism for AMPK activation in response to 
these agents. Notably, TZDs also increase plasma adiponectin and decrease plasma resistin 
levels, which may indirectly contribute to the effects on AMPK activity  (Yamauchi et al., 
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1.2.6.3  AICAR 
AICAR was the first drug demonstrated to activate AMPK in intact cells (Sullivan et al., 
1994; Corton et al., 1995; Henin et al., 1995). AICAR is a pro-drug taken up into cells by
 
adenosine transporters (Gadalla et al., 2004) then converted to its active component (ZMP, 
an AMP analogue) inside the cell, which acts as a mimetic of AMP thus activating AMPK 
(Corton et al., 1995). When administered to rodent models of obesity and insulin resistance 
such as the ob/ob mouse, the fa/fa rat, and high fat-fed rat, AICAR has been demonstrated 
to reverse many of the adverse abnormalities (Song et al., 2002; Bergeron et al., 2001; 
Iglesias  et  al.,  2002;  Buhl  et  al.,  2002). For  a  number  of  reasons  AICAR  is  not used 
clinically including its tendency to cause bradycardia in perfused hearts and hypoglycemia 
when administered intravenously (Young et al., 2005). 
1.2.6.4  A-769662 
A-769662, a newly identified small molecule from the thienopyridone family, activates 
AMPK  both allosterically and by inhibiting dephosphorylation of the kinase at Thr-172 
(Sanders  et al., 2007a;  Goransson et al., 2007; Cool et al., 2006). A-769662 has been 
shown to act independently of the upstream kinases LKB1 and CaMKK (Goransson et al., 
2007), and in cell-free assays has been shown to have no direct effect on the ability of 
LKB1 or CaMKK to phosphorylate AMPK (Sanders et al., 2007a). Whilst activation of 
AMPK by A-769662 is similar to that caused by AMP (Sanders et al., 2007a; Goransson et 
al., 2007) the drug has not been demonstrated to have any effect on adenine nucleotide 
levels (Sanders et al., 2007a; Cool et al., 2006), and a number of observations suggest its 
mechanism of action is distinct from activation by AMP. Indeed A-769662, unlike AMP, 
retains the ability to activate AMPK containing a mutation in the γ subunit (Sanders et al., 
2007a). Furthermore, a mutation in the β1 subunit (Ser-108 to alanine) which prevents 
activation by A-769662 is only partially effective in reducing activation as a result of AMP 
(Sanders et al., 2007a).  
Current evidence indicates that the β1 subunit plays a key role in mediating the activation 
of AMPK by A-769662. Indeed it has been reported recently that A-769662 exclusively 
activates AMPK complexes containing the β1 subunit isoform (Scott et al., 2008). The 
activation of AMPK by A-769662 seems to involve an interaction between the β1 subunit 
GBD and residues from the γ subunit (that are not involved in AMP binding) (Scott et al., 
2008). The mechanism of A-769662 action however does not seem to involve binding of 
the drug to the GBD nor the nucleotide binding sites of the γ subunit (Scott et al., 2008). At James A Reihill, 2009    Chapter 1, 40 
present  it  is  unclear  as  to  why  β2-containing  AMPK  complexes  are  insensitive  to  A-
769662 as there is little variation in the GBD of these two isoforms.  
In vivo A-769662 has previously been reported to lower plasma glucose levels in obese 
mice, likely through a primary  action on the liver (Cool et al., 2006). However, more 
recently Scott and co-workers have demonstrated that the glucose lowering effects of A-
769662 occur independently of AMPK activation in hepatocytes generated from AMPK 
β1-null  mice (Scott  et  al.,  2008).  This  observation  and  the  finding  that  A-769662 can 
inhibit non-proteolytic components of the 26S proteosome (Moreno et al., 2008) highlight 
the potential for off-target effects of the drug. 
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Figure 1-1  Domain structure of AMPK subunit isoforms and splice variants 
Regions shown in the same colour are related, and their functions, where known, are indicated. (Figure 
adapted from (Towler and Hardie, 2007)). 
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Figure 1-2  Activation of AMPK by upstream kinases 
 (A) As LKB1 appears to be constitutively active activation of AMPK in response to an increase in the 
AMP:ATP ratio is proposed to occur through inhibition of the dephosphorylation reaction, catalysed by 
protein phosphatases (PP). The net result is increased phosphorylation of Thr-172. Inactivation of AMPK 
would occur following a drop in the AMP:ATP ratio, and relief of inhibition of dephosphorylation. (B) 
Activation of AMPK in response to increased intracellular Ca
2+ occurs through increased CaMKKβ activity. 
In this model, AMPK would be rapidly dephosphorylated following a fall in Ca
2+ levels and this may account 
for the transient nature of AMPK activation observed after CaMKKβ activation. It should be noted that these 
pathways do not need to be mutually exclusive and activation of AMPK by both LKB1 and CaMKKβ could 
occur under conditions where AMP and Ca
2+ levels rise in concert. (Figure adapted from (Carling et al., 
2008)). 
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1.3 Downstream of AMPK activation 
The signalling cascades initiated by the activation of AMPK exert both short and long term 
effects through its action on a range of processes including glucose and lipid metabolism, 
gene expression and protein synthesis (for review see (Kahn et al., 2005). In general (as 
summarised  in  Figure  1.3),  AMPK  switches  on  catabolic  processes  that  generate  ATP 
(e.g., glucose uptake, glycolysis, fatty acid oxidation and mitochondrial biogenesis), while 
switching  off  anabolic  processes  that  consume  ATP,  (e.g.,  fatty  acid,  triglyceride, 
cholesterol, glucose (via gluconeogenesis) and glycogen synthesis (reviewed in (Kahn et 
al., 2005)).  
1.3.1  AMPK substrate specificity 
As of 2007 there were almost 20 direct physiological targets identified for AMPK (Towler 
and Hardie, 2007); though given the critical
 importance of maintaining energy balance at 
both the cellular
 and whole body levels, it is likely there are many more which remain, as 
of yet, undiscovered.  
As discussed in section 1.1.2.3, the amino acids that are situated immediately N-terminal 
and C-terminal to the phosphorylation site (P-site) often contribute substantially to kinase-
substrate  recognition  (concensus  sequence  model).  Early  studies  on  the  substrate 
specificity of AMPK, using variant synthetic peptides, indicated basic and hydrophobic 
residues in the substrate are important specificity determinants (Weekes et al., 1993; Dale 
et al., 1995). The SAMS peptide has been most widely used, and the consensus recognition 
sequence  around  the  phosphorylation  site  established  from  synthetic  peptide  studies  is 
hydrophobic ( ) at P−5 and P+4 and at least one basic (ß) between P−1 and P−4 - i.e. 
[ß,X]-X-X-S/T-X-X-X-  (Weekes et al., 1993; Dale et al., 1995). A number of subsequent 
studies have further confirmed this concensus phosphorylation motif for AMPK substrates 
(Scott  et  al.,  2002;  Towler  and  Hardie,  2007;  Gwinn  et  al.,  2008).  Figure  1.4  is  an 
alignment of 14 sequences containing sites
 phosphorylated by AMPK in cell-free assays, 
all of which are believed to be targets in vivo. Although a
 serine residue is phosphorylated 
in each instance, threonine can
 be phosphorylated by AMPK in synthetic peptide substrates 
(Weekes et al., 1993). In most cases, there are bulky hydrophobic residues (shown in
 bold) 
at positions P-5 and P+4, and at
 least 1 basic residue (underlined) at either P-4 or P-3 in 
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Two  major  AMPK  targets  ACC  and  eNOS  (Figure  1.4),  are  central  to  the  present 
investigation. ACC, phosphorylated by AMPK on Ser-80 (human sequence), is regarded as 
perhaps the most efficient substrate for AMPK (Towler and Hardie, 2007). Knowledge of 
AMPK substrate recognition has been enhanced by modeling studies using the
 binding of 
the sequence around Ser-79 on rat ACC1 to a 3D model of the α1 kinase
 domain (Scott et 
al., 2002). Briefly this work, indicates a basic residue at P-6 and additional hydrophobic 
side chains on the N-terminal side
 occurring every third or fourth residue, i.e., at P-9, P-13, 
and
 P-16 may be an additional positive determinants of substrate specificity. This pattern 
of  hydrophobic  residues  is  also  discernible
  in  a  few  of  the  other  substrates,  including 
HMGR,
 eNOS, TSC2, and TORC2.  Although Ser-1177 on eNOS is known to be the 
consensus phosphorylation site of AMPK (Chen et al., 1999),  Figure 1.4 demonstrates that 
the basic–hydrophobic–basic
  motif  that  usually  occurs  at  the  P-6,  P-5,  and P-4  or P-3 
positions is
 displaced by 1 residue, i.e., at P-5, P-4, and P-3 (similar to cardiac PFK2). 
1.3.1.1  ACC 
In animals the storage of body fat provides a crucial reserve to sustain energy metabolism 
during starvation, hibernation and migration, as well as providing thermal insulation and 
other functions (Brownsey et al., 2006). However, excess body fat, especially in certain 
adipose  depots  and  other  tissue  sites,  can  be  maladaptive  in  humans,  substantially 
increasing  the  risk  of  diabetes  and  cardiovascular  diseases  (Gurevich-Panigrahi  et  al., 
2009). ACC is a key regulator of lipid storage and overall energy metabolism through the 
synthesis  of  malonyl-CoA,  an  essential  substrate  for  fatty  acid  synthesis  and  a  potent 
inhibitor of fatty acid oxidation (McGarry, 2002). As mentioned previously ACC was one 
of the first substrates identified for AMPK (Carlson and Kim, 1973). AMPK is a negative 
regulator of ACC activities and as such the AMPK-ACC system is a major therapeutic 
target against insulin resistance and type 2 diabetes (Ruderman and Prentki, 2004). 
1.3.1.2  ACC isoforms 
ACC orthologues have been demonstrated in yeast, animals and higher plants, including 
two major mammalian isoforms; ACC1 (265 kDa) and ACC2 (280 kDa) (Lane et al., 1974; 
Cronan, Jr. and Waldrop, 2002; Barber et al., 2005). The predicted amino acid sequence of 
ACC2 contains an additional 136 amino acids relative to ACC1, 114 of which constitute 
the unique N terminal sequence of ACC2. The N-terminal sequence of ACC2 contains a 
potential mitochondrial targeting motif. Indeed the expressed N-terminal domain appears 
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that is supported by a number of genetic studies (Abu-Elheiga et al., 2003; Abu-Elheiga et 
al.,  2005;  Abu-Elheiga  et  al.,  2001).  Immunofluorescence  microscopic  analysis  has 
demonstrated that ACC1 is a cytosolic protein (Abu-Elheiga et al., 2000).  
1.3.1.3  ACC and the regulation of fatty acid synthesis and oxidation 
 
ACC  acts  as  key  metabolic  enzyme  through  the  formation  of  malonyl-CoA.  ACC1-
generated malonyl CoA is utilised by fatty acid synthase (FAS) for the synthesis of fatty 
acids in the cytosol (Davies et al., 1990), whereas ACC2-generated malonyl-CoA functions 
as a potent inhibitor of CPT-1, a rate limiting step for the entry of long chain fatty acids 
into mitochondria for oxidation (McGarry, 2002). ACC2
-/- mice have a normal lifespan, a 
higher  fatty  acid  oxidation  rate  and  accumulate  less  fat,  thus  making  it  a  potential 
therapeutic target for obesity and its related disorders. Mutant mice lacking ACC1, unlike 
ACC2-null mice, are embryonically lethal (Abu-Elheiga et al., 2005) demonstrating the 
importance of de novo fatty acid synthesis in development, and further highlighting that 
ACC1 and ACC2 have distinct roles in fatty acid metabolism.  
1.3.1.4  ACC as a fuel sensor 
When metabolic fuel is low (glucose deprivation, increased energy expenditure) and ATP 
is required, both ACC1 and ACC2 are turned off by phosphorylation and the consequential 
reduction in malonyl-CoA leads to the generation of ATP through increased fatty acid 
oxidation and a decrease in ATP consumption for fatty acid synthesis (Ruderman et al., 
2003). Conversely, in response to an increase in glucose availability, many cells inhibit the 
oxidation of fatty acids (Ruderman et al., 2003). Indeed, just as AMPK acts as a fuel sensor 
(in response to an increase in the AMP:ATP ratio), ACC may also act as a metabolic 
sensor,  allosterically  (via  citrate  and  fatty  acids)  and  through  AMPK  phosphorylation, 
directing fatty acid synthesis (fuel storage) and β oxidation (fuel supply) (Steinberg et al., 
2006).  
1.3.1.5  Regulation of ACC 
ACC is tightly regulated through a variety of dietary, hormonal and metabolic responses. 
The gene expression of ACC is largely regulated by SREBP1c (Andreolas et al., 2002; 
Diraison  et  al.,  2004),  whereas  acute  changes  are  mediated  by  allosteric  and  covalent 
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1.3.1.5.1  Gene expression 
 
ACC1 is highly expressed (10–50 µg/g of wet weight) in white and brown fat, liver and 
lactating  mammary  gland,  with  expression  being  inhibited  during  starvation  or  insulin 
deficiency and restored by refeeding a low-fat diet or by insulin treatment (Iritani, 1992). 
The  ACC1  gene is  under  the  control  of  at  least  three promoters  with  distinct roles in 
constitutive or inducible expression in response to a variety of factors including glucose, 
insulin, thyroid hormone, catabolic hormones and leptin (Kim, 1997; Mao et al., 2003; 
Zhang et al., 2003). 
ACC2 is expressed at low levels (1–2 µg/g of wet weight) in heart and skeletal muscle 
(Thampy, 1989), whereas much higher concentrations of ACC2 are found in liver, where it 
represents approximately 20–25% of total hepatic ACC (Winz et al., 1994). The expression 
of ACC2 is increased during the differentiation of heart and skeletal-muscle cells, with a 
parallel decline in expression of ACC1 (Lopaschuk et al., 1994). In contrast, in liver cells, 
the  expression  of  ACC2  appears  to  parallel  that  of  ACC1,  being  decreased  during 
starvation and restored on refeeding (Iverson et al., 1990).  
Among the key transcription factors SREBP1c plays a major role in controlling genes for 
ACC1 and other lipogenic enzymes, in adipogenesis and in nutritional regulation (Shimano 
et al., 1999). Other transcription factors that contribute to the control of ACC expression 
include liver X receptor, retinoid X receptor, PPARs, FOXO and PGC isoforms (Barber et 
al., 2005). 
1.3.1.5.2  Allosteric control 
The activity of ACC1 is acutely controlled by allosteric modulators. Exposure of cells to 
insulin  in  vivo  or  in  vitro  leads  to  rapid  activation  of  ACC1  (Stansbie  et  al.,  1976); 
conversely catecholamines or glucagons rapidly inhibit the enzyme (Brownsey et al., 1979; 
Hardie, 1992). The allosteric effectors of ACC1; which include citrate, other carboxylic 
acids and glutamate, activate the enzyme by promoting polymerization of ACC, resulting 
in the formation of high order oligomers (Lane et al., 1974; Boone et al., 2000; Thampy 
and Wakil, 1985). On the other hand, long chain fatty acids such as malonyl-CoA, free-
CoA and fatty acyl-CoA esters inhibit the enzyme and promote disassociation of these 
oligomers (Ogiwara et al., 1978; Moule et al., 1992). However, while allosteric ligands 
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following  enzyme  isolation,  indicating  the  presence  of  additional  control  mechanisms 
(Brownsey et al., 2006). 
 ACC2 is also activated by citrate and glutamate but does not polymerize as readily as 
ACC1. In spite of this it has been suggested that allosteric control of ACC2 by citrate is 
crucial in skeletal muscle (Saha et al., 1999). 
1.3.1.5.3  Multisite phosphorylation 
Experiments  involving  metabolic  labeling  with  [
32P]-phosphate  demonstrate  ACC1  is 
phosphorylated on at least four hormone-responsive sites in fat and liver cells (Brownsey 
et  al.,  2006).  Exposure  of  these  cells  to  adrenaline  or  glucagon  leads  to  rapid 
phosphorylation  and  inactivation  of  ACC1  (Brownsey  et  al.,  2006).  The  effects  of the 
inhibitory hormones are mediated by cAMP, whereas the phosphorylation of ACC1 at Ser
 -
79, Ser-1200 and Ser-1215 is carried out largely by AMPK (Hardie, 1992). Purified ACC2, 
like ACC1, has been demonstrated as a substrate for AMPK in heart and skeletal muscle 
(Kudo et al., 1995; Winder et al., 1997). The regulation of ACC by AMPK is summarised 
in Figure 1.5. 
In skeletal muscle AMPK is activated by an increase in energy expenditure (exercise) and 
by  fuel  deprivation  and  hypoxia  (Winder  and  Hardie,  1999;  Ruderman  et  al.,  1999). 
Activated  AMPK  phosphorylates  ACC  (to  its  inactive  form)  and  phosphorylates  and 
activates malonyl-CoA decarboxylase, resulting in a decrease in malonyl-CoA levels thus 
relieving the tonic inhibition of CPT1 and thereby increasing mitochondrial import and 
oxidation of long chain fatty acids (Park et al., 2002). In fat-fed rats a single injection of 
AICAR (Iglesias et al., 2002) or prior exercise (Oakes et al., 1997), both of which increase 
AMPK activity, has been demonstrated to cause sustained decreases in malonyl-CoA, and 
furthermore  increase  insulin  stimulated  glucose  uptake  by  the  muscle  of  control  rats 
(Iglesias et al., 2002; Fisher et al., 2002).  
A  number  of  reports  has  demonstrated  that  a  malonyl-CoA  fuel  sensing  mechanism, 
similar to that in muscle, is in operation in the endothelial cell (Dagher et al., 1999; Dagher 
et al., 2001). In HUVEC deprived of glucose for several hours (i.e. no ATP derived from 
glycolysis), a 3 fold increase in AMPK activity and fatty acid oxidation occurred, and the 
concentration of malonyl-CoA was diminished by 80 % (Dagher et al., 2001). Notably 
ATP levels were not reduced in these cells indicating fatty acids can be utilised as their 
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was of limited importance as a fuel source in the endothelial cell (Krutzfeldt et al., 1990). 
Indeed it has been reported that HUVEC oxidise fatty acids from both extracellular and 
intracellular  sources,  and  when  considered  together  can  account  for  a  substantial 
percentage of calculated ATP production in these cells (Dagher et al., 2001).  
It has also been demonstrated that HUVEC incubated in hyperglycemic conditions (30mM 
glucose) exhibit an increase in apoptosis (72h) an effect preceded at 24h by an elevated 
concentration of malonyl-CoA, inhibition of fatty acid oxidation, increased diacylglycerol 
synthesis, an increase in caspase 3 activity and an impaired ability of insulin to activate 
PKB (Ido et al., 2002). Addition of the AMPK activator AICAR both increased AMPK 
activity several fold and completely prevented all the observed abnormalities at 24h (Ido et 
al., 2002). In addition, HUVEC incubated with excess fatty acid (0.2-0.4 mM palmitate) 
and normal glucose resulted in greater amount of apoptosis, again an effect prevented by 
AICAR treatment (Ido et al., 2002). The endotheliopathy associated with insulin resistance 
syndrome  appears  to  largely  result  from  excessive  free  fatty  acid  exposure  (McCarty, 
2005). Therefore, one could argue, pharmacological activation of endothelial AMPK has 
the potential to decrease the free fatty acid content of endothelial cells thus improving 
vascular health. 
1.3.1.6  eNOS  
In endothelial cells, NO is synthesized from the amino acid L-arginine, through a five 
electron oxidation step involving the formation of the intermediate N
G-hydroxy-L-arginine, 
by the constitutively expressed eNOS (Palmer et al., 1988; Zembowicz et al., 1991). The 
substrates  for  eNOS-mediated  NO  production  are  the  amino  acid  arginine,  molecular 
oxygen,  NADPH,  while  the  cofactors  BH4,  FAD  and  FMN  are  also  required  for  NO 
production (Govers and Rabelink, 2001). 
Structurally,  eNOS  consists  of  oxygenase  and  reductase  domains  with  an  interposed 
Ca
2+/calmodulin binding domain (Figure 1.6). While Ca
2+/calmodulin binding is required 
for  eNOS  activity  eNOS  regulation  also  involves  multiple  levels  of  post-translational 
regulation including numerous protein–protein interactions (Kone et al., 2003; Fulton et 
al., 2001) and tightly regulated multi-site phosphorylation involving numerous kinases and 
phosphatases (Figure 1.7), feedback inhibition from NO, the bioavailability of BH4 and by 
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As the main producer of endothelial NO, eNOS is of major importance to the normal 
function of the cardiovascular system. eNOS is activated by hormonal factors, including 
insulin (Sobrevia et al., 1996; Zeng and Quon, 1996), catecholamines and vasopressin, as 
well as by mechanical forces such as shear stress generated by blood flow through the 
blood vessels and increases in intracellular Ca
2+ (Andrew and Mayer, 1999).  
1.3.1.7  Post translational modification of eNOS 
Reversible phosphorylation of eNOS, which occurs on Ser-114, -615, -633, and -1177 and 
Thr-495 (human amino acid sequence) in response to a range of stimuli, is important in 
regulating  enzyme  activity,  which  varies  depending  on  the  protein  kinase  and  residue 
involved.  
eNOS activity is increased by phosphorylation at both Ser-1177 and Ser-633  (Chen et al., 
1999;  Fulton  et  al.,  1999;  Bauer  et  al.,  2003;  Michell  et  al.,  2002).  In  contrast, 
phosphorylation of Thr-495 in the Ca
2+/calmodulin binding domain is inhibitory (Chen et 
al.,  1999;  Matsubara  et  al.,  2003).  The  effect  of  eNOS  Ser-114  and  Ser-615 
phosphorylation remain controversial (Bauer et al., 2003; Michell et al., 2002). 
The phosphorylation of Ser-1177 has
 been demonstrated as critical for eNOS activation 
responding
 to several stimuli, including shear stress, bradykinin, insulin, adiponectin, and 
statins (Chen et al., 2003; Harris et al., 2004; Montagnani et al., 2001; Boo et al., 2002b). 
Phosphorylation  of  eNOS  at  Ser-1177  increases  eNOS  activation  mediated  by 
Ca
2+/calmodulin  binding  (Chen  et  al.,  1999;  Bauer  et  al.,  2003),  and  can  also  lead  to 
activation of eNOS at resting levels of intracellular Ca
2+ (Bauer et al., 2003; Montagnani et 
al., 2001).  
As discussed in section 1.3.1 (and highlighted in figures 1.3 and 1.4) Ser-1177 of eNOS is 
a known target for AMPK (Chen et al., 1999). Based on the consensus sequence for PKB 
sites  (RXRXXS/T)  Ser-1177  is  also  a  putative  phosphorylation  site.  Indeed  a  study 
conducted  by  (Dimmeler  et  al.,  1999)  has  confirmed  that  Ser-1177  is  a  key 
phosphorylation  site  of  eNOS  in  intact  cells  that  is  subject  to  PKB-mediated 
phosphorylation with a distinct consequence for eNOS activity. As highlighted in figure 
1.7  a number  of other  protein  kinases,  namely  PKA (Michell  et  al.,  2002; Boo et al., 
2002a),  CaMKII (Fleming et al., 2001a), and PKG (Butt et al., 2000), have also been 
implicated as potential mediators of eNOS Ser-1177 phosphorylation (Mount et al., 2007). James A Reihill, 2009    Chapter 1, 50 
In addition to its effect on Ser-1177 PKB also phosphorylates eNOS on Ser-615 (Figure 
1.7) (Michell et al., 2002; Harris et al., 2004). PKC mediates phosphorylation of Thr-495 
resulting in a decrease in eNOS activity (Matsubara et al., 2003; Fleming et al., 2001a; 
Michell et al., 2001), an effect prevented by PKC inhibitors. Evidence suggests that PKA is 
the kinase responsible for phosphorylation of eNOS at Ser-633 (Figure 1.7) (Michell et al., 
2002; Harris et al., 2004; Boo et al., 2002a).  
The  eNOS  monomer  is  heavily  post-translationally  modified  by  myristoylation, 
palmitoylation,  farnesylation,  acetylation  and,  following  activation,  phosphorylation 
reviewed in (Stuehr, 1999). These modifications serve partly to target eNOS to various 
subcellular locations.  
Acetylation,  for  example,  is  responsible  for  targeting  eNOS  to  the  plasma  membrane 
(Shaul et al., 1996), where it is anchored to caveolae via the scaffolding proteins caveolin-
1 (Garcia-Cardena et al., 1996) and -3 (Garcia-Cardena et al., 1997). The localisation of 
eNOS  within  caveolae  renders  the  enzyme  inactive  with  eNOS  activity  inhibited  by 
caveolin-1 (Ju et al., 1997). The interaction between eNOS and the caveolin-1 scaffolding 
domain (amino acid residues 82-101) strongly reduces eNOS activity because caveolin-1 
interferes with the binding of calmodulin to eNOS when cytosolic Ca
2+ levels are low 
(Michel et al., 1997). In the presence of shear stress (Rizzo et al., 1998), or Ca
2+ mobilising 
agents such as bradykinin (Prabhakar et al., 1998), acetylcholine or Ca
2+ ionosphere (Feron 
et al., 1998) and estradiol (Kim et al., 1999), Ca
2+ bound calmodulin associates with eNOS, 
whereas caveolin-1 is displaced. Another protein that has been demonstrated to interact 
and enhance the activation of eNOS is the 90 kDa heat shock protein (HSP-90) (Garcia-
Cardena et al., 1998) which is rapidly recruited to the eNOS complex by agonists that 
stimulate production of NO such as VEGF, histamine and fluid shear stress. Not only does 
fluid shear stress activate eNOS, it causes a rise in the levels of eNOS transcripts, which is 
also achieved by exercise and hypoxia (Nathan and Xie, 1994).  In addition, eNOS is 
regulated  in  endothelial  cells  by  reversible  and  inhibitory  interactions  with  G-protein 
coupled receptors and these interactions can be modulated by receptor phosphorylation 
(Marrero et al., 1999). 
1.3.1.8  NO function 
NO is a free radical (Mayer and Hemmens, 1997) with a half-life of only a few seconds in 
vivo (Moncada and Higgs, 1991; Griffith et al., 1984). However, since it is soluble in both 
aqueous and lipid media, it readily diffuses through the cytoplasm and plasma membranes. James A Reihill, 2009    Chapter 1, 51 
Once produced, NO has several targets, including the enzyme soluble guanylate cyclase 
(sGC),  which  catalyses  the  formation  of  cyclic  guanosine  monophosphate  (cGMP),  a 
secondary messenger that relays information to cGMP-responsive molecules. In the case of 
NO-mediated vasodilation, the cGMP-targeted  molecules include two  cGMP-dependent 
protein kinases, PKG I and PKG II (also known as cGK-I and -II) (Gewaltig and Kojda, 
2002).  PKG  I  mediates  vasodilation by phosphorylating  various  molecules involved in 
smooth  muscle  relaxation,  including  inositol  1,4,5-trisphosphate  receptor-associated  G 
kinase
 (IRAG), myosin light chain (MLC) phosphatase, and phospholamban (Gewaltig and 
Kojda,  2002).  In  all  these  cases,  phosphorylation  ultimately  results  in  decreased 
intracellular Ca
2+ levels (Ammendola et al., 2001; Surks et al., 1999; Rivero-Vilches et al., 
2003). 
 A  further NO-mediated  vasodilatory  mechanism  is the  activation  of Ca
2+-activated K
+ 
(BKCa)  channels  by  NO  through  the  cGMP-PKG  I  pathway.  Activation  of  the  BKCa 
channels can occur either through direct activation of the BKCa channels by NO (Bolotina 
et al., 1994) or by PKG I-dependent phosphorylation of the channel protein (Alioua et al., 
1998) or of a protein phosphatase (Hall and Armstrong, 2000; Sausbier et al., 2000). BKCa 
channel activation increases the K
+ efflux, thus causing membrane hyperpolarisation and 
vasodilation (Gewaltig and Kojda, 2002). 
eNOS-derived NO is vitally important as a vasodilator: Disruption of the eNOS gene in 
mice results in mild hypertension (Gewaltig and Kojda, 2002; Huang et al., 1995); and 
increased  blood  pressure  is  also  seen  in  humans  when  NO  synthesis  is  inhibited 
pharmacologically (Stamler et al., 1994).  
In  addition  to  its  vasodilatory  effects,  NO  released  from  endothelial  cells  mediates 
numerous  additional  functions  in  the  endothelium;  inhibiting  platelet  aggregation, 
leukocyte  adherence  and  vascular  smooth  muscle  proliferation  (Kubes  et  al.,  1991; 
Gewaltig  and  Kojda,  2002).  Platelet  aggregation  is  prevented  by  lowering  their 
intracellular Ca
2+ concentration through activation of phospholamban and SERCA via the 
cGMP-PKG I pathway (Gewaltig and Kojda, 2002). Monocyte adhesion is dependent on 
the expression of attractant and attachment molecules, including VCAM-1, MCP-1 and 
cytokines, on the surface of vascular endothelial cells. As leukocyte adherence is an early 
event  in  the  development  of  atherosclerosis,  NO  may  protect  against  the  onset  of 
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Smooth  muscle  cell proliferation  is  inhibited in  vitro by NO (Garg  and  Hassid,  1989) 
through interference with O2
--producing enzymes (e.g. NADPH oxidase) (Clancy et al., 
1992).  Proliferation  may  also  be  blocked  by  cGMP-dependent  activation  of  PKA  and 
cGMP-inhibition  of  cAMP  phosphodiesterase  (PDE  III).  Activated  PKA  is  thought  to 
inhibit the mitogenic molecule Raf-1, thus preventing smooth muscle cell proliferation 
(Gewaltig  and  Kojda,  2002).  Unregulated  vascular  smooth  muscle  cell  proliferation  is 
proatherogenic    in  that  it  can  lead  to  artery  thickening,  thus  increasing  the  risks  for 
hypertension, stroke and infarction (Newby et al., 1995; Newby and George, 1996). 
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Figure 1-3  Targets for AMPK 
Target proteins and processes activated by AMPK activation are shown in green, and those inhibited by 
AMPK activation are shown in red. Where the effect is caused by a change in gene expression, an upward-
pointing  green arrow  next to the protein indicates an increase,  whereas a downward-pointing red arrow 
indicates a decrease in expression. Abbreviations: CD36/FAT, CD36/fatty acid translocase; CFTR, cystic 
fibrosis transmembrane regulator; nNOS, neuronal isoforms of nitric oxide synthase; G6Pase, glucose-6-
phosphatase; GLUT1/4, glucose transporters; GS, glycogen synthase; HSL, hormone-sensitive lipase; MEF2, 
myocyte-specific  enhancer  factor-2;  NRF1,  nuclear  respiratory  factor-1;  PEPCK,  phosphoenolpyruvate 
carboxykinase; TOR, mammalian target of rapamycin. (Figure adapted from (Hardie, 2004)). 
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Figure 1-4   AMPK concensus recognition motif 
Alignment  of  the  consensus  recognition  motif  for  AMPK  and  sequences  around  sites  believed  to  be 
phosphorylated by AMPK on physiological substrates. Sequences are from the human, although in many 
cases the sites were identified with enzymes from other species. The serine residues phosphorylated are 
shown by the arrow labeled "P" at the top, and "P-x or P+x" refers to residues x residues N or C terminal to 
the phosphorylated serine. In the consensus recognition motif,   refers to a hydrophobic residue (M, L, I, F, 
or V) and ß to a basic residue (R, K, or H). Hydrophobic and basic residues believed to be important in 
recognition of the target sequences are in bold or underlined respectively. (Figure adapted from (Towler and 
Hardie, 2007)) 
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Figure 1-5  ACC regulation by AMPK 
ACC  activity  is  regulated  both  allosterically  (via  citrate-induced  polymerisation  and  fatty  acid-induced 
depolymerisation) and covalently (via AMPK and PKA-mediated phosphorylation). ACC activation results 
in malonyl CoA synthesis, the precursor for fatty acid synthesis in liver and fat and allosteric inhibitor of 
CPT1, the transferase regulating the transfer of fatty acid into the mitochondria for β-oxidation in skeletal 
and heart muscle. Not shown here is the regulation of ACC phosphorylation by PKA, which is essentially 
similar but independent of that of AMPK. (Figure adapted from (Steinberg et al., 2006)). 
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Figure 1-6  eNOS phosphorylation sites 
Phosphorylation sites of endothelial nitric oxide synthase. Sites are numbered according to the human eNOS 
sequence. The arrows indicate the effect of phosphorylation on eNOS activity. Phosphorylation of Ser-633 
and Ser-1177 increases eNOS activity, whereas phosphorylation of Thr-495 is inhibitory. The effects of 
phosphorylation of Ser114 and Ser615 remain controversial. Figure adapted from (Mount et al., 2007) 
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Figure 1-7  The role of kinases and phosphatases on eNOS activation 
Activation of NO synthesis by eNOS involves multiple and coordinated phosphorylation events and protein–
protein  interactions.  Important  activators  of  eNOS  include  bradykinin,  VEGF,  shear  stress  and 
pharmacological stimuli such as statins. Numerous kinases and phosphatases contribute to the regulation of 
eNOS  phosphorylation,  although  the  specific  kinases  and  phosphatases  involved  can  vary  depending  on 
either the activating stimulus or the tissue bed. + indicates kinase-mediated phosphorylation. − indicates 
phosphatase-mediated dephosphorylation. PKB is referred to as Akt in this Figure. This Figure is adapted 
from (Mount et al., 2007) James A Reihill, 2009    Chapter 1, 58 
1.4 Vascular effects of AMPK 
AMPK  activation  is  a  possible  target  for  the  prevention  and  treatment  of  disorders 
associated with insulin resistance, including atherosclerotic vascular disease (Tomas et al., 
2002). AMPK is important in the normal development of heart as mutations in AMPK lead 
to severe heart defects. Greater interest in AMPK as a potential cardiovascular target has 
arisen  with  recent  evidence  that  AMPK  has  a  cardioprotective  role  against myocardial 
injury and apoptosis in the ischemic heart (Russell, III et al., 2004). Furthermore, there is 
mounting evidence that AMPK may exert anti-atherosclerotic effects in the vasculature. 
A  number  of  reports  indicate  AMPK  activation  may benefit  the  cardiovascular system 
through  various  mechanisms.  For  example,  vascular  smooth  muscle  proliferation  is  a 
critical  event  in  the  development  and  progression  of  vascular  diseases,  including 
atherosclerosis. It has been reported that AMPK suppresses vascular smooth muscle cell 
proliferation via cell cycle regulation by p53 upregulation (Igata et al., 2005). It has also 
been  shown  that  α  lipoic  acid  improves  vascular  dysfunction  by  normalizing  lipid 
metabolism and activating AMPK in endothelial cells (Lee et al., 2005). Furthermore, it 
has also been demonstrated that activation of AMPK contributes to protection of the heart 
against  hypoxic  injury  through  attenuation  of  endoplasmic  reticulum  stress,  and  the 
attenuation of protein synthesis via eukaryotic elongation factor 2 inactivation may be the 
mechanism of cardioprotection by AMPK (Terai et al., 2005). 
However,  perhaps  the  importance  of  AMPK  in  cardiovascular  functions  is  best 
demonstrated by recent studies demonstrating that widely used drugs, including statins, 
metformin  and  rosiglitazone,  which  activate  AMPK,  execute  protective  effects  in  the 
vasculature. The endothelium, the dysfunction of which is associated with the aetiology of 
disorders  including  type  2  diabetes,  obesity,  atherosclerosis  and  cardiovascular  disease 
(Bonora,  2006),  is  a  key  tissue  in  which  AMPK  activation  may  promote  improved 
cardiovascular health.  
1.4.1    The function of the vascular endothelium 
The endothelium, also known as the tunica intima, is located at the interface between the 
blood and vessel wall, anchored to the underlying basal lamina (Hurairah and Ferro, 2004). 
The endothelium is composed of flattened cells anchored together by adhesion junctions, 
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layer forms a barrier between the elements of the blood and the tissues by virtue of its 
direct contact with the circulating blood (Wheatcroft et al., 2003). 
In  the  past  the  endothelium  was  seen  as  a  semi-permeable  monolayer  of  inert  cells 
passively  allowing passage  of  water  and  other  small  molecules  across  the  vessel wall. 
However, it is now evident that this dynamic tissue performs many active functions, such 
as  the  secretion  and  modification  of  vasoactive  substances  and  the  contraction  and 
relaxation  of  vascular  smooth  muscle  (Hurairah  and  Ferro,  2004;  Davies  and  Hagen, 
1993).  The  intact  structure  and  function  of  the  endothelium  is  prerequisite  for  the 
maintenance of normal vascular function (Davies and Hagen, 1993).  
Vascular tone is regulated by a number of endothelium-derived substances with vasodilator 
or vasoconstrictor function, acting on vascular smooth muscle cells (Ganz and Vita, 2003). 
The vasodilators include prostacyclin, endothelium derived hyperpolarising factor and NO, 
whilst the vasoconstrictors include endothelin-1 and thromboxane A2 (Hurairah and Ferro, 
2004; Michiels, 2003). NO released from endothelial cells is an important regulator of 
vascular  homeostasis  promoting  vasodilatation  and  inhibiting  platelet  aggregation, 
leukocyte adherence and vascular smooth muscle proliferation (Garg and Hassid, 1989; 
Nabah et al., 2005; de Graaf et al., 1992). Reduced NO production or bioavailability is a 
characteristic of many cardiovascular disorders (Davignon and Ganz, 2004; Verma et al., 
2003). Adrenergic vasoconstrictor tone is unopposed leading to increased vascular tone 
whilst  reduced  NO  can  also  lead  to  increased  platelet  adhesion  and  aggregation,  and 
therefore  enhanced  thrombogenesis.  Altered  NO  bioavailability  is  a  key  feature  of 
endothelial dysfunction (Forstermann and Munzel, 2006). 
1.4.2    Endothelial dysfunction  
Endothelial dysfunction is characterised by an imbalance of the mediators that regulate 
cardiovascular  homeostasis,  evidenced  by  reduced  vasodilator/increased  vasoconstrictor 
secretion,  increased  superoxide  production,  decreased  NO  bioavailability  and  impaired 
endothelium-dependent vasodilation (Steinberg et al., 2000; Artwohl et al., 2004). Chronic 
dysfunction  of  the  endothelium  is  implicated  in  the  pathophysiology  of  several 
cardiovascular  disorders,  including  atherosclerosis,  hypertension,  diabetic  vasculopathy 
and heart failure (Harrison et al., 2003). Several factors including hyperglycemia and free 
fatty acids (which are induced by insulin resistance syndrome and diabetes) contribute to 
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number  of  pathophysiological  changes  at  the  molecular  level,  including  inflammation 
(Libby, 2001a), endothelial cell apoptosis (Artwohl et al., 2004; Ido et al., 2002), increases 
in cell Ca
2+, ROS (Inoguchi et al., 2000) and NF-κB activation, (Pieper and Riaz, 1997) 
and decreases in eNOS activity and NO bioavailability, which contribute to or accelerate 
endothelial damage and dysfunction (Steinberg et al., 2000).  
1.4.2.1  AMPK as a therapeutic target in the dysfunctional endothelium 
A  number  of  reports  have  provided  evidence  that  AMPK  activation  may  be  anti-
artherogenic and function as a protector of endothelial function by alleviating many of 
these adverse effects associated with endothelial dysfunction and damage.  
(i) Induction of the eNOS/NO pathway resulting in increased NO bioavailability;  
Ser-1177 on eNOS is  a substrate for AMPK (Figure 1.4) (Chen et al., 1999) shown to be 
phosphorylated in endothelial cells in response to a range of agonists including hypoxia, 
metformin, adiponectin and shear stress (Chen et al., 2003; Nagata et al., 2003; Zou et al., 
2004; Nagata et al., 2003). Furthermore, it has been demonstrated that AICAR causes a 
time-  and  dose-dependant  stimulation  of  AMPK  activity,  with  concomitant  increase in 
eNOS  Ser-1177  phosphorylation  and  NO  production  in  human  aortic  endothelial  cells 
(Morrow et al., 2003). Disruption of the eNOS gene in mice results in mild hypertension 
(Huang  et  al.,  1995);  and  increased  blood  pressure  is  also  seen  in  humans  when  NO 
synthesis is inhibited pharmacologically (Stamler et al., 1994). In addition, infusion of the 
AMPK activator AICAR into rats has been shown to significantly reduce mean arterial 
pressure  (Foley  et  al.,  1989)  and  has  also  been  reported  to  lower  blood  pressure  in 
hypertensive, obese Zucker rats (Buhl et al., 2002). AMPK therefore provides an additional 
mechanism whereby local vascular tone may be controlled. Impairment of endothelium-
dependent relaxation represents reduced eNOS-derived NO bioavailability and is present in 
atherosclerotic vessels in advance of any changes in vascular structure (Kawashima and 
Yokoyama, 2004).  
 (ii) Suppression of endothelial ROS production induced by deleterious stimuli, such as 
hyperglycemia or high free fatty acids;  
ROS have been shown to cause insulin resistance in adipose and other tissues (Tirosh et 
al., 2001). Incubation of endothelial cells with excess glucose has been shown to increase 
Ca
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Dondlinger, 1997), and NF-κB as assessed by increases in its translocation to the nucleus 
(Pieper and Dondlinger, 1997; Nishikawa et al., 2000). Fatty acids have been shown to 
have a similar effect on ROS production. Evidence has been provided suggesting AMPK 
activation may prevent these adverse effects. Hyperglycemic medium and fatty acid (0.4 
mM palmitate) increased ROS, an effect inhibited by the AMPK activator AICAR (Ido et 
al., 2002). 
(iii)  Improving  endothelial  free  fatty  acid  oxidation,  leading  to  suppression  of  lipid 
accumulation 
In  cultured  endothelial
  cells,  AMPK  activation  using  AICAR  or  glucose  deprivation, 
stimulates ACC phosphorylation
 and fatty acid oxidation (Dagher et al., 2001). HUVEC 
incubated with excess fatty acid (0.2-0.4 mM palmitate) exhibit an increase in apoptosis, 
an effect prevented by AICAR treatment (Ido et al., 2002). 
(iv) Anti-apoptotic and anti-inflammatory effects 
Inflammation has been implicated in the early pathogenesis of endothelial cell damage 
(Ross,  1999;  Libby,  2001b)  while  activation  of  the  transcription  factor  NF-κB  and  an 
increase in circulating vascular adhesion molecules are thought to be early events in the 
development of atherosclerosis (Razani et al., 2008; Libby, 2001b). Both are prevalent in 
patients  at  risk  from  cardiovascular  disease  due  to  diabetes,  obesity  and  metabolic 
syndrome, all of which have associated increased fatty acid concentrations (Grundy et al., 
2004). Incubation of cultured endothelial cells with polyunsaturated fatty acids, such as 
linoleate, increases the activation of the inflammatory mediators NF-κB and AP1, as well 
as  the  expression  of  VCAM-1 (Hennig  et al.,  1996).  It  has been  reported that AMPK 
activation inhibits fatty acid induced increases in NF-κB transactivation (Cacicedo et al., 
2004) and cytokine-induced NF-κB activation in vascular endothelial cells (Hattori et al., 
2008). In addition, in vascular endothelial cells AMPK activation inhibits TNFα-stimulated 
leukocyte adhesion by a rapid NO-dependent mechanism associated with reduced MCP-1 
secretion (Ewart et al., 2008). As mentioned previously leukocyte adherence is an early 
event in the development of atherosclerosis. Furthermore, AMPK mediates the inhibitory 
effect  of  the  high  molecular  weight  form  of  adiponectin  on  endothelial  cell  apoptosis 
(Kobayashi et al., 2004). 
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1.5 VEGF 
VEGF  is  a  major  regulator  of  endothelial  cell  function  that  stimulates  differentiation, 
survival, migration, proliferation, vascular permeability and NO production in these cells 
(Cross et al., 2003). Manipulation of VEGF signalling is seen as a promising therapeutic 
target for a number of disorders yet its role in the endothelium is incompletely understood. 
1.5.1  Identification of VEGF 
Angiogenesis,  a  process  involving  the  growth  of  new  blood  vessels  from  pre-existing 
vessels, and vasculogenesis, the spontaneous development of blood vessels, are processes 
predominantly  regulated  by  a  group  of  growth  factors  which  act  via  their  associated 
receptor  tyrosine  kinases  (Ferrara,  2005a).  The  most  prominent  of  these  is  the 
VEGF/VEGF receptor (VEGF-R) family. More than a century ago it was observed that 
tumour growth can be accompanied by increased vascularity (Ferrara, 2002a), and in 1939 
the existence of a tumour-derived blood vessel growth-stimulating factor was postulated on 
the basis of the strong neovascular response induced by tumours transplanted in transparent 
chambers (Ide et al., 1939). Compelling evidence for the presence of diffusible angiogenic 
factors was reported in 1968 when it was demonstrated that transplanted melanoma or 
choriocarcinoma cells  promoted blood vessel proliferation even when a Millipore filter 
was interposed between the tumour and the host (Greenblatt and Shubi, 1968; Ehrmann 
and Knoth, 1968). In 1983, a factor was purified from the conditioned medium of a guinea-
pig tumour cell line that was shown to increase dye extravasation in the skin (Senger et al., 
1983). The authors proposed that this factor, termed “tumour vascular permeability factor 
(VPF), could be a mediator of the high permeability of tumour blood vessels. In 1989 an 
endothelial  cell-  specific  mitogen  was  isolated  from  medium  conditioned  by  bovine 
pituitary  follicular  cells,  which  was  termed  “vascular  endothelial  cell  growth  factor” 
(Ferrara  and  Henzel,  1989).  As  other  endothelial  cell  mitogens,  such  as  FGF,  do  not 
increase vascular permeability it was of great surprise when subsequent work identified 
that VPF and VEGF were in fact the same molecule (Leung et al., 1989; Keck et al., 1989). 
The characterisation of VEGF as a potent, diffusible and endothelial cell-specific factor led 
to the hypothesis that this molecule might play a role in the regulation of physiological and 
pathological  growth  of  blood  vessels  (Ferrara  and  Henzel,  1989;  Leung  et  al.,  1989; 
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1.5.2  Activities of VEGF 
1.5.2.1  Mitogenic effects 
Angiogenesis  and  vasculogenesis  are  largely  regulated  by  growth  factors  and  their 
associated receptor tyrosine kinases. Foremost among these is the VEGF family and their 
associated VEGF receptors. The loss of a single VEGF allele is lethal in the mouse embryo 
between  days  11  and  12  (Carmeliet  et  al.,  1996;  Ferrara  et  al.,  1996),  with  VEGF
+/- 
embryos exhibiting significant defects in the vasculature of several organs. Homozygous 
loss of the VEGF-R1 or VEGF-R2 gene results in embryonic lethality between days 8.5 
and 9.5 (Fong et al., 1995; Shalaby et al., 1995). In VEGF-R1 deficient mice this is due to 
the obstruction of vessels by an overgrowth of endothelial cells (Fong et al., 1995), while 
loss of the VEGF-R2 gene results of an early defect in the development of haematopoietic 
and endothelial cells (Shalaby et al., 1995). 
In adult endothelial cells, derived from arteries, veins and lymphatics, VEGF has been 
demonstrated as a potent mitogen both in vitro, (reviewed in (Ferrara and Davis-Smyth, 
1997), and in a number of in vivo models including the chick chorioallantoic membrane 
(Leung et al., 1989; Plouet et al., 1989), the rabbit cornea (Phillips et al., 1994) and the 
Matrigel plug in mice (Mesri et al., 1995). VEGF delivery has also been demonstrated to 
induce lymphangiogenesis in mice (Nagy et al., 2002).  
1.5.2.2  Pathophysiological angiogenesis 
 
VEGF is expressed in most tumours and is closely linked with their progression (Ferrara, 
2005b). Tumour-associated stroma, in addition to tumour cells, is an important source of 
VEGF (Fukumura et al., 1998). VEGF mRNA is abundantly expressed in hypoxic tumour 
cells adjacent to necrotic areas (Ferrara and Davis-Smyth, 1997), facilitating the growth of 
new blood vessels into tumours which would otherwise become necrotic and apoptotic in 
the absence of an adequate vasculature (Holmgren et al., 1995). It appears that VEGF-R1 
signalling  plays  a  more  prominent  angiogenic  role  under  pathological,  rather  than 
physiological, conditions (Hiratsuka et al., 2001; Carmeliet et al., 2001). Indeed VEGF-R1  
is  involved  in  tumour  metastasis,  being  linked  to  the  induction  of  MMP-9  in  lung 
endothelial cells and to the facilitation of lung-specific metastasis (Hiratsuka et al., 2002). 
VEGF  has  also  been  demonstrated  to  impair  the  endothelial  barrier,  which  facilitates 
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disruption of hepatocellular tight junctions, which may promote tumour invasion (Schmitt 
et al., 2004). Inhibition of VEGF-R2 has been shown to stabilize the endothelial barrier 
function and suppresses tumour cell extravasation in vivo (Weis et al., 2004a). Capturing of 
VEGF  or  blocking  of  its  signalling  receptor  VEGF-R2  by  a  VEGF-R  tyrosine  kinase 
inhibitor,  antisense  oligonucleotides,  vaccination  or  neutralizing  antibodies  has  been 
demonstrated to reduce tumour angiogenesis and growth in preclinical studies (Ferrara et 
al., 2004). The addition of a humanized anti-VEGF monoclonal antibody (bevacizumab) to 
fluorouracil-based  combination  chemotherapy  results  in  a  significant  improvement  in 
survival among patients with metastatic colorectal cancer (Hurwitz et al., 2004). 
1.5.2.3  Vascular permeability 
VEGF  was  originally  known  as  VPF based  on  its  ability  to  induce  increased vascular 
permeability of microvessels to circulating macromolecules (Senger et al., 1983; Dvorak et 
al., 1995; Bates et al., 2002b). Increased vascular permeability is often observed in areas of 
pathological angiogenesis in solid tumours, wounds and chronic inflammation (Gratton et 
al.,  2003;  Potgens  et  al.,  1995).  VEGF  has  also  been  shown  to  induce  an  increase  in 
hydraulic  conductivity  of  isolated  microvessels;  an  effect  mediated  by  increased  Ca
2+ 
influx  (Bates  and  Curry,  1997).  Consistent  with  this  role,  VEGF  induces  endothelial 
fenestrations  in  some  vascular  beds  (Roberts  and  Palade,  1995)  and  cultured  adrenal 
endothelial cells (Esser et al., 1998), and furthermore promotes the extravasation of ferritin 
by way of the vesiculo-vacuolar organelle (Bates and Harper, 2002) and disorganization of 
endothelial junctional proteins such as VE-cadherin and occludin (Kevil et al., 1998).  
1.5.2.4  Survival 
VEGF is a survival factor for endothelial cells in vitro and in vivo (Alon et al., 1995; 
Gerber et al., 1998b; Benjamin et al., 1999; Gerber et al., 1998a; Yuan et al., 1996) and has 
been demonstrated to prevent against serum-starvation induced apoptosis of endothelial 
cells by a PI3K/PKB-dependent mechanism (Gerber et al., 1998b; Fujio and Walsh, 1999). 
In  addition,  VEGF  induces  the  expression  of  the  anti-apoptotic proteins  Bcl-2  and A1 
(Gerber et al., 1998a). Inhibition of VEGF has been demonstrated to increase apoptosis of 
endothelial cells isolated from liver in neonatal but not adult mice (Gerber et al., 1999), 
and VEGF dependence of endothelial cells has been demonstrated in newly formed but not 
of  established  vessels  within  tumours  (Benjamin  et  al.,  1999;  Yuan  et  al., 1996).  It is 
believed that coverage by pericytes is an important factor in the loss of VEGF dependence 
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1.5.2.5  Haematopoiesis and blood cell function 
VEGF  has  also  been  observed  to  have  effects  on  bone  marrow-derived  cells.  VEGF 
promotes monocyte chemotaxis (Clauss et al., 1990), and has been demonstrated to have 
haematopoietic  effects  inducing  colony  formation  by  mature  subsets  of  granulocyte-
macrophage progenitor cells (Broxmeyer et al., 1995). Delivery of VEGF to adult mice 
inhibits dendritic cell development (Gabrilovich et al., 1996), increases production of B 
cells and the generation of immature myeloid cells (Hattori et al., 2001). VEGF has been 
reported to regulate haematopoietic stem cell survival during haematopoietic repopulation 
in lethally irradiated hosts (Gerber et al., 2002). Interestingly in Drosophila, which are 
devoid of a vascular system, a VEGF-dependent pathway is important in the regulation of 
blood cell migration (Cho et al., 2002) and proliferation (Munier et al., 2002) indicating an 
ancestral conserved role for VEGF-regulated blood cell function (Evans et al., 2003). 
1.5.2.6  Vasodilatation 
VEGF induces vasodilatation in vitro in a dose-dependent fashion (Ku et al., 1993; Yang et 
al., 1996), and produces transient tachycardia, hypotension and a decrease in cardiac output 
when injected intravenously in rats (Yang et al., 1996). These effects appear to result from 
reduction in venous return mediated primarily by endothelial-derived NO (Yang et al., 
1996). Indeed, hypotension was a dose-limiting side effect in human trials where VEGF 
was systemically administered (Henry et al., 2003). Conversely, administration of anti-
VEGF monoclonal antibodies to cancer patients has been shown to cause elevated blood 
pressure (Yang et al., 2003).  
1.5.2.7  NO 
It  should  be  noted  that  in  addition  to  vasodilation  NO  underlies  a  number  of  VEGF-
mediated effects. For example it is clear that NO plays a critical role in VEGF-induced 
vascular permeability and angiogenesis (Parenti et al., 1998; Ziche et al., 1997; Morbidelli 
et al., 1996). Angiogenesis, vessel diameter, blood flow rate and vascular permeability are 
proportional to NO levels and are impaired in eNOS
-/- mice (Fukumura et al., 2001).  
1.5.3  VEGF Isoforms 
The VEGF gene family consists of VEGF-A (referred to as VEGF throughout this study), 
PIGF, VEGF-B, VEGF-C and VEGF-D. A number of VEGF-related proteins have also 
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(svVEGFs)  (Takahashi  and  Shibuya,  2005).  Each  VEGF  isoforms  exhibits  variable 
selectivity for three related receptor tyrosine kinases (VEGF-R1, VEGF-R2 and VEGF-
R3) (summarised in Figure 1.8).  
1.5.3.1  VEGF 
VEGF has significant homology to PDGF, and all the eight cysteines
 found in the A and B 
chains  of  PDGF  are  conserved  in  VEGF (Leung  et  al.,  1989;  Keck  et al.,  1989). The 
human VEGF gene is organized in eight exons, separated
 by seven introns (Houck et al., 
1991; Tischer et al., 1991) and is localized in chromosome 6p21.3
  (Vincenti et al., 1996). 
Alternative exon splicing results in the generation of
 four different isoforms, having 121, 
165, 189, and 206 amino
 acids, respectively, after signal sequence cleavage (VEGF121,
 
VEGF165, VEGF189, VEGF206) (Houck et al., 1991; Tischer et al., 1991). VEGF165, the 
predominant
 isoform, lacks the residues encoded by exon 6, whereas VEGF121
 lacks the 
residues encoded by exons 6 and 7. Less frequent splice
 variants have been also reported, 
including  VEGF145  (Poltorak  et  al.,  1997),  VEGF183
  (Jingjing  et  al.,  1999),  VEGF162 
(Lange et al., 2003), and VEGF165b, a variant reported to have
 paradoxically an inhibitory 
effect  on  VEGF-induced  mitogenesis  (Bates  et  al.,  2002a).  VEGF165b  has  a  3'-splicing
 
structure  that  predicts  a  novel  COOH-terminal  peptide  sequence.
  Usually,  the  COOH 
terminus of VEGF consists of six amino acids
 encoded by the first 18 nucleotides of exon 
8. In VEGF165b,
 that is replaced by six amino acids coded for by an 18-nucleotide
 open-
reading frame formed from a more distal splice site
 selection in exon 8. Native VEGF is a 
heparin binding homodimeric glycoprotein of 45 kDa (Ferrara and Henzel, 1989). Such 
properties closely correspond to those of VEGF165, the predominant VEGF isoform which 
potently stimulates angiogenesis (Houck et al., 1992) (and is the VEGF subtype used in the 
present study unless stated otherwise).  
The  amino  acids  encoded  by  exons  1-5  are  conserved  in  all  isoforms  but  alternative 
splicing can occur in exons 6-7 which encodes 2 heparin binding domains that influence 
receptor binding and solubility. The isoforms that encode exon 6 are highly basic and bind 
to  heparin  with  high  affinity  and  thus  are  tightly bound  to  the  cell  surface (VEGF145, 
VEGF189, and VEGF206). VEGF165, which lacks exon 6 has intermediate properties, in that 
it is secreted yet a significant fraction remains bound to the cell surface and extracellular 
matrix  (Park  et  al.,  1993).  VEGF121,  which  lacks  both  exon  6  and  7,  is  an  acidic 
polypeptide that fails to bind heparin and is freely released from the cell (Houck et al., 
1992). The ECM-bound isoforms may be released into a diffusible form by heparin or 
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cleavage at the COOH terminus which generates a bioactive fragment 110 amino acids 
long (Houck et al., 1992). This proteolytic mechanism is important in regulating the local 
activity and bioavailability of VEGF. The loss of the heparin-binding domain results in the 
mitogenic activity of VEGF. 
It  seems  the  intermediate  properties  of  VEGF165  enable  optimal  bioavailability  and 
biological  potency.  An  important  feature  of  VEGF  is  its  increased  expression  during 
conditions of hypoxia which is regulated by a hypoxia-responsive element in its promoter 
(discussed in detail in section 1.3.4.1). Thus, VEGF is crucial for vascular development as 
well as physiological and pathophysiological angiogenesis. VEGF is particularly important 
because loss of even a single
 VEGF allele results in embryonic lethality at days 11 to 12
 
(Ferrara et al., 1996; Carmeliet et al., 1996). 
1.5.3.2  VEGF-B 
VEGF-B is a highly basic heparin binding growth factor which is structurally similar to 
VEGF. Although widely expressed VEGF-B is particularly abundant in tissues such as 
heart, skeletal muscle and pancreas and may act in paracrine fashion to regulate endothelial 
cell  function  (Olofsson  et  al.,  1996).  Human  VEGF-B  has  two  isoforms  generated  by 
alternative splicing; VEGF-B167 and VEGF-B186. The VEGF-B isoforms bind and activate 
VEGF-R1 and can also bind to NRP-1 (discussed in detail in section 1.3.4.5) (Olofsson et 
al., 1999). Whilst VEGF-B
-/- mice are viable and fertile one study has reported that these 
animals  have  smaller  hearts,  dysfunctional  coronary  arteries  and  an  impaired  recovery 
from  experimentally  induced  myocardial  ischemia  (Bellomo  et  al.,  2000).  However, 
another group has demonstrated that these mice only display a subtle cardiac phenotype, 
and  have  suggested  that  VEGF-B  is  not  required  for  proper  development  of  the 
cardiovascular system either during development or angiogenesis in adults (Aase et al., 
2001).  Further  work  using  VEGF-B
-/-  mice  has  demonstrated  a  role  for  VEGF-B  in 
pathological  vascular  remodeling  in  inflammatory  arthritis  (Mould  et  al.,  2003)  and 
protection of the brain from ischemic injury (Sun et al., 2004). 
1.5.3.3  VEGF-C and VEGF-D 
VEGF-C is closely related to VEGF-D by virtue of the presence of N- and C-terminal 
extensions that are not found in other VEGF family members (Lohela et al., 2003). Both 
VEGF-C and VEGF-D bind and activate VEGF-R3 (a member of the VEGF-R family that 
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cells. VEGF-C also binds to NRP-2 (Lohela et al., 2003). Proteolytic cleavage, which is at 
least partly regulated by the serine protease plasmin (McColl et al., 2003), is required to 
produce the fully processed form of VEGF-C and VEGF-D, which are initially produced as  
preproteins (Lohela et al., 2003). It has been demonstrated that VEGF-C (VEGF-C
-/-) is 
required  for  the  initial  steps  in  lymphatic  development  and  both  VEGF-C  alleles  are 
required for normal lymphatic development (Karkkainen et al., 2004). Overexpression of 
VEGF-C in the epidermis of transgenic mice results in the development of a hyperplastic 
lymphatic vessel network (Jeltsch et al., 1997). VEGF-D has been shown to induce the 
formation  of  lymphatics  within  tumours  and  promote  the  metastasis  of  tumour  cells 
(Stacker et al., 2001). 
1.5.3.4  PlGF 
Although initially characterized in the placenta (Maglione et al., 1991), where it is highly 
expressed at all stages of gestation, PlGF, a VEGF-R1 specific ligand (Sawano et al., 1996; 
Park et al., 1994), is expressed in a wide variety of cells, tissues, and organs including 
heart, lung, thyroid gland and skeletal muscle (Persico et al., 1999). The crystal structure of 
human PlGF has shown that this protein is structurally similar to VEGF (Iyer et al., 2001). 
However, unlike VEGF, N-glycosylation in PlGF plays an important role in VEGF-R1 
binding  (Errico  et  al.,  2004).  PlGF  deficiency  (PlGF
-/-)  does  not  affect  embryonic 
angiogenesis in mice, however, loss of PlGF impairs angiogenesis, plasma extravasation 
and collateral growth during ischemia, inflammation, wound healing and cancer (Carmeliet 
et al., 2001). 
1.5.3.5  VEGF-E 
VEGF-E, a viral VEGF homologue encoded by an Orf virus, which affects sheep, goats 
and occasionally humans, is structurally similar to VEGF and binds only to VEGF-R2 
(Lyttle et al., 1994). The lesions induced in sheep and humans after infection with the virus 
show extensive dermal vascular endothelial proliferation and dilatation, and it is likely that 
this is a direct effect of the expression of the VEGF-like gene. VEGF-E seems to be as 
potent  as  VEGF  at  stimulating  endothelial  cell  proliferation  despite  lacking  a  heparin-
binding basic domain (Takahashi and Shibuya, 2005).  
1.5.3.6  svVEGFs 
A  group  of  proteins  structurally  related  to  VEGF  have  been  identified  in  svVEGFs, 
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(Trimeresurus flavoviridis svVEGF) (Takahashi et al., 2004) from pit vipers, in addition to 
hypotensive factor (Komori et al., 1999), increasing capillary permeability protein (Gasmi 
et al., 2002) and vammin (Yamazaki et al., 2003) from vipers. Vammin binds VEGF-R2 
with high affinity (Yamazaki et al., 2003), whereas TfsvVEGF binds VEGF-R1 with high 
affinity resulting in increased vascular permeability but a weak stimulation of endothelial 
cell proliferation (Takahashi et al., 2004). Both vammin and TfsvVEGF are unable to bind 
VEGF-R3 or NRP-1.  
1.5.4  Regulation of VEGF production  
1.5.4.1  Oxygen tension 
Hypoxia  is  a  major  stimulator  of  VEGF  expression
  (Shweiki  et  al.,  1992).  Hypoxia-
induced
 transcription of VEGF mRNA is largely mediated by the binding of HIF-1
 to a 
HIF-1 binding site located in the VEGF promoter (Levy et al., 1995; Liu et al., 1995).
 In 
addition  to  the  induction
  of  transcription,  hypoxia promotes the  stabilization of VEGF 
mRNA by proteins that bind to sequences located in the 3' untranslated region (Stein et al., 
1995; Stein et al., 1995; Damert et al., 1997; Claffey et al., 1998; Levy et al., 1998) and the 
5'  untranslated  region  of  VEGF  mRNA  (Stein  et  al.,  1998;  Akiri  et  al.,  1998).  
Furthermore,  VEGF  expression  can  be  regulated  at  the  translational  level.  The  5´ 
untranslated region of VEGF mRNA contains two functional internal ribosome entry sites 
that  maintain  efficient  cap-independent  translation  and  ensure  efficient  production  of 
VEGF,  even  under  unfavourable  stress  conditions  such  as  hypoxia  (Xie  et  al.,  2004). 
Under normal oxygenation conditions, HIF-1 is scarcely detectable because it is targeted 
for rapid destruction by an E3 ubiquitin ligase containing vHL. However, under hypoxic 
conditions HIF-1 protein accumulates thus increasing the transcription of VEGF (Gerald et 
al., 2004). Interestingly the production of other VEGF family members such as VEGF-B,
 
VEGF-C, and PlGF does not seem to be potentiated by hypoxia
 even though some of these 
factors such as VEGF-C are strong
 angiogenic factors (Jeltsch et al., 1997; Enholm et al., 
1997). 
1.5.4.2  Tumour suppressors 
Inactivation of tumour suppressors, such as vHL and p53, is an additional mechanism
 that 
leads to overexpression of VEGF in tumour cells. Wild-type vHL inhibits
 the production of 
several  hypoxia-regulated  proteins  including  VEGF  via  transcriptional
  and  post 
transcriptional mechanisms (Mukhopadhyay et al., 1997; Iliopoulos et al., 1996). At the James A Reihill, 2009    Chapter 1, 70 
post  transcriptional
  level,  vHL  inhibits  the  activity  of  PKC  ζ  and  δ (Pal  et  al., 1997). 
Mutation of the vHL gene in tumour cells may be a mechanism for increased angiogenesis 
in these cells (Maher and Kaelin, Jr., 1997; Siemeister et al., 1996; Stratmann et al., 1997). 
The  loss  of  the  wild-type  p53  is
  associated  with  increased  angiogenesis  in  developing 
tumours
 (Van Meir et al., 1994). Wild-type p53 has been reported as an inhibitor of VEGF
 
production  (Mukhopadhyay  et  al.,  1995),  and  mutated  p53  has  been  demonstrated  to 
enhance
  VEGF  expression  (Kieser  et  al.,  1994).  However,  Agani  and  coworkers  have 
reported findings which indicate wild-type p53 may not function
 as an inhibitor of VEGF 
expression (Kieser et al., 1994).
 
1.5.4.3  Growth factors, cytokines, oncogenes and extracellular molecules 
Cytokines, growth factors, and gonadotropins that do not stimulate
 angiogenesis directly 
can  modulate  angiogenesis  (positively  or  negatively)  via  the  modulation  of
  VEGF 
expression. Factors that can potentiate
 VEGF production include FGF-4 (Deroanne et al., 
1997), PDGF (Finkenzeller et al., 1997), TNFα  (Ryuto et al., 1996), TGF-β (Pertovaara et 
al., 1994), KGF (Frank et al., 1995), IGF-1 (Goad et al., 1996), IL-1β (Li et al., 1995),
 and 
IL-6 (Cohen et al., 1996). Cytokines such as IL-10 and IL-13 can inhibit
 the release of 
VEGF (Matsumoto et al., 1997). The observation that inflammatory cytokines such as IL-
1α and IL-6 induce expression of VEGF in several cell types is in agreement with the 
hypothesis  that  VEGF  may  be  a  mediator  of  angiogenesis  and  permeability  in 
inflammatory disorders (Neufeld et al., 1999). Another small molecule that up-regulates 
VEGF  expression  is  NO.  The  production  of  NO  is  in  turn  up-regulated  by  VEGF, 
indicating that a positive feedback loop exists between these
 two factors (Hood et al., 1998; 
Dembinska-Kiec  et  al.,  1997).  Specific  transforming  events  also  result  in  induction  of 
VEGF gene expression. Oncogenic mutations or amplification of Ras lead to VEGF up-
regulation (Grugel et al., 1995; Okada et al., 1998). These studies indicate that mutant Ras-
dependent  VEGF  expression  is  necessary,  albeit  insufficient,  for  progressive  tumour 
growth in vivo. 
1.5.5  The VEGF receptors 
Initially, VEGF binding sites were identified on the cell surface of vascular endothelial 
cells in vitro and in vivo. Subsequently, it became apparent that receptors for VEGF also 
occur on bone marrow-derived cells (Ferrara and Davis-Smyth, 1997)
   VEGFs bind with 
different affinities to three related receptor tyrosine kinases, VEGF-R1 (also known as 
fms-like  tyrosine  kinase),  VEGF-R2  (also  known  as  fetal  liver  kinase  1-murine James A Reihill, 2009    Chapter 1, 71 
homologue/kinase  inset  domain  containing  receptor-human  homologue)  and  VEGF-R3 
(also  known  as  flt-4).  Whereas  VEGF-R1  and  VEGF-R2  are  primarily  restricted  to 
vascular  endothelial  cells  VEGF-R3  is predominantly  found  in  lymphatic  endothelium. 
Each  of  these  VEGF  receptors  have  seven  immunoglobulin  like  domains  in  the 
extracellular  domain,  a  single  transmemebrane  region  and  a  consensus  tyrosine  kinase 
sequence interrupted by a kinase-insert domain (Shibuya et al., 1990; Terman et al., 1991). 
In addition to these RTKs, VEGF interacts with a family of co-receptors, the neuropilins. 
Binding of VEGF to receptor tyrosine kinases leads to receptor dimerisation, activation
 and 
subsequent  autophosphorylation  on  certain  tyrosine  residues,
  which  in  turn  triggers 
intracellular signalling cascades mediated
 by several effectors.  
The  importance  of  the  VEGF-R  family  is  highlighted by  a number  of  genetic  studies. 
VEGF-R2
-/- mice die at embryonic days 8.5 to 9.5 due to a defect in the development of 
haematopoietic and endothelial cells resulting in impaired vasculogenesis (Shalaby et al., 
1995). VEGF-R1
-/- mice die due to an overgrowth of endothelial cells and disorganization 
of blood vessels. However the observation that there is normal vascular development in 
mice lacking the tyrosine kinase domain of VEGF-R1 (Hiratsuka et al., 1998) indicates 
VEGF-R2  is  the  major  positive  signal  transducer,  whereas  VEGF-R1  has  a  negative 
regulatory role in angiogenesis early in embryogenesis. NRP-1 is important not only for 
neuronal development, but also for vascular formation (Kawasaki et al., 1999). NRP-1
-/- 
mice suffer from severe defects in the cardiovascular system in addition to a disorganized 
neural development, resulting in the death of homozygous embryos by embryonic day 14 
(Kawasaki  et  al.,  1999).  Studies  conducted  using  NRP-2
-/-  mice  indicate  NRP-2  is 
selectively required for the formation of small lymphatic vessels and capillaries during 
development  whereas  arteries,  veins  and  larger  collecting  lymphatic  vessels  develop 
normally (Yuan et al., 2002).  
1.5.5.1  VEGF-R1 signalling 
 
VEGF-R1, originally cloned from a placental cDNA library (Shibuya et al., 1990), is a 180 
kDa transmemebrane protein that binds VEGF, PIGF and VEGF-B (Park et al., 1994). In 
addition  to  endothelial  cells  VEGF-R1  is  also  expressed  on  monocytes,  oesteoblasts, 
macrophages,  pericytes,  haematopoietic  stem  cells,  vascular  smooth  muscle  cells  and 
colorectal tumour cells (Barleon et al., 1996; Zachary and Gliki, 2001; Ishida et al., 2001; 
Fan et al., 2005). The second Ig domain of VEGF-R1 is the major binding site for VEGF 
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2004). VEGF-R1 binds VEGF with at least 10-fold higher affinity than VEGF-R2 (Kd =10-
30 pM) (Ferrara and Davis-Smyth, 1997). However, the effects of VEGF-R2 activation on 
endothelial cells, such as those on cell survival and proliferation, can be induced only 
weakly or slightly by treatment with VEGF-R1-specific ligands. VEGF-R1 is a negative 
regulator of angiogenesis during early development, but seems to play a more prominent 
regulatory role in adult tissues. Under some circumstances, VEGF-R1 may transmit a pro-
survival signal in endothelial cells, possibly mediated by induction of the anti-apoptotic 
gene survivin (Adini et al., 2002). It has also been demonstrated that vascular permeability, 
which  is  largely  regulated  by  VEGF-R2  (discussed  in  detail  in  section  1.3.5.2.4),  is 
enhanced  by  activation  of  VEGF-R1  (Takahashi  et  al.,  2004).  VEGF-R1-blocking 
antibodies  have  been  demonstrated  to  prevent  the  migration,  but  not  proliferation,  of 
HUVEC  in  response  to  VEGF  (Kanno  et  al.,  2000).  In  addition,  VEGF-R1-mediated 
signalling appears to preferentially modulate the reorganization of actin via p38 MAPK, 
whereas  VEGF-R2  contributes  to  the  re-organization  of  the  cytoskeleton  by 
phosphorylating FAK and paxillin, suggesting a different contribution of the two receptors 
to the chemotactic response. Monocyte migration (Barleon et al., 1996), recruitment of
 
endothelial cell progenitors (Lyden et al., 2001), haematopoietic stem cell survival
 (Gerber 
et al., 2002), and release of growth factors from liver endothelial cells
 (LeCouter et al., 
2003) have also
 been shown to be mediated by VEGF-R1. 
VEGF-R1  signalling  is  of  particular  interest  in  relation  to  a  number  of  pathological 
disorders (Hiratsuka et al., 2001; Carmeliet et al., 2001). VEGF-R1-dependent induction of 
MMP-9
  expression  in  premetastatic  lung  endothelial  cells  and  macrophages
  has  been 
reported to promote lung metastasis (Hiratsuka et al., 2002). Moreover, it has been shown
 
that VEGF-R1 activates ERK1/2 and stress-activated protein kinase/c-Jun NH2-terminal 
kinase (Fan et al., 2005) and Src family kinases (Lesslie et al., 2006) to mediate growth 
and migration
 of human colorectal carcinoma cells. Furthermore, a recent study has shown
 
that activation of VEGF-R1 in breast cancer cells supports their
 growth and survival (Wu 
et al., 2006). An alternatively spliced form of VEGF-R1 that encodes a soluble truncated 
form of the receptor (sVEGF-R1), containing only the first six Ig domains, has been cloned 
from a HUVEC cDNA library (Ferrara and Davis-Smyth, 1997). sVEGF-R1 sequesters 
VEGF from signalling receptors and forms non-signalling heterodimers with VEGF-R2 
thus inhibiting VEGF activity (Kendall et al., 1996). Elevated plasma levels of sVEGF-R1 
have been  reported  in  individuals  with  cancer,  ischemia  and pre-eclampsia (Toi et al., 
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R1 in patients with pre-eclampsia are associated with decreased circulating levels of free 
VEGF and PlGF, resulting in general endothelial dysfunction (Maynard et al., 2003). 
1.5.5.2  VEGF-R2 signalling 
VEGF-R2 is a 230 kDa glycoprotein that binds VEGF (with high affinity Kd =75-125 pM) 
(Terman et al., 1992), VEGF-C, VEGF-D and VEGF-E (Takahashi and Shibuya, 2005). 
The binding site for VEGF has been mapped to the second and third Ig domains (Fuh et al., 
1998). It is generally accepted that VEGF-R2 is the primary mediator of VEGF signalling 
(Gille  et  al.,  2001).  In  addition  to  endothelial  cells,  haematopoietic  stem  cells, 
megakaryocytes, retinal progenitor cells, and vascular smooth muscle cells express VEGF-
R2. VEGF-R2, along with VEGF-R1, has also been identified in tumour cell lines, non-
small cell lung carcinomas, breast, neuroblastoma and gastric cancer cells (Neufeld et al., 
1999; Ishida et al., 2001; Price et al., 2001; Meister et al., 1999; Tian et al., 2001). The key 
role of VEGF-R2 in developmental angiogenesis and haematopoiesis is evidenced by a 
lack of vasculogenesis and failure to develop blood islands and organized blood vessels in 
VEGF-R2-null mice, resulting in death in utero between days 8.5 and 9.5 (Shalaby et al., 
1995).  VEGF-R2  is  accepted  as  the  major  mediator  of  the  mitogenic,  angiogenic  and 
permeability-enhancing effects of VEGF. Tyrosine autophosphorylation sites for human 
VEGF-R2 bound to VEGF are Y951 and Y996 in the kinase insert domain (Matsumoto et 
al., 2005), Y1054 and Y1059 in the kinase domain (Kendall et al., 1999; Dougher and 
Terman, 1999), and Y1175 and Y1214 in the C-terminal tail of VEGF-R2 (Takahashi et 
al., 2001). In addition Y1305, Y1309 and Y1319 in the C-terminal tail are though to be 
minor phosphorylation sites (Matsumoto et al., 2005). 
1.5.5.2.1  Cell proliferation 
Phosphorylation  of  tyrosine  Y1175  leads  to  activation  of  PLC-γ1  which  indirectly 
mediates  activation  of  the  PKC/Raf/MEK  signalling  pathway.  This  signalling  pathway 
(summarised  in  Figure  1.9)  represents  a  major  component  of  VEGF-stimulated  cell 
proliferation.  A knock in mutation of Y1173 in mice (corresponding to Y1175 in human 
VEGF-R2) to phenylalanine in the VEGF-R2 gene is embryonically lethal due to severe 
defects in endothelial and haematopoietic stem cells similar to those observed in VEGF-
R2-null mice (Sakurai et al., 2005). VEGF mutants that bind selectively to VEGF-R2 are 
fully active endothelial cell mitogens, whereas mutants specific for VEGF-R1 are devoid 
of such activity (Takahashi et al., 1999). The activation of the PI3K/p70 S6 kinase pathway 
by VEGF-R2 is also involved in VEGF-induced endothelial cell proliferation (Vinals et al., James A Reihill, 2009    Chapter 1, 74 
1999).  Puromycin-intensive  leucyl-specific  aminopeptidase  plays  a  crucial  role  in  the 
activation of this pathway via the binding and modification of PDK1 (Yamazaki et al., 
2004).  Various  other  downstream  mediators  of  VEGF-induced  angiogenic  signalling 
include DAG kinase α and serum response factor (Baldanzi et al., 2004), SREBP (Zhou et 
al.,  2004)  and  IQGAP1  (Yamaoka-Tojo  et  al.,  2004).  There  are  a  number  of  possible 
endogenous feedback inhibitors for VEGF-induced angiogenesis. Vasohibin and DSCR1 
are significantly induced by VEGF in endothelial cells (Watanabe et al., 2004; Hesser et 
al., 2004). Up-regulation of DSCR1 in endothelial cells inhibits the nuclear localization of 
NFAT,  proliferation  and  tube  formation  (Minami  et  al.,  2004).  A  naturally  occurring 
soluble truncated form of VEGF-R2 has been detected in mouse and human plasma (Ebos 
et al., 2004). Similar to sVEGF-R1, sVEGF-R2 (soluble VEGF-R2) may have regulatory 
consequences with respect to VEGF-mediated angiogenesis.  
1.5.5.2.2  Cell migration  
Phosphorylated  Y1175  creates  a  binding  site  for  Shb  (Holmqvist  et  al.,  2004)  which 
mediates  the  activation  of  PI3K  and  the  assembly  of  focal  adhesions,  thus  regulating 
VEGF-stimulated migration (Holmqvist et al., 2004). Y1214, is involved in activation of 
Cdc42  and
  MAPK  (Lamalice  et  al.,  2004),  a  pathway  which  also  contributes  to  the 
regulation of
 cell migration. Mice with a mutation of Y1212 (corresponding to Y1214 in 
human VEGF-R2) to phenylalanine are viable and fertile indicating Y1214 signalling is 
not essential for vascular development in mouse embryos (Sakurai et al., 2005). Another 
important  tyrosine  autophosphoylation  site  Y951  binds  and  mediates  tyrosine 
phosphorylation  of  the  T-cell-specific  adaptor  protein  (TSAd),  which  is  expressed  in 
endothelial  cells.  Y951-mediated  coupling  of  VEGF-R2  and  TSAd,  which  forms  a 
complex with Src when activated (Matsumoto et al., 2005), is critical for VEGF-induced 
cell migration and actin reorganization, but not for VEGF-induced cell proliferation of 
endothelial cells (Matsumoto et al., 2005). VEGF-R2 intracellular signalling for vascular 
endothelial cell migration is summarised in Figure 1.10.  
1.5.5.2.3  Cell survival 
VEGF-R2 also activates PI3K which results in increased levels PIP3 and the activation of 
several  important  intracellular  molecules,  including  PKB  and  the  small  GTP-binding 
protein Rac. The PKB pathway regulates cell survival by inhibiting involvement of pro-
apoptotic pathways, such as BAD and caspase 9 (Gerber et al., 1998b). However, it seems 
likely that another pathway may be involved, since the signal to activate PI3K by VEGF-James A Reihill, 2009    Chapter 1, 75 
R2 is usually relatively weak. Indeed it has been reported that the activation of VEGF-R2 
by VEGF results in the PI3K/PKB-dependent activation of several integrins, leading to 
enhanced cell adhesion and migration (Byzova et al., 2000). This synergic interaction with 
integrins  is  required  for  productive  signalling  from  VEGF-R2.  VEGF-R2  intracellular 
signalling for vascular endothelial cell survival is summarised in Figure 1.11. 
1.5.5.2.4  Vascular permeability 
VEGF mutants that bind selectively to VEGF-R2, unlike those for VEGF-R1, are fully 
active  permeability-enhancing  agents  (Takahashi  et  al.,  1999).  A  number  of  signalling 
mechanisms have been reported to underlie VEGF-stimulated vascular permeability. In 
mesenteric microvessels VEGF increases vascular permeability by activation of VEGF-R2 
on endothelial cells with subsequent activation of PLC. This causes increased production 
of DAG that results in influx of Ca
2+ (Bates and Harper, 2002). In mice deficient in Src 
family kinases (Src
-/- or Yes
-/-) VEGF-dependent vascular permeability is ablated (Eliceiri 
et al., 1999). Moreover, it seems that the activity of specific Src family kinases is essential 
for the VEGF-induced enhancement of vascular permeability through the disruption of the 
VEGF-R2/cadherin/catenin  complex  (Weis  et  al.,  2004b).  The  PKB  pathway,  which 
activates  eNOS  (Fulton  et  al.,  1999;  Dimmeler  et  al.,  1999),  thus  generating  NO  is 
recognised  as  another  important  mediator  of  VEGF-induced  vascular  permeability. 
Furthermore,  it  has  been  reported  that  inhibition  of  MAPK  activity  abrogates  VEGF-
induced vascular permeability in vivo and in vitro, thus suggesting a role for this kinase in 
the regulation of vascular permeability (Issbrucker et al., 2003).  
There  is  some  debate  as  to  whether  there  is  a link between  vascular permeability  and 
angiogenesis. Whilst the extravasation of proteins such as fibrin may act as a scaffold for 
endothelial cell proliferation and migration (Dvorak et al., 1987), growth factors such as 
bFGF, which are potent inducers of angiogenesis, have no effect on vascular permeability. 
Indeed vascular leakage is not necessarily accompanied by angiogenesis (Ferrara, 1995; 
Murata et al., 1992). It has also been reported that vascular permeability and angiogenesis 
are differentially regulated by members of the Src family, and furthermore it has been 
demonstrated  that  VEGF-vascular  permeability  signalling  may  be  interrupted  without 
affecting VEGF-stimulated angiogenesis (Eliceiri et al., 1999). 
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A number of reports have further indicated that the activation of VEGF-R2 also promotes 
lymphangiogenesis (Nagy et al., 2002; Hong et al., 2004). 
1.5.5.3  VEGF-R3 signalling 
VEGF-R3, a 170 kDa glycosylated protein was first cloned from human erythroleukemia 
cells and placental cDNA libraries (Galland et al., 1993). VEGF-R3, which binds VEGF-C 
and VEGF-D, is expressed on embryonic endothelial cells, though its expression levels 
decease with development and thus is restricted to lymphatic endothelium in adult tissues 
(Kaipainen  et  al.,  1995).  Several  tyrosine  residues  have  been  predicted  to
  become 
autophosphorylated  on  activation  and  dimerisation  of
  VEGF-R3  (Olsson  et  al.,  2006). 
However, a limited number of signalling effectors
 have been shown to act downstream of 
this  receptor.  Y1337  is
  required  for  Grb2  and  SHC-mediated  transforming  capacity  of
 
VEGF-R3 (Fournier et al., 1995). Moreover, VEGF-R3 mediates anti-apoptotic effects
 as 
well as proliferation and migration of lymphatic endothelial
 cells through PKB and the 
PKC-MAPK signalling cascade (Makinen et al., 2001). 
1.5.5.4  The neuropilins 
NRP-1, a cell-surface glycoprotein first identified as a semaphorin receptor involved in 
neuronal guidance (Neufeld et al., 2002), has also been identified  as an isoform-specific 
receptor for VEGF (Soker et al., 1998). NRP-1 is able to bind VEGF, VEGF-B, PlGF-2 
and some VEGF-E variants. NRP-2 which was identified based on sequence homology 
with NRP-1 (Neufeld et al., 2002) can bind VEGF, VEGF145, PlGF-2 and VEGF-C. The 
intracellular  domains  of  NRPs  are  not  sufficient  for  the  independent  transduction  of 
biological signals subsequent to semaphorin or VEGF binding. However, VEGF-induced 
proliferation and migration of cells expressing VEGF-R2 is enhanced in the presence of 
NRP-1. Recent studies have demonstrated that this effect is the result of the formation of a 
complex  between  VEGF-R2  and  NRP-1  (Whitaker  et  al.,  2001;  Soker  et  al.,  2002).     77 
 
Figure 1-8  Interactions of VEGF family members with their receptors 
The VEGF ligand family includes VEGF-A, -B, -C, -D, -E and PIGF, all of which bind in a specific manner 
to three different receptor tyrosine kinases, VEGF-R1, -2 and -3. Both PIGF and VEGF-B are selective 
ligands for VEGF-R1, whereas VEGF-A binds to both VEGF-R1 and VEGF-R2. VEGF-E is a selective 
ligand for VEGF-R2. VEGF-C and –D interact with both VEGF-R2 and VEGF-R3. Although both VEGF-
R1  and  VEGF-R2  are  expressed  in  the  vascular  endothelium,  their  angiogenic  activities  are  mainly 
transduced  through  VEGF-R2.  VEGF-R1  is  also  expressed  on  monocytes  and  macrophages,  and  its 
activation leads to cell migration. VEGF-R3 is expressed mainly in lymphatic endothelium and is involved in 
lymphangiogenesis. (Adapted from (Matsumoto and Mugishima, 2006). 
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Figure 1-9  VEGF-R2 signalling and vascular endothelial cell proliferation 
Ligand binding to the extracellular domain induced the dimerisation and autophosphorylation of specific 
intracellular tyrosine residues (Y951, Y1054, Y1059, Y1175 and Y1214). Phosphorylation of Y1175 creates 
a binding site for PLC-γ1 and leads to activation of the protein. PLC-γ1 activation results in the hydrolysis of 
PIP2  creating  IP3  and  DAG  which  stimulate  the  release  of  Ca
2+  from  internal  stores  and  activate  PKC 
respectively.  Activation of PKC plays a crucial role in VEGF mitogenic signalling via the raf-MEK-ERK 
pathway.  Ras-dependent  and  independent  pathways  have  been  reported  in  PKC-induced  Raf  activation. 
(Figure adapted from (Matsumoto and Mugishima, 2006) 
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Figure 1-10  VEGF-R2 signalling and vascular endothelial cell migration 
Activated VEGF-R2 is associated with adaptor proteins TSAd, Shb and Grb2 via Y951, Y1175 and Y1214, 
respectively. Phosphorylated TSAd binds to Src and regulates VEGF-induced actin reorganisation and cell 
migration. The PI3K/Rac/Rho pathway is thought to be downstream of TSAd. Other components implicated 
in VEGF-R2-dependent cytoskeletal regulation and cell migration include FAK and p38 MAPK. Activated 
Shb mediates VEGF-induced FAK phosphorylation followed by the recruitment of actin-anchoring proteins 
to focal adhesion plaque. VEGF-induced activation of p38 MAPK is required for Y1214 phosphorylation. 
Thus, multiple pathways appear to regulate endothelial cell migration. (Figure adapted from (Matsumoto and 
Mugishima, 2006). 
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Figure 1-11  VEGF-R2 signalling and vascular endothelial cell survival 
Activated PI3K induces PKB phosphorylation. The PKB pathway regulates cellular survival by inhibiting 
pro-apoptotic pathways, such as those involving BAD and caspase 9. Complex formation of VE-cadherin, 
VEGF-R2, β-catenin and PI3K in response to VEGF is required for PKD-dependent cell survival signalling. 
(Figure adapted from (Matsumoto and Mugishima, 2006). James A Reihill, 2009    Chapter 1, 81 
1.6 Project aim 
The overall objective of this project is to characterise the role of AMPK in human vascular 
endothelial  cell  function  in  response  to  VEGF  exposure.  Both  VEGF  and  AMPK  are 
important signalling molecules in the endothelium, and a number of reports demonstrate 
that activation of either has the potential to promote NO production.  
VEGF stimulates NO production, proposed to be a result of phosphorylation and activation 
of eNOS at Ser-1177, a site also phosphorylated after activation of AMPK in cultured 
endothelial cells. Therefore, whether AMPK, at least in part, underlies VEGF-stimulated 
NO production formed the initial basis of this study. 
As  reduced  NO  bioavailability  characterises  the  dysfunctional  endothelium,  a  disorder 
closely linked with the aetiology of type 2 diabetes, obesity and cardiovascular disease, the 
signal transduction pathways which regulate NO bioavailability, which are incompletely 
understood, are of particular clinical interest.     82 
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2.1 Materials 
2.1.1  General reagents 
Acros Organics (Loughborough, Leicestershire, UK) 
Glacial acetic acid (nitrogen-flushed), sodium nitrite (NaNO2), tetrasodium pyrophosphate 
(NaPPi) 
Alexis Biochemicals 
RHC-80267 (DAG lipase inhibitor) 
Beckman Coulter (High Wycombe, UK) 
Ultra-Clear™ ultracentrifuge tubes 
BOC gases, Manchester, UK 
N2 
Calbiochem (Nottingham, UK) 
A23187  (from  Streptomyces  chartreusensius),  L-NAME,  BAPTA-AM,  compound  C, 
DAG kinase inhibitor II (R-59949), OAG, SU1498, U73122 
Fisher Scientific UK Ltd (Loughborough, UK) 
Acetone,  dimethylsulpoxide  (DMSO),  ethanol,  D-glucose,  glycine,  NaOH,  Tris 
(hydroxylmethyl)-aminothane (Tris base) 
Fisons Scientific Equipment, Loughborough, Leicestershire, UK 
1,1,2-trichlorotrifluoroethane (arklone P) 
Formedium, Hunstanton, UK 
Bacto-agar, tryptone, yeast extract 
GE Healthcare UK Ltd (Little Chalfont, Buckinghamshire, UK) 
ECL HRP-linked secondary antibodies, prepacked glutathione sepharose 4B, Protein G 
Sepharose 4 Fast Flow 
Hopkin & Williams (Chadwell Heath,UK) James A Reihill, 2009     Chapter 2, 84 
Sodium azide (NaN3) 
Inverclyde Biologicals (Bellshill, Lanarkshire, UK) 
Nitrocellulose membrane (0.45 µm pore size) 
Invitrogen Ltd (Paisley, UK) 
AlexaFluor488-  and  alexaFluor  568-linked  secondary  antibodies,  MLV-RT,  One  Shot 
TOP10 Chemically Competent Cells, S.O.C medium  
Kodak Industrie (Chalon-sur-Saône, France) 
Kodak MXB film 
Melford Laboratories Ltd (Ipswich, UK) 
DTT, IPTG 
Millipore (formerly Upstate Biotech) (Livingston, UK) 
Streptavidin immobilised beads 
National Diagnostics (Hessle-Hull, UK) 
Scintillation fluid 
Neuro Probe, Inc., Gaithersburgh, MD, USA; via Receptor Technologies Ltd., 
Adderbury, UK 
Polyvinylpyrrolidone  (PVP)-free  polycarbonate  track-etch  (PCTE)  membranes  for 
migration assays (8 µm pore size) 
New England Biolabs (Hitchin, UK) 
Prestained protein marker 
Pepceutical Ltd (Nottingham, UK) 
SAMS peptide (HMRSAMSGLHLVKRR) 
Premier International Foods Ltd (Spalding, UK) 
Dried skimmed milk 
Promega (Southampton, UK) 
Taq DNA polymerase, molecular grade MgCl2, dATP, dCTP, dGTP, dTTP James A Reihill, 2009     Chapter 2, 85 
Qiagen (Crawley, West Sussex, UK 
DNase I 
RELIAtech GmbH (Braunschweig, Germany) 
VEGF-E 
Sartorius Biotech GmbH (Göttingen, Germany) 
Sterile syringe filters (0.2 µm) 
Schleicher & Schuell 
Protran nitrocellulose membrane, Whatman P81 chromatography paper 
Severn Biotech Ltd (Kidderminster, Worcester, UK) 
Acrylamide:bisacrylamide (37.5:1; 30 % (w/v) acrylamide) 
Sigma-Aldrich Ltd (Poole, Dorset, UK, Steinheim, Germany; Seelze, Germany; St 
Louis, MO, USA), including all Riedel-de-Haën chemicals 
AMP, ampicillin, 2-APB, APS, ATP, bromophenol blue, BSA, Comassie brilliant blue, 
fatty acid free BSA, CsCl, benzamidine, L-carnitine, coumaric acid, Dowex 1X8-200, D-
mannitol, DMSO,  EDTA, EGTA, gadolinium, glycerol, H3PO4, hexanucleotide primers, 
isopropanol,  L-carnitine,  L-NAME,  luminol,  lyzozyme,  methanol,  NaF,  NaHCO3, 
Na2HPO4,  NaH2PO4,  NaI  (nitrogen-flushed),  Na4VO3,  protein  G  peroxidase,  RT-PCR 
primers,  SBTI,  SDS,  TCA,  Triton  X-100,  trypan  blue,  tween-20,  Type  IV  collagen, 
U73122, VEGF, VEGF-B 
Tocris (Avonmouth,UK)            
STO-609 acetate      
Toronto Research Chemicals (Toronto, ON, Canada)   
AICAR   
VWR International (Lutterworth, Leicestershire, UK), including all BDH chemicals   
CaCl2  solution,  30%  (v/v)  H2O2,  HEPES,  KCl,  KH2PO4,  MgCl2,  NaCl,  Na2HPO4, 
NaH2PO4, Nickel  James A Reihill, 2009     Chapter 2, 86 
2.1.2  Kits 
Cell Biolabs (San Diego, USA) 
QuickTiter™ Adenovirus Titer Immunoassay Kit  
Promega (Southampton, UK) 
CellTiter 96® AQueous One Solution Cell Proliferation Assay Kit  
Qiagen (Crawley, West Sussex, UK) 
Qiafilter™ Plasmid Maxi Kit, RNeasy mini kit  
2.1.3  Specialist equipment and suppliers 
Analytix Ltd (Durham, UK) 
Sievers® Nitric Oxide Analyzer 280, exmire microsyringe and needles for NO analysis 
Beckman CoulterTM (High Wycombe, UK) 
OptimaTM XL-80K ultracentrifuge, SW40TI rotor 
Bio-Rad Laboratories (Hemel Hempstead, UK) 
Agarose gel (Mini-Sub/Wide Mini-Sub Cell GT), protein gel casting and Western blotting 
equipment (Mini Protean III)  
Herolab (Wiesloch, Germany) 
UVT-28 MP UV transilluminator 
Optika Microscopes (Ponteranica, Italy) 
XDS-1B light microscope 
Helena Biosciences (Sunderland, UK) 
Proteus thermal cycler 
Shimadzu Europa GmbH (Duisburg, Germany) 
UV-1201 spectrophotometer 
WPA (Cambridge, UK) 
S2000 spectrophotometer James A Reihill, 2009     Chapter 2, 87 
2.1.4  Radiochemicals 
GE Healthcare Life Sciences (Little Chalfont, Buckinghamshire) 
γ-[
32P]-ATP, [9,10(n)-
3H]-palmitic acid 
Perkin Elmer Life and Analytical Sciences (Beaconsfield, Buckinghamshire, UK) 
γ-[
32P]-ATP 
2.1.5  Tissue culture plasticware and reagents 
Becton Dickinson Biosciences (Oxford, UK) 
Corning cell culture flasks, 10 cm-diameter cell culture dishes and multiwell plates 
Corning, NY, USA 
CoStar 25 ml, 10 ml, 5 ml and 1 ml sterile pipettes, 75 cm
2 tissue culture flasks, 150 cm
2 
tissue culture flasks 
Invitrogen Ltd (Paisley, UK) 
FCS (EU origin), L-glutamine, Lipofectamine™2000, penicillin and streptomycin, trypsin 
(0.05 % (v/v) in 0.53 mM EDTA•4Na), zeocin, blastacidin 
Sigma-Aldrich Ltd (Poole, Dorset, UK) 
Tetracycline 
VWR International (Lutterworth, Leicestershire, UK) 
Falcon™ 10 cm-diameter cell culture dishes and multi-well plates 
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2.1.6  Cells and media 
Cell type & 
supplier 
Basal media & supplier  Additions for complete media 
formulation 
HEK293 
 
DMEM 
Invitrogen  
Catalogue # 41965 
5 % (v/v) FCS 
2 mM glutamine (final concentration) 
100 µg/ml streptomycin   
100 U/ml penicillin 
HeLa 
 
DMEM 
 
 
10 % (v/v) FCS 
2 mM glutamine (final concentration) 
100 µg/ml streptomycin 
100 U/ml penicillin 
HeLaLKB1-KD/WT 
(A generous gift 
provided by Prof. 
D. Alessi, 
University of 
Dundee) 
EMEM  
Lonza (Walkersville, MD, 
USA) 
Catalogue # BE12-611F 
 
10 % (v/v) FCS 
2 mM glutamine (final concentration) 
100 µg/ml streptomycin 
100 U/ml penicillin 
2 mM non-essential amino acids 
5 µg/ml blasticidin  
100 µg/ml zeocin 
HAEC 
Lonza,  
PromoCell 
(Heidelberg, 
Germany), 
TCS CellWorks 
(Botolph Claydon, 
UK) 
Large vessel endothelial cell 
basal medium 
TCS cellworks 
Catalogue # ZHM-2951 
Endothelial cell basal 
medium (EBM®-2) 
Lonza 
Catalogue # CC-3162 
Large vessel endothelial cell growth 
supplement (ZHS-8945) and antibiotic 
supplement (ZHR-9939) were added 
to ZHM-2951 
Bullet kit (growth factors) CC-3156 & 
CC-4176 were added to CC-3162 
 
Table 2-1  Cells and media 
Routinely used cell types and their associated basal and complete culture media formulations. 
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2.1.7  Antisera 
2.1.7.1  Primary antibodies for Western blotting 
Epitope  Host 
species 
Dilution  Source 
AMPKα1/ 
AMPKα2 
Sheep (P)  1:1000  in  1  % 
(w/v) MP 
A  generous  gift  from  Prof.  D.G. 
Hardie, University of Dundee (Woods 
et al., 1996) 
AMPK Thr-172  Rabbit (P)  1:1000  in  5  % 
(w/v) BSA 
Cell Signalling Technology (# 2531) 
ACC Ser-80  Rabbit (P)  1:1000  in  5  % 
(w/v) BSA 
Cell Signalling Technology (# 3661) 
ACC1/ACC2  Sheep (P)  1:1000  in  5  % 
(w/v) MP  
These were a kind gift from Prof. D.G. 
Hardie, University of Dundee  
CaMKKα  Mouse (M)  1:1000  in  5  % 
(w/v) MP 
Santa Cruz Biotechnology (# F-2 sc-
17827)  
CaMKKβ  Goat (P)  1:500  in  5  % 
(w/v) MP 
Santa  Cruz  Biotechnology  (  #  L:19: 
sc-9629) 
eNOS  Rabbit (P)  1:5000  in  1  % 
(w/v) BSA 
Sigma  (# N-2643) 
eNOS Ser-1177  Rabbit (P)  1:1000  in  5  % 
(w/v) BSA 
Cell Signalling Technology (# 9571) 
FLAG  Mouse (M)    1:1000  in  1  % 
(w/v) MP 
Sigma (# F-3165) 
GAPDH  (clone 
6C5) 
Mouse (M)  1:1500  in  5  % 
(w/v) MP 
Ambion (# 4300) James A Reihill, 2009     Chapter 2, 90 
PKB  Rabbit  (P)  1:1000  in  5  % 
(w/v) MP 
Cell Signalling Technology (# 9272) 
PKB Ser-473  Rabbit (M)  1:1000  in  5  % 
(w/v) BSA 
Cell Signalling Technology (# 4058) 
VEGF-R1  Mouse (M)  1:200  in  5  % 
(w/v) MP 
Abcam (# ab11934) 
VEGF-R2  Rabbit (M)  1:1000  in  5  % 
(w/v) BSA 
Cell Signalling Technology (# 2479) 
 
Table 2-2  Primary antibodies for Western blotting and their conditions of use 
Monoclonal (M) or polyclonal (P) antibodies are denoted in brackets. All BSA or MP solutions were made in 
TBST (made as described in section 2.2.1).  
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2.1.7.2  Secondary detection agents for Western blotting 
Linked 
molecule 
Epitope  Host 
species 
Dilution  Source 
HRP  Mouse IgG  Sheep  1:1000-1:2000 in 1 % 
(w/v) MP 
GE Healthcare (# NA931) 
HRP  Rabbit IgG  Donkey  1:1000-1:2000 in 1 % 
in (w/v) MP 
GE Healthcare (# NA934) 
HRP  Streptococcus 
sp. Protein G 
n/a  1:1000-1:2000 in 1 % 
(w/v) MP 
Sigma (# P8170) 
 
Table 2-3  Secondary detection agents for Western blotting  
Secondary detection agents for Western blotting and their conditions of use. 
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2.2 Buffers 
2.2.1  General buffers and solutions 
Unless stated all buffers and reagents were made up with distilled water 
Bradford’s reagent 
35 mg/L Coomassie brilliant blue, 5.0 % (v/v) ethanol, 5.1 % (v/v) H3PO4 
Bradford’s reagent was filtered and stored in the dark 
 
Earles-HEPES 
20 mM HEPES (pH 7.4), 5.5 mM glucose, 1.8 mM CaCl2, 0.8 mM MgSO4, 5.3 mM KCl, 
116 mM NaCl, 1 mM NaH2PO4 
 
Enhanced chemiluminescence (ECL) detection reagents 
Solution 1: 0.1 mM Tris-HCl (pH 8.5), 450 mg/L luminol in 2 % (v/v) DMSO, 130 mg/L 
coumaric acid in 1 % (v/v) DMSO 
Solution 2: 0.1 mM Tris-HCl (pH 8.5), 0.06 % (v/v) H2O2 
 
HEPES-Brij buffer 
50 mM HEPES-NaOH (pH 7.4 at 4°C), 1 mM DTT, 0.02 % (v/v) Brij-35 
 
HEPES-Brij buffer (high salt) 
50 mM HEPES-NaOH (pH 7.4 at 4°C), 1 mM DTT, 0.02 % (v/v) Brij-35, 850 mM NaCl 
 
Immunoprecipitation buffer 
50 mM Tris-HCl pH 7.4 (at 4°C), 150 mM NaCl, 50 mM NaF, 5 mM NaPPi, 1 mM 
EDTA, 1 mM EGTA, 1 % (v/v) Triton X-100, 1 % glycerol, 1 mM DTT, 1 mM Na3VO4, 
0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml SBTI 
 
Krebs-Ringer-HEPES (KRH) buffer 
20 mM HEPES-NaOH (pH 7.4), 119 mM NaCl, 5 mM NaHCO3, 5 mM glucose, 4.8 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 0.1 mM L-arginine 
 
KRH buffer (Ca
2+-free) 
20 mM HEPES-NaOH (pH 7.4), 119 mM NaCl, 5 mM NaHCO3, 5 mM glucose , 4.8 mM 
KCl, 1.2 mM MgSO4, 1.2 mM NaH2PO4, 0.1 mM L-arginine, 1 mM EGTA James A Reihill, 2009     Chapter 2, 93 
 
KRH buffer (High K
+) 
20 mM HEPES-NaOH (pH 7.4), 59.5 mM NaCl, 5 mM NaHCO3, 5 mM glucose,  64.3 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM NaH2PO4,  0.1 mM L-arginine 
 
Lysis buffer 
50 mM Tris-HCl (pH 7.4 at 4°C), 50 mM NaF, 1 mM NaPPi , 1 mM EDTA, 1 mM EGTA, 
1 % (v/v) Triton X-100, 250 mM mannitol, 1 mM DTT, 1 mM Na3VO4, 0.1 mM 
benzamidine , 0.1 mM PMSF, 5 µg/ml SBTI 
 
Phosphate-buffered saline (PBS) (pH 7.2) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 
 
Ponceau S stain 
0.2 % (w/v) Ponceau S, 1 % (v/v) acetic acid 
 
SDS-PAGE running buffer 
190 mM Glycine, 62 mM Tris, 0.1 % (w/v) SDS 
 
SDS sample buffer 
200 mM Tris-HCl  pH 6.8, 40 % (v/v) glycerol, 8 % (w/v) SDS, 0.4 % (w/v) bromophenol 
blue 
The above recipe for 4X SDS sample buffer was used neat, or diluted with distilled water 
to 2X or 1X working concentration as required. DTT was added to a final concentration of 
200 mM before use (i.e. 20 % (v/v) from 1 M stock). 
 
Tris-buffered saline + Tween-20 (TBST) 
20 mM Tris-HCl  (pH 7.4), 137 mM NaCl, 0.1 % (v/v) Tween-20 
 
Transfer buffer 
25 mM Tris base, 192 mM glycine, 20 % (v/v) ethanol 
 
2.2.2  Molecular biology solutions 
2YT media  
1.6 % (w/v) tryptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl 
2YT media was autoclaved before use 
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LB broth 
1 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl 
LB media was autoclaved before use 
 
6X DNA loading buffer 
0.5 % (w/v) bromophenol blue, 15 % (w/v) ficoll 
 
 
TAE buffer (50x)  
40 mM Tris, 1 mM EDTA, 5.71 % (v/v) glacial acetic acid 
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2.3 Molecular biology protocols 
2.3.1  Preparation of agar plates 
2 % (w/v) bacto-agar was added to 2YT media (as described in section 2.2.2), autoclaved 
and allowed to cool to 50ºC, prior to the addition of 50 µg/ml ampicillin (YT-amp). 2 % 
(w/v) bacto-agar was added to LB media (as described in section 2.2.2) containing 2 % 
(w/v)  glucose  and  50  µg/ml  ampicillin  (LB-amp).  In both  cases  media  were mixed to 
ensure equal distribution of antibiotic and approximately 25 ml poured per 10 cm
2 plate. 
The plates were left to set at room temperature then stored at 4ºC. 
2.3.2  Transformation of competent bacterial cells 
An aliquot of competent bacteria (One Shot TOP10 Competent Cells) was allowed to thaw 
on ice. 5-10 ng of DNA was then added to “TOP10” cells and incubated on ice for 15 
minutes. The cells were subjected to heat shock at 42ºC for 45 seconds and returned to ice 
for  1  minute.  250  µl  S.O.C.  medium  was  added  to  the  cells  and  placed  in  a  shaking 
incubator at 37ºC for 1h. 100 µl of the reaction was spread onto an agar plate (YT-amp) (as 
described  in  section  2.3.1)  and  incubated  upside  down  at  37ºC  overnight.  Plates  were 
removed the following day and stored at 4ºC. 
2.3.3  Preparation of plasmid DNA  
The Qiagen Qiafilter kit (as described in section 2.1.2) was used to produce large scale 
DNA samples. Purification of DNA was carried in accordance with the manufacturer’s 
instructions. A single colony from a freshly streaked plate was used to innoculate 50 ml 
2YT  media  containing  50  µg/ml  ampicillin  and  incubated  for  16h.  The  transformed 
bacteria were harvested by centrifugation at 1,370 x g for 20 minutes at 4ºC. All traces of 
media were removed and the bacterial pellet re-suspended in 10 ml of chilled buffer P1 (50 
mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/µl Rnase A). Cell lysis was achieved by the 
addition of 10 ml buffer P2 (200 mM NaOH, 1 % (w/v) SDS) for 5 minutes at room 
temperature. 10 ml of buffer P3 (3 M potassium acetate pH 5.5) was added to neutralise the 
reaction  and  the  solution  immediately  applied  to  a  QIAfilter  cartridge  and  left  for  10 
minutes at room temperature to settle. Meanwhile, a Qiagen tip 500 was equilibrated by the 
addition of buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0), 15 % (v/v) isopropanol). 
The DNA was eluted by the addition of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, James A Reihill, 2009     Chapter 2, 96 
15 % (v/v) isopropanol) to the tip. DNA was precipitated by the addition of 10.5 ml of 
isopropanol and pelleted by centrifugation at 1,370 x g for 1h at 4ºC. The DNA pellet was 
washed with 5 ml of room temperature 70 % (v/v) ethanol and then centrifuged at 1, 370 x 
g for 15 minutes at 4ºC. The supernatant was carefully removed and the pellet allowed to 
air dry prior to resuspension in 200 µl DEPC treated sterile water. 
2.3.4  Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance of a 1:100 
dilution of the sample at 260 nm. An A260 value of 1 unit was taken to correspond to 50 
µg/ml of double stranded DNA.  
2.3.5  RT-PCR 
2.3.5.1  RNA extraction 
HAEC were grown to 80-100 % confluency in 10 cm petri dishes. Total RNA was isolated 
according  to  the  Qiagen  RNeasy  Mini  Kit  centrifugation  protocol,  utilising  15  second 
centrifugation steps (at 16,352 x g in a bench top centrifuge) for the lysate application and 
wash steps, discarding the flowthrough between each step. Cells were lysed by addition of 
0.6 ml lysis (RLT) buffer and subsequently collected with a cell scraper. Lysates were 
homogenised by passing at least five times through a sterile 23-gauge needle and syringe. 
The lysate was mixed gently with an equal volume of 70 % (v/v) ethanol and applied to a 
RNeasy mini columns in 700 µl aliquots until the entire lysate volume had been passed 
over  the  column.  Columns  were  washed  with  350  µl  of  wash  buffer  1  (RW1)  before 
treatment with DNase I (Qiagen): 10 µl of DNase I stock premixed with 70 µl dilution 
buffer (RDD) were pipetted directly onto the silica gel membrane of each column and 
incubated at room temperature for 15 minutes. Columns were washed again with 350 µl 
buffer RW1 and were transferred to fresh 2 ml collection tubes prior to addition of 2 x 500 
µl wash buffer 2 (RPE). After discarding the flowthrough, columns were centrifuged at 
27,635 x g for 2 minutes to dry the RNeasy silica gel membrane and to eliminate any 
chance of accidental carryover of buffer RPE. Columns were transferred to fresh, 1.5 ml 
collection tubes and RNA was eluted with 30-50 µl RNase-free water by spinning for 1 
minute  at  27,635  x  g.  The  RNA  concentration  was  determined  at  A260  in  a  UV-1201 
spectrophotometer (Shimadzu) prior to storage at -80°C.  James A Reihill, 2009     Chapter 2, 97 
2.3.5.2  First strand cDNA synthesis 
For cDNA synthesis, total RNA extracted from HAEC was reverse transcribed using MLV 
RT as described by the manufacturer. In each reaction ~1 µg DNase-free RNA was added 
to 2.5 ul random hexamers (corresponding to 250 ng total), 1µl 10mM dNTP mix (10mM 
each dATP, dGTP, dCTP, dTTP) and sterile distilled water added to a final volume of 13 
µl. The mixture was heated at 65ºC for 5 minutes and after a quick chill on ice the contents 
were collected by brief centrifugation. 4 µl of 5X first strand buffer and 2 µL 0.1 M DTT 
was then added, the contents mixed and incubated at 37ºC for 2 minutes. 1 µl of M-MLV 
RT  was  then  added,  gently  mixed  and  incubated  at  25ºC  for  10  minutes.  A  further 
incubation period of 50 minutes at 37ºC was carried out. The reaction was inactivated by 
heating at 70ºC for 5 minutes. Resulting cDNA was stored at -20°C. 
2.3.5.3  PCR and gel resolution of PCR products 
In order to amplify cDNA from HAEC, the relevant human gene sequences were retrieved 
from  the  NCBI  database  (www.ncbi.nlm.nih.gov).  PCR  primers  were  designed  with 
“FastPCR” software and are detailed in table 2.4. 
For amplification of gene transcripts, equal volumes of cDNA (not exceeding 10 % of the 
total reaction volume of 50 µl) were mixed with a PCR mastermix (see below), and gene-
specific primers to the transcript of interest were added. The PCR mastermix contained 
equal amounts (0.2 µM each) of the gene-specific forward and reverse primer (Sigma-
Proligo), 1 µl of 10 mM dNTPs, 3 µl of 25 mM MgCl2, 5 µl of 10X Taq polymerase buffer, 
0.4 µl Taq polymerase (Promega), and water to a total volume of 50 µl. PCR reactions 
were carried out in a gradient thermocycler under the following conditions. Pre-heating (2 
minutes, 94°C), thirty five cycles of [denaturation (1 minute, 94°C), primer annealing (1 
minute,  58°C),  extension  (50  sec,  72°C)],  and final  extension  (5  minutes,  72°C). PCR 
products were stored at -20°C. Analysis of PCR products was performed on 2 % (w/v) 
agarose gels, resolved for 20-25 minutes at 100 V, using a Mini-Sub or Wide Mini-Sub 
Cell GT gel system (Bio-Rad). PCR products were mixed 5:1 with 6x DNA loading buffer, 
and equal volumes (18-20 µl/ lane) of PCR products were applied to the agarose gels.  
2.3.5.4  Visualisation of DNA bands 
DNA gels were visualised on a UVT-28 MP transilluminator (Herolab), photographed and 
scanned into Adobe Photoshop software using a Mercury 1200c scanner. James A Reihill, 2009     Chapter 2, 98 
Primer 
name 
5’-3’ Sequence 
of primer 
Tm (°C)  GC 
content 
(%) 
Product 
size (bp) 
TRPC3 
forward 
AAGCCCATCCCTGAGACGCATGAC  57  58   
TRPC3 
reverse 
GCTCAGAGTGAGACGCTTGCTG  62  59  400 
TRPC6 
forward 
GGATCTGACAACAGACTGGCTCAC  57  54   
TRPC6 
reverse 
TTGCTGGAGTTCAGACTGGCTA  54  50  435 
TRPC7 
forward 
CCGCCTACATGTTCAACGAGAAGG  61 
 
54   
TRPC7 
reverse 
GTGCACGATCTCATACTCCTGGCA  60  54  458 
18S  RNA 
forward 
AAA CGG CTA CCA CAT CCA AG  64.1  50   
18S  RNA 
reverse 
CGCTCCCAAGATCCAACTAC  63.9  55  250 
 
Table 2-4  Primer sequences for RT-PCR 
nts: nucleotides; Tm: melting temperature. Accession numbers; TRPC3 NM_003305, TRPC6  NM_004621, 
TRPC7 NM_020389. 
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2.4 Cell culture 
2.4.1  Cryopreservation of cells 
HEK293,  HAEC,  HeLa  or  HeLaLKB1-KD/WT  cells  (~80%  confluence)  cells  were 
cryopreserved after centrifugation at 146 x g for 5 minutes and re-suspended in 90 % (v/v) 
complete  medium  and  10 %  (v/v)  DMSO, by  overnight  incubation  in  a polycarbonate 
freezing container at -80°C. The following day, cells were transferred to liquid nitrogen for 
storage. 
2.4.2  Revival and culture of cryopreserved cells 
Aliquots of cryopreserved HAEC were rapidly thawed in a 37°C water bath. Cells were 
then added to complete cell medium pre-equilibrated in a humidified incubator containing 
5 % (v/v) CO2, 95 % (v/v) air, at 37°C. The cell suspension was divided equally between 
6-10  25  cm
2  cell  culture  flasks  and  incubated  at  37°C  in  a  humidified  incubator 
supplemented with 5 % (v/v) CO2, 95 % (v/v) air, at 37°C. Cell medium was replaced after 
24h,  and  every  48h  thereafter  with  fresh  complete  medium.  After  thawing  HeLa, 
HeLaLKB1-KD/WT and  HEK293  cells  were  divided  into  2-3  75  cm
2 flasks, but  otherwise 
treated as described above.    
2.4.3  Determination of endothelial cell phenotype of cultured HAEC 
In order to prevent differentiation from the endothelial phenotype of HAEC, only HAEC in 
passages  4-6  were  used  for  experiments.  To  assess  the  maintenance  of  the endothelial 
phenotype,  the  presence  of  the  endothelial  cell  marker  CD31  in  cultured  HAEC  was 
ascertained by immunocytochemistry. Dr Ian Montgomery (University of Glasgow) carried 
out these studies. For immunocytochemistry, HAEC were grown on coverslips and fixed 
with methanol for 10 minutes. After washing, the coverslips were attached to glass slides 
using vaseline and were circled using a Dako PAP pen to form a watertight seal. The cells 
were  rinsed  in  PBS  and  blocked  with  1:30  goat  serum  in  PBS.  Anti-CD31  primary 
antibody (1:40 dilution in PBS + 1 % (w/v) BSA) was incubated in a humidified chamber 
on an orbital shaker for 1h. After washing in PBS, the coverslips were incubated with 
biotinylated goat anti-mouse IgG (1:20 dilution in PBS + 1 % (w/v) BSA) for 30 minutes. 
After  thorough  washing  in  PBS,  cells  were  incubated  for  a  further  30  minutes  in 
ExtrAvidin Peroxidase (1:20 dilution in PBS + 1 % (w/v) BSA). Following washing in James A Reihill, 2009     Chapter 2, 100 
PBS, the AEC substrate reagent was prepared and incubated for 5-10 minutes. Coverslips 
were then rinsed with distilled water, stained with haematoxylin for 1 minute and rinsed 
gently. The coverslips were carefully removed from the glass slides and mounted on clean 
slides using Aquamount mounting medium and left to dry overnight. Stained cells were 
examined using a Zeiss Axiophot microscope and images were captured using a JVC video 
camera and AverCAP video card in a Viglen computer. The cytoplasm of CD31-positive 
cells was rose-red to brownish-red and the nucleus was stained pale blue/purple. As a 
negative control, HAEC were stained in the absence of primary antibody. 
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Figure 2-1  HAEC stained with anti-CD31 antibody and haematoxylin 
In order to confirm the endothelial phenotype of HAEC, immunocytochemistry was carried out by Dr Ian 
Montgomery as described in section 2.4.3. HAEC positive for the endothelial cell marker CD31 show red-
stained cytoplasm (panel A), while the cytoplasm of unlabelled control cells does not stain (panel B). Cell 
nuclei appear blue after staining with haematoxylin (both panels). James A Reihill, 2009    Chapter 2, 102 
2.4.4  Passaging of cells 
Cells were routinely subdivided 1/3-1/6 in 75 cm
2 tissue culture flasks. HeLa, HeLaLKB1-
KD/WT and HEK293 cells were subdivided 1/5-1/10 in 75 cm
2 tissue culture flasks. For 
passaging, cells (~80% confluence) were washed once in 2-4 ml of basal medium and 
detached with 1-2 ml trypsin (0.05 % (v/v) in EDTA). Cells were briefly incubated at 37°C 
until the cells fully detached upon tapping of the cell culture flask. Trypsin was neutralised 
by addition of 1-3 ml of complete medium. Cells were pooled in a 50 ml centrifuge tube 
and centrifuged at 146 x g for 5 minutes. The supernatant was aspirated and the cell pellet 
resuspended in 5 ml complete medium prior to dilution into an appropriate volume of 
complete medium. The cell suspension was divided between 75 cm
2 tissue culture flasks 
and 10 cm-diameter cell culture dishes and/or multiwell plates, as required. 
2.4.5  LKB1 kinase dead and LKB1 wild type expressing HeLa cell lines 
HeLa cells expressing the Tet-ON tetracycline repressor (Sapkota et al., 2002) were kindly 
provided by Professor Dario Alessi (University of Dundee). Kinase dead (HeLaLKB1-KD) or 
wild type (HeLaLKB1-WT) FLAG-epitope tagged LKB1 was induced in these cell lines by 
the addition of 1 µg/ml tetracycline for 24h prior to lysis. 
2.4.6  Transient transfection of HeLa cells 
VEGF-R1 and VEGF-R2 cDNA (Cheng et al., 2006; Fragoso et al., 2006) was kindly 
provided by Professor Segio Dias (Angiogenesis laboratory, CIPM, Lisbon, Portugal) and 
Professor David Bates (University of Bristol, UK) respectively. VEGF-R1 and VEGF-R2 
cDNA was transfected into HeLa cells using Lipofectamine™2000, in accordance with the 
manufacturer’s instructions. Cells were grown to 90-95 % confluency in 6-well plates in 
complete media containing no antibiotics. For each sample 4 µg of DNA was diluted in 
250 µl  of  Opti-MEM (Gibco  #  31985-047) reduced  serum  medium  and  gently mixed. 
Lipofectamine™2000 was mixed before use then 10 µl added to 250 µl of Opti-MEM and 
incubated for 5 minutes at room temperature. The diluted DNA was combined with the 
diluted  Lipofectamine™2000  and  incubated  for  20  minutes  at  room  temperature. 
Complexes were then added to each well containing cells and medium and incubated at 5 
% (v/v) CO2, 95 % (v/v) air, at 37°C for 24-36h prior to testing for transgene expression. 
Opti-MEM was exchanged for complete medium 6h after complexes had been added. James A Reihill, 2009     Chapter 2, 103 
2.4.7  Lysate preparation 
Unless otherwise stated, all treatments were carried out in duplicate for each experiment. 
Cells, stimulated as indicated in the Figure legends, were serum-starved by aspirating the 
cell culture medium, washing the cells once with 10 ml of fresh, pre-warmed KRH buffer 
and replacing it with 5 ml/10 cm dish of fresh KRH buffer. Cells were incubated for 2-3h 
at 37°C. Thereafter, the buffer was aspirated and dishes were placed on ice. To each dish, 
0.4 ml fresh, ice-cold lysis buffer was added and cells were scraped off using a cell lifter. 
Resulting  cell  lysates  were  transferred  to  pre-cooled  1.5  ml-microcentrifuge  tubes, 
vortexed  for  30  seconds  and  centrifuged  at  17,530  x  g  for  3  minutes  at  4°C.  Lysate 
supernatants were transferred to fresh, pre-cooled 1.5 ml-microcentrifuge tubes and stored 
at -20°C short-term or at -80°C long-term. The protein concentration of each sample was 
determined  by  spectrophotometric  analysis  at  595  nm  according  to  the  method  of 
(Bradford, 1976). Duplicates of 2 µg, 4 µg and 6 µg BSA were made up to 100 µl with 
H2O and utilised as reference standards. Duplicates of 5 µl from each sample were added 
to 95 µl distilled H2O. To all samples and reference standards, 1 ml Bradford’s reagent 
(made as described in section 2.2.1) was added and spectrophotometric analysis performed 
in  a  WPA  2000  spectrophotometer  within  10  minutes  of  reagent  addition.  The  mean 
absorbance  for  each  sample  duplicate  was  calculated  and  the  protein  concentration 
determined by comparison to the calculated mean A595/µg BSA derived from the linear 
portion of the BSA reference standard curve.  
2.4.8  Specific inhibitors 
A  number  of  specific  inhibitors,  added  to  HAEC  or  HeLa  cell  lines  prior  to  lysate 
preparation (as described in the figure legends), were used to determine the contribution of 
certain molecules in the VEGF-AMPK signalling cascade. Table 2.5 is an overview of 
these inhibitors. 
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Compound/formula  Description  References 
2-APB 
(C6H5)BOCH2CH2NH2 
Membrane-permeable  modulator  of 
intracellular  IP3-induced  calcium 
release. 
(Maruyama et al., 1997; 
Ascher-Landsberg et al., 
1999) 
Compound C 
C24H25N5O 
A cell-permeable compound that acts 
as a potent, selective, reversible, and 
ATP-competitive inhibitor of AMPK. 
Does  not  affect  the  activities  of 
ZAPK, Syk, PKCθ, PKA, or JAK3. 
(Zhou et al., 2001) 
L-NAME 
C7H15N5O4.HCl 
Cell permeable. More soluble analog 
of arginine and a competitive, slowly 
reversible inhibitor of eNOS. 
(Moore  et  al.,  1990; 
Moncada et al., 1991) 
PP1 
C19H19N5 
A potent and cell-permeable inhibitor 
of Src-family tyrosine kinases. 
(Bishop  and  Shokat, 
1999;  Bishop  et  al., 
2000;  Hanke  et  al., 
1996) 
R-59949 
C28H25F2N3OS 
Inhibits  DAG  kinase  in  isolated 
platelet  membranes  and  in  intact 
platelets  by  binding  to  the  catalytic 
domain. 
(de  Chaffoy  de  et  al., 
1989;  Rodriguez-
Linares et al., 1991).  
RHC-80627 
C20H34N4O4 
Selective  inhibitor  of diacylglycerol 
lipase activity. 
(Sutherland  and  Amin, 
1982) 
STO-609 
C19H10N2O3.C2H4O2` 
Selective,  cell-permeable  inhibitor  of 
CaMKKα/β;  competes  for  the  ATP-
binding  site.  Displays  >  80-fold 
selectivity  over  CaMKI,  CaMKII, 
CaMKIV,  MLCK,  PKC,  PKA  and 
MAPK. 
(Tokumitsu et al., 2002) James A Reihill, 2009     Chapter 2, 105 
SU1498  A  potent  and  selective  inhibitor  of 
VEGF-R2 that has a weak inhibitory 
effect on PDGFR, EGFR and HER-2 
kinases 
(Strawn et al., 1996) 
U73122 
C29H40N2O3.xH2O 
Acts as an inhibitor of agonist-induced 
phospholipase C activation in human 
platelets and neutrophils. 
(Thompson et al., 1991; 
Yule  and  Williams, 
1992; Stam et al., 1998) 
Wortmannin 
C23H24O8 
 
A  specific  irreversible  inhibitor  of 
PI3K catalytic activity. 
(Powis et al., 1994) 
 
Table 2-5  Specific inhibitors 
An overview of the actions of the specific inhibitors utilised in the present study. These agents are discussed 
in further detail in the subsequent results chapters as appropriate. 
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2.5 Recombinant AMPK adenovirus preparation 
Control  and  recombinant  adenovirus  expressing  dominant  negative  and  constitutively 
active AMPK, described previously in (Woods et al., 2000), were generous gifts from Dr. 
F. Foufelle, Centre Biomédical des Cordeliers, Paris.  
2.5.1  Propagation 
Thirty confluent 150 cm
2 flasks of HEK293 cells were infected with crude viral extract 
retained from previously infected HEK293 cells. Once the cytopathic effects of the virus 
had  caused  the  cells  to  detach  from  the  flasks,  cells  were  harvested  and  pelleted  by 
centrifugation at 146 x g for 5 minutes. The supernatant was removed and the cell pellet re-
suspended  in  10  ml  sterile  PBS  and  frozen  at  -20ºC,  ready  for  viral  harvesting  and 
purification. 
2.5.2  Purification 
Cell pellets were defrosted on ice and 10 ml of Arklone P was added and shaken for 10 
seconds. The adenovirus was centrifuged at 252 x g for 15 minutes at room temperature. 
The  top  layer  containing  the  adenovirus  was  extracted  and  purified  by  CsCl  density 
centrifugation. 2.5 ml of sterile CsCl was dissolved in 5 mM Tris-HCl, 1 mM EGTA pH 
7.8 at a density of 1.33 g/ml (0.44 g/ml CsCl) and added to a sterile Beckman Coulter 
Ultraclear™ centrifuge tube. 1.5 ml of sterile 1.45 g/ml CsCl (made as above by adding 
0.6 g/ml CsCl) was slowly added below the less dense CsCl layer. The clarified adenovirus 
was then carefully added to the top of the CsCl gradient and centrifuged in an Optima XL-
80K ultracentrifuge using a Beckman SW40TI rotor at 100,000 x g, 8ºC for 90 minutes 
with the deceleration set to zero resulting in the production of a translucent white band 
between  the  two  layers  of  CsCl,  representing  pure  adenovirus.  This  viral  band  was 
extracted into a sterile 2.5 ml syringe using a 21-gauge needle. The viral band was then 
transferred to a slide-a-lyzer dialysis cassette (Pierce) and dialysed in 500 ml cold 5 mM 
Tris-HCl, 1 mM EDTA buffer pH 7.8 overnight. The following day the virus was further 
dialysed for 2-4 hours against fresh 5 mM Tris, 1 mM EDTA buffer containing 10 % (v/v) 
glycerol, then removed, aliquoted and stored at -80ºC. James A Reihill, 2009     Chapter 2, 107 
2.5.3  Titration 
Purified  adenovirus  was  titered  using  the  Cell  Biolabs  QuickTiter™  Adenovirus  Titer 
Immunoassay Kit as recommended by the manufacturer. HEK293 cells were harvested and 
re-suspended in complete medium at 2.5x10
5 cells/ml. 1 ml was seeded in each well of a 
24 well plate and incubated in 5 % (v/v) CO2, 95 % (v/v) air, at 37°C for 1h. Immediately 
prior to infection a 10-fold serial dilution of viral sample from 10
-3 to 10
-7 was set up. 100 
µl of the viral sample, and a negative control, was added to duplicate wells. Infected cells 
were incubated in 5% (v/v) CO2, 95% (v/v) air, at 37°C for 2 days. Culture medium was 
removed from wells, infected cells fixed with 0.5 ml of cold methanol, then incubated at -
20ºC for 20 minutes. Fixed cells were washed 3 times with PBS then blocked with 1 % 
(w/v) BSA in PBS for 1h. Cells were then immunostained for 1h with 0.25 ml of α-hexon 
antibody (supplied). The hexon proteins are the largest and most abundant of the structural 
proteins  of  the  adenovirus  capsid.  After  3  PBS  washes  secondary  antibody  (HRP-
conjugated) was added for a further hour. Binding of the HRP-conjugated antibody was 
subsequently  detected  by  incubation  with  a  solution  of  the  HRP  substrate, 
diaminobenzidine  (DAB:  supplied).  DAB  undergoes  oxidative  polymerisation  in  the 
presence of HRP to produce a dark brown precipitate. Adenovirus-infected cells stained 
rapidly and were clearly visible under light microscopy as discrete brown patches in the 
cell monolayer. Positively stained cells were counted in ten fields at a virus dilution that 
gave 5-50 positive cells/field when viewed using a 10 x objective. The mean result was 
determined  and  used  to  calculate  the  number  of  infected  cells  per  ml  of  the  original 
adenovirus preparation to give a titre value in plaque forming units/ml (pfu/ml). 
2.5.4  Infection of cells with recombinant adenovirus 
HAEC  were  infected  with  25 pfu/cell  adenovirus  and  cultured  for  24h  prior  to 
experimentation, unless stated otherwise. Within 24h of infection with a GFP-expressing 
virus, the majority (>95 %) of HAECs expressed GFP. 
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2.6 Biochemical assays 
2.6.1  SDS-polyacrylamide gel electrophoresis and Western blotting 
2.6.1.1  SDS-polyacrylamide gel electrophoresis  
Protein samples (as described in section 2.4.7) were resolved by SDS-PAGE. Cell lysate 
samples were mixed 3:1 with 4X SDS-containing sample buffer and heated to 95°C in a 
heating block for 4-5 minutes. SDS-gels for cell lysates routinely consisted of 6-10 % 
(w/v) acrylamide resolving gels overlaid with 5 % (w/v) stacking gels. All gels were cast in 
Mini-Protean  III  gel  casting  equipment  (Bio-Rad).  Gel  lanes  were  loaded  with  equal 
amounts of protein (3-15 µg). Broad range pre-stained molecular weight markers (15 µl) 
(New England Biolabs) were added to at least one lane. Samples were resolved at 60 V 
until the samples had reached the resolving gel, then the voltage was increased to 150 V 
and the samples were resolved until the dye front had migrated the entire length of the gel. 
2.6.1.2  Western blotting and immunodetection of proteins 
Protein-containing samples were transferred from SDS-gels onto nitrocellulose membranes 
at 60 V for 2h, or at 40 mA overnight, using Mini-Protean II/III equipment (Bio-Rad). 
Membranes were briefly stained with Ponceau S to check for equal loading of the gels, and 
blocked for 1h in TBST containing 5 % (w/v) non-fat dried milk. Following brief washing 
in  TBST,  the  membranes  were  incubated  overnight  with  primary  antibody,  diluted  as 
shown in (2.1.7.1). All washes and incubation steps were carried out under agitation. After 
primary antibody probing, membranes were washed three times in TBST and incubated for 
1h in HRP-linked species-specific secondary antibodies, diluted 1:1000-1:2000 in TBST 
containing  1  %  (w/v)  milk  (for  primary  antibodies  raised  in  sheep,  a  HRP-conjugated 
protein  G  secondary  detection  agent  was  used  (2.1.7.2).  Following  three  washes  with 
TBST, 2 ml of each of the ECL reagents (as described in section 2.2.1) was added to each 
nitrocellulose membrane and incubated for 1 minute. Chemiluminescence was detected 
with a Kodak X-Omat using Kodak MXB blue-sensitive X-Ray film. In order to quantify 
phosphorylation levels of a protein, the Western blot band intensity of a phosphorylated 
protein, detected with a site-specific phospho-antibody, was measured and expressed as a 
ratio to the corresponding total protein within the same sample. James A Reihill, 2009     Chapter 2, 109 
2.6.1.3  Densitometric quantification of protein bands 
The antibody-detected bands on the developed film were scanned on a Mercury 1200c 
scanner, using Adobe Photoshop software. The intensity of the immunodetected protein 
bands on the film was measured using ImageJ software. 
2.6.2  NO assay 
2.6.2.1  NO measurement 
NO released from cells reacts with dissolved oxygen in the cell culture medium or buffer 
to form nitrate and, predominantly, nitrite. NO production by HAEC was hence analysed 
by a nitrite reduction method (described below) using a Sievers Nitric Oxide Analyzer 280 
(Figure 2.2). The NO analyser calculates the amount of NO produced by the cells from the 
amount of nitrite present in the cell culture supernatant sample. To set up the NO analyser 
for nitrite reduction, a reducing agent (composed of 5 ml nitrogen-flushed glacial acetic 
acid and 50 mg nitrogen-flushed NaI dissolved in 1.5 ml of de-ionised water) was added to 
the purge vessel and flushed with N2 gas to purge any traces of NO2
- from the vessel. After 
30 minutes of purging, the purge vessel was sealed with a septum and the reducing agent 
was refluxed under N2 gas. Prior to each experiment, a nitrite standard curve was prepared: 
From a standard solution of 100 mM NaNO2, serial dilutions of 50 µM, 10 µM, 1 µM and 
100 nM were prepared and injected into the purge vessel using an Exmire microsyringe. 
Under the nitrite-reducing conditions used, nitrite present in the standards was reduced to 
NO as shown in equation 1. The NO produced was then detected by the NO analyser and 
reacted  with  O2  to  produce  O3,  which  was  detected  by  chemiluminescence.  The 
chemiluminescence signal was converted to an electrical potential and displayed as mV by 
the NO analyser. The amount of NO produced by duplicates of each nitrite standard was 
recorded by the analyser and used to produce a calibration curve. After calculation of the 
standard curve, cell culture supernatant samples (prepared as described in 2.6.2.2) were 
injected into the purge vessel using an Exmire microsyringe. Samples were injected at 1 
minute intervals to allow the output curve to return to baseline. The output in mV was then 
related  to  the  amount  of  nitrite  present  in  the  sample  using  the  nitrite  standard  curve 
prepared on that day.     110 
I
- + NO2
- + 2H
+    NO + ½I2 + H2O 
Equation 2-1  Production of nitric oxide from nitrite 
The  chemical  reaction  between  sodium  iodide  and  acetic  acid  results  in  reducing 
conditions that cause the reduction of nitrite (NO2
-) to NO in the liquid sample injected 
into the Sievers NO meter purge vessel. 
 
 
 
 
 
 
Figure 2-2  The Sievers nitric oxide analyser 
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2.6.2.2  Preparation of cell culture supernatants for NO analysis 
HAEC cultured in 6-well plates were pre-incubated for 2h at 37 °C in 0.5 ml/well KRH 
buffer at 37°C. The medium was removed and replaced with 0.4 ml fresh KRH buffer in 
the  presence  or  absence  of  VEGF  (10 ng/ml),  wortmannin  (100 nM)  and/or  L-NAME 
(1 mM)  for  15 min.  The  medium  was  removed  and  refluxed  in  glacial  acetic  acid 
containing  NaI.  Under  these  conditions,  NO2
-,  a  stable  breakdown  product  of  NO,  is 
quantitatively
 reduced to NO. NO-specific chemiluminescence was then analyzed
 using a 
Sievers 280A NO meter (Figure 2.2). Values were corrected for NO2
-present in media in 
the  absence  of  cells,  and  the
  appropriate  control  experiments  were  performed  in  the 
presence  of  the  eNOS  inhibitor,  L-NAME.  NO  production  (adjusted  for  L-NAME-
insensitive production) is expressed per hour per well.
  
2.6.3  AMPK activity assay 
Total catalytic AMPK was immunoprecipitated from lysates and AMPK activity assessed 
by the incorporation of [γ-
32P]-ATP into a synthetic AMPK substrate, SAMS peptide. 
2.6.3.1  Immunoprecipitation of catalytic AMPK 
1ml  of  IP  buffer  was  added  to  10  µl  (per  sample)  protein  G-  Sepharose  beads  and 
centrifuged at 17,530 x g at 4ºC for 30 seconds. The supernatant was removed and the 
beads washed 3 times with IP buffer. 2 µg of AMPKα1 and α2 antibody (per sample) was 
added to 10 µl (per sample) of protein G-Sepharose slurry in IP buffer (50 % v/v) and 
rotated at 4ºC for 2-3h. Immune complexes were then isolated by brief centrifugation at 17, 
030 x g at 4ºC and washed 3 times with 1ml of IP buffer. 10 µl of the antibody-protein G-
Sepharose mixture (per sample) was added to cell lysates (150-200 µg protein), to which 
an appropriate amount of IP buffer was added leaving each with an equal final volume. 
Each sample was then rotated for 3h at 4ºC to allow antibody-antigen complexes to form. 
Samples were briefly centrifuged at 17,530 x g at 4ºC and pellets washed as follows: twice 
with 1 ml high salt IP buffer, twice with 1 ml IP buffer and once with 1 ml HBD buffer 
(buffers were made as described in section 2.2.1). After the final wash the supernatant was 
completely removed and the pellet stored at -20ºC. 
2.6.3.2  AMPK activity assay 
Immunoprecipitated AMPK pellets (as described in section 2.6.3.1) were re-suspended in 
20 µl of HBD buffer. 5 µl of this immunoprecipitate was added, along with 5 µl HBD, 5 µl James A Reihill, 2009     Chapter 2, 112 
1mM AMP and 5 µl 1mM SAMS peptide to a pre-chilled micro-centrifuge tube. 5 µl of 
0.2 µCi/µl [γ-
32P]-ATP made up in HBD, containing 1 mM ATP and 25 mM MgCl2, was 
then  added  to  each  sample  (giving  a  final  25  µl  volume).  Samples  were  assayed  in 
duplicate with an additional sample included where SAMS peptide was replaced with HBD 
and taken as a blank. All samples were incubated at 30ºC for 10 minutes on a vibrating 
platform. 15 µl from each sample was then removed and spotted onto a 1.5 cm x 1.5 cm 
square of phosphocellulose paper (P81,Whatman) which was dropped into 500 ml (1 % 
v/v) H3PO4 stopping the reaction. The squares were washed for ~20 minutes as follows: 
two water washes, one H3PO4 wash and then two final water washes. Squares were then air 
dried, added to 5 ml scintillation fluid and counted in a Beckman LS6500 scintillation 
counter. 5 µl of the [γ-
32P]-ATP mix was added to phosphocellulose paper and placed 
directly into 5 ml of scintillation fluid and measured to assess the total counts. 
2.6.4  LKB1 activity assay 
5 µg of α-LKB1 antibody (a kind gift from Prof. D.G Hardie, University of Dundee) added 
to HAEC lysate (100 µg protein) was adjusted to a final volume of 300 µl with lysis buffer 
and rotated overnight at 4ºC. 5 µl of protein G- Sepharose slurry made up in IP buffer (50 
% v/v) was then added to each lysates and mixed by rotation at 4ºC for 4h. After brief 
centrifugation 17,530 x g at 4ºC the pellet was washed 3 times in ice cold buffer (50 mM 
HEPES  pH  7.4,  1  %  Triton  X-100).  600  ng  of  recombinant  AMPKα1  kinase  domain 
(constructed  and  expressed  as  described  in  section  1.6.4.1)  was  added  to  the  LKB1 
immunoprecipitate in a total volume of 25 µL assay buffer (50 mM HEPES, 1 mM DTT, 
0.1 mM ATP, 5 mM MgCl2 and shaken at 37ºC for 30 minutes. Subsequently, the mixture 
was centrifuged (17,530 x g at 4ºC for 30 seconds) and the supernatant assayed for AMPK 
activity using the SAMS peptide substrate as described in section 1.6.3.2 
2.6.4.1  AMPKα1 kinase domain 
50 µl glycerol stock of E. coli (BL21) transformed with a plasmid encoding the kinase 
domain of the α1 AMPK subunit (Scott et al., 2002) was plated overnight (LB-amp) (plates 
described in section 1.3.1). A single colony was placed in 400 ml of LB broth (described in 
section 1.2.2) containing 2 % (w/v) glucose and ampicillin (50 µg/ml) until A600 reached 
0.4. IPTG was added to a final concentration of 1 mM, and the culture was incubated for a 
further three hours. The cells were harvested by centrifugation and purification was carried 
out at 4°C. Cell pellets were re-suspended in 8 ml of ice-cold lysis buffer (50 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 mM benzamidine, 0.1 mM PMSF, James A Reihill, 2009     Chapter 2, 113 
5 µg/ml SBTI, 1 mg/ml lysozyme). The suspensions were left on ice for 30 minutes, Triton 
X-100 added to 2 % (v/v), and the suspension vortex mixed for one minute. The lysate 
were clarified by centrifugation (45,000 x g for 1h at 4 °C). A pre-packed glutathione-
sepharose  column  (2  ml)  was  washed  with  six  volumes  of  lysis  buffer  and  the  lysate 
applied. The column was washed with ten volumes of lysis buffer containing 1 % (v/v) 
Triton X-100 and 1 M NaCl, followed by six volumes of lysis buffer without Triton X-100. 
The protein was eluted with 15 ml of elution buffer (50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, 1 mM DTT, 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml of SBTI, 
20 mM reduced glutathione). The eluate was concentrated by centrifugation in Vivaspin-4 
microconcentrators (Vivascience) (4200 x g for 3h at 4 °C). The protein was exchanged 
into kinase storage buffer (50 mM Na Hepes (pH 7.4), 50 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 0.1 mM benzamidine, 0.1 mM PMSF, 5 µg/ml of SBTI) and stored at −80 °C. 
2.6.5  Fatty acid oxidation assay 
Palmitate oxidation was measured on the basis of 
3H2O production as described previously 
(Moon and Rhead, 1987). In order to account for intracellular fatty acid pools, HAEC 
cultured in 12 well plates until 90-95 % confluent were pre-labelled with 2 µCi/ml [
3H]-
palmitic acid 24h prior to the start of the experiment (Dagher et al., 2001). The reaction 
mixture  was  prepared  by  adding  50  µCi  of  [
3H]-palmitic  acid  to  300  µl  of  2.2  mM 
unlabelled palmitic acid in absolute ethanol. After complete evaporation of the solvent 
under  N2  gas,  the  fatty  acid  was  re-suspended  in  300  µl  of  Earles-HEPES  solution 
containing 50 µM carnitine (Dagher et al., 2001) and 10 mg/ml fatty acid free BSA. The 
mixture was incubated at 37ºC for 30 minutes in a water bath and for a further 30 minutes 
with  sonication.  The  reaction  mixture  was  further  diluted  with  5.7  ml  Earles-HEPES 
(containing 50 µM carnitine) to a final concentration of 110 µM palmitic acid. HAEC were 
washed  twice  with  warm  PBS  before  being  pre-incubated  with  Earles-HEPES  for  30 
minutes. Blanks were set by incubating cells with 500 µl methanol for 3-5 minutes before 
the addition of the reaction mixture. HAEC were incubated with 500 µl of the reaction 
mixture, to which AICAR or VEGF was added, for 2 hours at 37ºC. At the end of the 
incubation period 
3H2O was separated from the unreacted substrate.  30 µl of 10 % (w/v) 
fatty acid free BSA was added to the reaction mixture and mixed. 50 µl of 72 % (w/v) 
TCA  was  then  added  to  each  sample,  mixed,  and  left  on  ice  for  10  minutes  before 
centrifugation  at  2000  x  g  for  10  minutes  at  4ºC.  The  supernatant  was  subsequently 
removed and the pH adjusted to 7-9 using 1 M NaOH. Each sample then was transferred to 
a  Dowex  1X8-200  ion  exchange  column  constructed  set  in  5  ml  syringes  (Becton James A Reihill, 2009     Chapter 2, 114 
Dickinson  Plastipak)  to  separate  residual 
3H2O.  Samples  were  eluted  with  2  ml  of 
deionised water and collected in scintillation vials to which 10 ml of scintillant was added 
before counting in a Beckman LS6500 scintillation counter.  
2.6.6  Proliferation assay 
HAEC proliferation was determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation assay kit. This is a colorimetric method for determining the number of viable 
cells  in  proliferation  assays.  The  reagent  contains  a  tetrazolium  compound  (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, 
inner salt;MTS) and an electron coupling reagent (phenazine ethosulphate; PES). The MTS 
tetrazolium compound is bio-reduced by cells into a coloured formazan product that is 
soluble in tissue culture medium. The quantity of the formazan product as measured by the 
absorbance at 490 nm is directly proportional to the number of living cells in culture. 
HAEC  were  cultured  in  complete  media  until  50-60  %  confluent  (96-well  plate)  then 
incubated  in  serum-free  HAEC  media  for  2h.  Media  was  subsequently  removed  then 
VEGF was added for 20 hours in basal endothelial cell media + 0.2 % FCS (no other 
growth factors were added) in the presence or absence of inhibitors. 20 µl of the AQueous 
one solution was then added directly to each well for 4 hours and the absorbance measured 
at  490  nM.  Wells  which  had  not  been  seeded  with  HAEC  were  taken  as  a  blank.  In 
experiments  where  AMPK  adenovirus  was  used HAEC  were  infected  for  24h prior to 
serum starvation.  
2.6.7  Migration Assay 
Migration  assays  were  performed  in  a  modified  Boyden  chamber  using  a  48-well 
chemotaxis chamber (Neuroprobe).  A PCTE membrane was coated with 100 µg/ml type 
IV collagen in serum free media containing 0.5 % BSA for 1h. The filter was placed over a 
bottom chamber containing VEGF (10 ng/ml) in serum free media containing 0.5 % BSA. 
HAEC (1x10
6cells/ml) were suspended in serum free media containing 0.5 % BSA and 50 
µl added to each well in the upper chamber. For experiments using AMPK adenovirus 
HAEC  were  infected  with  25 pfu/cell  adenovirus  for  24h before  experimentation.  The 
assembled chemotaxis chamber was incubated for 5h at 37°C with 5% CO2 to allow cells 
to  migrate  through  the  collagen-coated  polycarbonate  filter.  Non-migrated  cells  on  the 
upper surface of the filter were removed by scraping, and the filter subsequently stained James A Reihill, 2009     Chapter 2, 115 
with  crystal  violet  (made  up  to  0.5  %  w/v  in  20  %  methanol).  Migrated  cells  were 
quantified  by  counting  the  average  number  of  cells  from  3  different  fields  at  40X 
magnification. Each condition was performed in triplicate. 
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2.7   Statistical analysis 
The “two-sample Student’s t-test assuming unequal variance” (“Student’s t-test”) was used 
for the statistical analysis of data as indicated in the results sections. Statistical significance 
was defined by a two-tailed p-value of less than 0.05.     117 
 
3  AMPK MEDIATES VEGF-STIMULATED NO 
PRODUCTION James A Reihill, 2009    Chapter 3, 118 
3.1 Introduction 
VEGF,  a  well-known  angiogenic  factor  important  for  the  vascular  development  and 
maintenance of all mammalian organs (Breen, 2007), is a key regulator of endothelial cell 
function,  stimulating  differentiation,  survival,  migration,  proliferation,  and  vascular 
permeability of endothelial cells (Cross et al., 2003; Ferrara et al., 2003). VEGF binds to 
VEGF  receptor  tyrosine  kinases,  which  have been  demonstrated  to  stimulate a  diverse 
array of signalling pathways, including PLC-γ, PI3K and Src (Cross et al., 2003; Ferrara et 
al., 2003).  
NO,  synthesized  by  eNOS,  is  an  important  regulator  of  cardiovascular  homeostasis.
 
Endothelium-derived  NO  promotes  vasodilation  and  inhibits  platelet
  aggregation, 
leukocyte adherence, and vascular smooth muscle
 proliferation (Moncada et al., 1991). 
These  effects  exert  a  profound  influence
  on  blood  flow,  vascular  remodeling,  and 
angiogenesis.  Upon  VEGF  stimulation,  NO  is  rapidly  synthesized  in  the  endothelium 
(Gelinas  et  al.,  2002;  Papapetropoulos  et  al.,  1997;  Michell  et  al.,  1999);  a  response 
proposed  to  be  the  result  of  PI3K-mediated  activation  of  PKB,  which  directly 
phosphorylates and activates eNOS at Ser-1177 (Michell et al., 1999). However, VEGF-
stimulated NO production has been reported  as only partially sensitive to wortmannin, 
suggesting that VEGF-stimulated NO production is mediated by both PI3K/PKB and a 
PI3K-independent kinase (Papapetropoulos et al., 1997; Gelinas et al., 2002; Thuringer et 
al., 2002).  
In addition to PKB, AMPK has also been shown to phosphorylate and activate eNOS at 
Ser-1177 in endothelial cells in response to a range of agonists including AICAR, hypoxia, 
metformin, adiponectin and shear stress (Morrow et al., 2003; Chen et al., 2003; Nagata et 
al., 2003; Zou  et al., 2004; Zhang  et al., 2006). Furthermore, commonly used in vitro 
(endothelial cell migration and differentiation assays) and in vivo (blood vessel growth in 
mouse Matrigel plug implantation) angiogenesis models  (reviewed in (Auerbach et al., 
2003) and discussed further in section 5.1) suggest that AMPK mediates angiogenesis in 
response to adiponectin (Ouchi et al., 2004; Shibata et al., 2004) and hypoxia (Nagata et 
al., 2003). Thus, whether the angiogenic factor VEGF stimulates NO production, at least in 
part, through AMPK was determined in the present study. 
These  studies  were  conducted  using  commercially  available  HAEC  (human  aortic 
endothelial cells) (Section 2.1.6) as a model. These cells were routinely characterised by James A Reihill, 2009     Chapter 3, 119 
the  suppliers  using  immunofluorescent  staining  (positive  for  acetylated  low-density 
lipoprotein  and  von  Willebrand  factor,  and  negative  for  smooth  muscle  α/β  actin).  In 
addition, expression of the endothelial cell marker CD31 was confirmed in these cells (as 
described  in  section  2.4.3)  by  Dr  Ian  Montgomery,  University  of  Glasgow.  Previous 
studies conducted in our laboratory have demonstrated that acute incubation
 of HAEC with 
AICAR stimulates AMPK activity, eNOS Ser-1177 phosphorylation,
 and NO production, 
effects inhibited by the expression of a dominant-negative AMPK mutant (Morrow et al., 
2003).  
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3.2 Results 
Initially, the effect of VEGF treatment on AMPK activity was assessed in HAEC. Total 
AMPK  activity  was  assayed  in  HAEC  incubated  with  10  ng/ml  VEGF  for  various 
durations  after  immunoprecipitation  with  a  mixture  of  AMPK  α1  and  α2  specific 
antibodies. VEGF elicited a transient activation of AMPK in HAEC reaching maximal 
~2.8-fold stimulation after 5 minutes (Figure 3.1A). Thereafter AMPK activity returned to 
basal levels within 30 minutes (Figure 3.1A). Activation of AMPK by VEGF was dose-
dependent with a maximal (~2.5-fold) stimulation resultant from treatment with 10 ng/ml 
VEGF  (Figure  3.1B),  a  concentration  which  was  used  for  all  subsequent  experiments 
unless indicated otherwise.  
The  effect  of  VEGF  stimulation  on  the  AMPK  substrate  eNOS  was  subsequently 
determined.  VEGF  elicited  a  transient  phosphorylation  of  eNOS  at  Ser-1177,  which 
reached  maximal  ~3.6-fold  stimulation  after  5 minutes  (Figure  3.2).  Thereafter,  eNOS 
phosphorylation rapidly returned to basal levels (Figure 3.2). Activation of eNOS at Ser-
1177 by VEGF was dose-dependent with maximal stimulation (~3.6-fold) elicited by 10 
ng/ml VEGF (Figure 3.3).  VEGF was found to stimulate phosphorylation of eNOS at Ser-
1177 in a time- (Figure 3.2) and dose-dependent (Figure 3.3) manner, parallel with VEGF-
stimulated AMPK activation (Figure 3.1), suggesting a causal relationship.      121 
 
 
Figure 3-1  Effect of VEGF treatment on AMPK activity in HAEC 
HAEC  were  incubated  with  10  ng/ml  VEGF  for  various  durations  (A)  or  incubated  with  various 
concentrations of VEGF for 5 minutes (B) and lysates prepared. Total AMPK was immunoprecipitated from 
both sets of lysates using AMPK α1 and α2 specific antibodies then AMPK activity assessed (described in 
detail  in  section  2.6.3).  The  results  are  expressed  as  a  mean  ±  SD  %  basal  AMPK  activity  for  three 
independent experiments in each case. *p<0.01 relative to value in absence of VEGF.      122 
 
 
Figure 3-2  Time course: VEGF-stimulated phosphorylation of eNOS at Ser-1177 
Lysates, prepared from HAEC incubated with 10 ng/ml VEGF for the indicated durations, were subjected to 
SDS PAGE, transferred to nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-
eNOS and α-eNOS Ser-1177 resulted in a single band at ~140 kDa in both instances. (A) Representative 
immunoblots are shown in, repeated with similar results on 3 different samples of lysates. (B) Quantification 
of eNOS Ser-1177 phosphorylation using NIH image software. The results are expressed as the mean ± SD 
% basal eNOS phosphorylation for three independent experiments. *p<0.01 relative to value in absence of 
VEGF.      123 
 
 
Figure 3-3  Dose response: VEGF-stimulated phosphorylation of eNOS at Ser-1177 
HAEC  were  incubated  with  the  indicated  concentrations  of  VEGF  for  5  minutes  and  lysates  prepared. 
Lysates were subjected to SDS PAGE, transferred to nitrocellulose and probed with the antibodies indicated. 
Probing  of  lysates  with  α-eNOS  and  α-eNOS  Ser-1177  resulted  in  a  single  band  at  ~140  kDa  in  both 
instances. The intensity of the resultant bands was quantified using NIH image software. (A) Representative 
immunoblots  are  shown  and  repeated  with  similar  results  on  3  different  samples  of  lysates  which  are 
quantified in (B). Quantification of eNOS Ser-1177 phosphorylation was done using NIH image software. 
The  results  are  expressed  as  the  mean  ±  SD  %  basal  eNOS  phosphorylation  for  three  independent 
experiments. *p<0.01 relative to value in absence of VEGF. 
# p<0.05 relative to value in absence of VEGF.  James A Reihill, 2009    Chapter 3, 124 
In order to determine the role of AMPK in VEGF-eNOS signalling adenovirus-mediated 
gene transfer was used to express a mutant form of AMPK (Woods et al., 2000), that acts 
as  a  dominant  negative  inhibitor  of  endogenous  AMPK.  Aspartate  157  within  the  α 
subunit, which lies in the conserved DFG motif (subdomain VII in protein kinase catalytic 
subunits), has been shown as essential for MgATP binding in protein kinases (Johnson et 
al., 1996). Mutation of this residue to alanine (in either α1 or α2) yields an inactive kinase, 
but does not affect the binding of βγ subunits within the complex (Stein et al., 2000). This 
overexpressed mutant form competes with native α subunits for βγ binding thus eliciting its 
dominant negative effect as the intact heterotrimeric AMPK complex (αβγ) is essential for 
kinase activity. Infection of HAEC with this mutant (Ad.DN) significantly reduced VEGF-
stimulated phosphorylation of  eNOS  at Ser-1177 (Figure 3.4). Quantification of eNOS 
phosphorylation status in Ad.DN-infected cells revealed VEGF-stimulated phosphorylation 
at Ser-1177 was reduced by approximately ~70 % (Figure 3.4B).  
Pre-treatment of HAEC with STO-609 (described in table 2.5), a selective inhibitor of the 
upstream AMPK kinase CaMKK (Tokumitsu et al., 2002), that has been shown to inhibit 
thrombin-induced AMPK activation in the endothelium (Stahmann et al., 2006), abrogated 
VEGF-stimulated eNOS phosphorylation at Ser-1177 (Figure 3.5B), supporting a role for 
CaMKK-AMPK in the regulation of this event in HAEC.      125 
 
 
Figure 3-4  Effect  of  Ad.DN  on  VEGF-stimulated  phosphorylation  of  eNOS  at   
Ser-1177 
HAEC were infected with Ad.DN or a null AMPK adenovirus (Ad.Null). Subsequently, HAEC lysates were 
prepared from cells incubated in the presence or absence of 10 ng/ml VEGF. Lysates were resolved by SDS 
PAGE, transferred to nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-
eNOS and α-eNOS Ser-1177 resulted in a single band at ~140 kDa in both instances.  (A) Representative 
immunoblots are shown, repeated with similar results on 4 different samples of lysates. (B) Quantification of 
eNOS Ser-1177 phosphorylation from four independent experiments using NIH image software. *p<0.05 
relative to value in control virus-infected cells. These experiments were performed by Dr I. Salt.      126 
 
 
Figure 3-5  Effect of STO-609 on VEGF-stimulated phosphorylation of eNOS at 
Ser-1177 
HAEC were treated in the presence or absence of 10 ng/ml VEGF for 5 minutes after pre-incubation with   
25 µM STO-609 for 15 minutes and lysates prepared. Lysates were resolved by SDS PAGE, transferred to 
nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-eNOS and α-eNOS Ser-
1177 resulted in a single band at ~140 kDa in both instances.  (A) Representative immunoblots are shown, 
repeated  with  similar  results  on  4  different  samples  of  lysates.  (B)  Quantification  of  eNOS  Ser-1177 
phosphorylation from four independent experiments using NIH image software. *p<0.05 relative to value in 
the absence of STO-609.  James A Reihill, 2009    Chapter 3, 127 
To characterise whether VEGF-stimulated NO production was indeed mediated by AMPK, 
VEGF-stimulated  NO  production  was  assayed  in  HAEC  infected  with  Ad.DN.  VEGF 
treatment elicited a ~2.2-fold stimulation of NO production (Figure 3.7). In agreement with 
other studies, pre-incubation of HAEC with the PI3K inhibitor wortmannin incompletely 
but  significantly  reduced  VEGF  stimulated  NO  production  (~65  %)  (Figure  3.7),  at  a 
concentration that completely inhibited phosphorylation of PKB at Ser-473 (Figure 3.6). 
These  data  suggest  both  PI3K/PKB  and  a  PI3K-independent  kinase  mediate  VEGF-
stimulated NO production. Infection of HAEC with Ad.DN caused a ~40 % reduction in 
VEGF-stimulated NO production (Figure 3.7). Treatment of HAEC with Ad.DN alone was 
without  effect  on  basal  NO  production  (Figure  3.7).  In  the  presence  of  wortmannin, 
infection  with  Ad.DN  significantly  reduced  VEGF-stimulated  NO  production  to  basal 
levels (Figure 3.7), suggesting that AMPK, as well as PKB, contributes to the regulation of 
VEGF-stimulated NO production.  
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Figure 3-6  Effect  of  wortmannin  on  VEGF-stimulated  PKB  phosphorylation  at 
Ser-473 
Lysates were prepared from HAEC incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes 
after  pre-treatment  with  100  nm  wortmannin  for  40  minutes.  Lysates  were  subjected  to  SDS-PAGE, 
transferred to nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-PKB and α-
PKB Ser-473 resulted in a single band at ~60 kDa in both instances.  This experiment was performed by Dr I. 
Salt. 
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Figure 3-7  Effect of Ad.DN on VEGF-stimulated NO production 
HAEC  were infected  with  Ad.Null or  Ad.DN adenoviruses. Cells  were subsequently  incubated in KRH 
buffer in the presence or absence of 10 ng/ml VEGF and/or 100 nM wortmannin. After 15 minutes, medium 
was removed and assayed for L-NAME-sensitive NO2
- content. The data shown represent the means ± SD 
NO synthesis from nine independent experiments. *p<0.05 relative to value in Ad.Null-infected cells. These 
experiments were performed by Dr I. Salt. James A Reihill, 2009    Chapter 3, 130 
Endothelial cells express VEGF-R1 and VEGF-R2 (Zachary, 2003; Cross et al., 2003). 
Due to the obstruction of vessels by an overgrowth of endothelial cells VEGF-R1 deficient 
mice exhibit embryonic lethality (Fong et al., 1995). Interestingly however, deletion of the 
intracellular  domain  of  VEGF-R1  is  compatible  with  normal  vascular  development 
(Hiratsuka et al., 1998; Barleon et al., 1996). As a result of these findings it has previously 
been postulated that VEGF-R1 acts as  a decoy, binding and neutralising VEGF in the 
absence  of  catalytic  activation.  Indeed  the  majority  of  known  biological  responses  of 
VEGF  in  endothelial  cells
  are  reported  to  be  mediated  by  the  activation  of  VEGF-R2 
(Cross et al., 2003; Zachary, 2003).  
The VEGF-R2 specific inhibitor SU1498 (described in table 2.5) was used to assess the 
role of this receptor subtype in VEGF-mediated AMPK activation in HAEC. SU1498 is a 
small molecule reported to specifically inhibit the enzymatic activity of VEGF-R2 (Strawn 
et  al.,  1996).  The  agent  has  been  shown  to  act  as  an  angiogenesis  inhibitor,  as 
demonstrated by its activity in the chorioallantoic membrane (CAM) assay and in an in 
vivo VEGF-induced permeability assay (Strawn et al., 1996; Jin et al., 2002). Angiogenesis 
assays are discussed further in section 5.1; for review see (Auerbach et al., 2003)). SU1498 
(low µM range) has been shown to inhibit endothelial VEGF signalling in several studies 
including (Xu et al., 2006; Feliers et al., 2005; Rajesh et al., 2005). Perhaps surprisingly, 
pre-treatment of HAEC with 5 µM SU1498 stimulated AMPK activity ~ 2.8-fold above 
basal even in the absence of VEGF treatment (278 ± 42 %, n=4, p<0.05) (Figure 3.8). 
Stimulation with VEGF did not significantly increase AMPK activity in the presence of 
SU1498 (Figure 3.8). 
However, as highlighted in section 1.5.5.1, a number of reports suggest VEGF-R1 may 
play a significant role, particularly in adult endothelia (Ahmed et al., 1997; Kanno et al., 
2000; Knight et al., 2000) Intriguingly, one report suggested VEGF-mediated NO synthesis 
is driven through VEGR-R1 in endothelial cells (Bussolati et al., 2001) Thus, it remained 
possible  that  either  VEGF-R1  or  VEGF-R2  may  be  responsible  for  mediating  the 
stimulation  of  AMPK/eNOS/NO  production  in  response  to  VEGF  treated  HAEC.  As 
described in section 1.5.3 and Figure 1.8 VEGF-B is a selective ligand for VEGF-R1, 
whereas VEGF-E is selective for VEGF-R2. In a preliminary experiment, HAEC treated 
with either VEGF-B or VEGF-E resulted in an increase in AMPK activity 174 ± 16 % and 
193 ± 9 % respectively compared to vehicle treated controls 100 ± 40 % (Figure 3.9), 
indicating that activation of either receptor alone has the potential to stimulate AMPK.  James A Reihill, 2009    Chapter 3, 131 
To  further  assess  the  role  of  individual  VEGF  receptor  subtypes,  HeLa  cells  were 
transfected with either receptor subtype, treated with VEGF and ACC phosphorylation 
determined as a measure of AMPK activity. As highlighted in section 1.3.1 and Figures 
1.3-1.6  ACC  is  a  major  substrate  for  AMPK  important  in  the  regulation  of  fatty  acid 
metabolism. 
Neither  endogenous  VEGF-R1  (data  not  shown)  nor  VEGF-R2  (Figure  3.10A)  was 
detected in HeLa lysates when probed with the appropriate receptor specific antibodies. 
VEGF-R2 was successfully transfected into HeLa cells (Figure 3.10A), whereas probing 
with a VEGF-R1 specific antibody failed to detect the receptor in HeLaVEGF-R1 or HAEC 
lysates  (data  not  shown).  Although  modest,  VEGF  treatment  was  found  to  increase 
phosphorylation  of  ACC  at  Ser-80  in  mock  transfected  cells  (Figure  3.10C),  thus 
suggesting, whilst not detected in the present study, an endogenous expression of VEGF 
receptor  may  be  present.  In  the  absence  of  VEGF  treatment  there  appeared  to  be  an 
increase in phosphorylation of ACC at Ser-80 in HeLaVEGF-R1 (136 ± 17.9 %, n=3, p>0.05) 
and  HeLaVEGF-R2  transfected  cells  (157  ±  26  %,  n=3,  p>0.05)  in  comparison  to  mock 
transfected  controls  (Figure  3.10C).  Similarly,  in  the  presence  of  VEGF  treatment, 
HeLaVEGF-R1 (167 ± 28 %, n=3) and HeLaVEGF-R2 (174 ± 26 %, n=3) both demonstrated a 
marked, but non-significant increase in phosphorylation of ACC at Ser-80 in comparison 
to mock transfected cells (111 ± 2 %, n=3) (Figure 3.10C).     132 
 
Figure 3-8  Effect of SU1498 on VEGF-stimulated AMPK activity 
HAEC were incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes after pre-treatment with   
5 µM SU1498 for 25 minutes and lysates prepared. Total AMPK  was immunoprecipitated from HAEC 
lysates (200 µg) and AMPK activity assessed. The results are expressed as a mean ± SEM % basal AMPK 
activity  for  four  independent  experiments.  *p<0.05  relative  to  value  in  absence  of  SU1498.  These 
experiments were performed in collaboration with Dr I. Salt. 
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Figure 3-9  Effect of receptor specific VEGF subtypes on AMPK activity 
HAEC were incubated with 10 ng/ml VEGF, VEGF-B or VEGF-E for 5 minutes and lysates prepared. Total 
AMPK was immunoprecipitated from HAEC lysates (200µg) and AMPK activity assessed. The results are 
expressed as a mean ± SEM % basal AMPK activity for one experiment carried out in duplicate.  
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Figure 3-10  Effect of VEGF receptors in HeLa cells 
(A) Lysates were prepared from HeLa cells transfected with mock, VEGF-R1 (R1) or VEGF-R2 (R2) DNA 
(as  described  in  section  2.4.6).  A  lysate  was  also  prepared  from  untransfected  HAEC.  Lysates  were 
subsequently subjected to SDS PAGE, transferred to nitrocellulose and probed with the antibody indicated. 
Probing of lysates with α-VEGF-R2 resulted in two distinct bands at ~210 and 230 kDa. (B) HeLa cells were 
transfected with mock, R1 or R2 DNA and subsequently treated in the presence and absence of 10 ng/ml 
VEGF  for  5  minutes  and  lysates  prepared.  Lysates  were  then  subjected  to  SDS  PAGE,  transferred  to 
nitrocellulose and probed with the antibodies indicated. Representative immunoblots are shown, repeated 
with similar results on 3 different samples of lysates quantified in (C). The results are expressed as the means 
± SEM % basal eNOS phosphorylation for three independent experiments.  *p<0.05 relative to  value in 
absence of VEGF. James A Reihill, 2009    Chapter 3, 135 
3.3 Discussion 
A central finding of the present study is the identification of VEGF as a novel activator of 
AMPK. Physiological concentrations of VEGF stimulate AMPK in a time- (Figure 3.1A) 
and dose-dependent manner (Figures 3.1B). The magnitude of VEGF-stimulated AMPK 
activity was found to be similar to that reported in other studies in response to a number of 
other stimuli (Morrow et al., 2003; Dagher et al., 2001; Zou et al., 2004; Zou et al., 2002). 
Furthermore, the effect of VEGF was specific to endothelial cells as VEGF had no effect 
on fibroblasts which do not express VEGF receptors (I.Salt, personal communication). 
At  the  start  of  this  work,  one  study  had  examined  the  effect  of  VEGF  on  AMPK 
phosphorylation in HUVEC (Nagata et al., 2003). Stimulation of HUVEC for 6h had no 
effect on AMPK phosphorylation (Nagata et al., 2003), in agreement with the present study 
in which VEGF-stimulated AMPK activity returned to basal levels within 30 minutes. In 
contrast, it has also been reported by another group that stimulation of BAEC with VEGF 
for 10 minutes was without effect on AMPK or ACC phosphorylation at Thr-172 or Ser-79 
respectively (Zou et al., 2003). In the current study, VEGF significantly stimulated AMPK 
activity after incubation for 5 minutes, and returned to basal levels within 15 minutes. 
Thus, it is possible that by the time Zou and colleagues had sampled these cells VEGF-
stimulated AMPK activity had returned to basal levels. It is also worth noting that different 
methods  to  assess  AMPK  activity  were  utilised  in  the  two  studies.  In  the  current 
investigation  AMPK  activity  was  assayed  using  kinase  assays  whereas  AMPK 
phosphorylation by Western blotting was used by (Zou et al., 2003). Indeed, a more recent 
study  conducted  in  BAEC  has  demonstrated  that  VEGF  (10  ng/ml)  increased  AMPK 
phosphorylation  within  1  minute  of  agonist  addition,  reaching  a  maximum  ~2.5-fold 
increase by 5 minutes, with a gradual return to basal levels within ~30 minutes (Levine et 
al., 2007). 
Previous studies have proposed that VEGF-stimulated eNOS phosphorylation at Ser-1177 
is mediated by PI3K/PKB (Gelinas et al., 2002; Fulton et al., 1999; Michell et al., 1999), 
yet complete inhibition of PKB with the PI3K inhibitor wortmannin only partially inhibited 
VEGF-stimulated NO production (Papapetropoulos et al., 1997; Thuringer et al., 2002; 
Gelinas et al., 2002). Consistent with these observations, in the present study wortmannin 
significantly but incompletely (~65 %) reduced VEGF-stimulated NO production (Figure 
3.6), at a concentration that completely inhibited PKB phosphorylation at Ser-473 (Figure 
3.6A).  These  data  suggest  that  both  PI3K/PKB  and  a  PI3K-independent  mechanism James A Reihill, 2009    Chapter 3, 136 
mediate VEGF-stimulated NO production. Direct activation of AMPK has previously been 
shown to stimulate eNOS at Ser-1177 in HAEC (Morrow et al., 2003), and  adenoviruses 
expressing dominant negative AMPK or dominant negative PKB have been demonstrated 
to inhibit VEGF-stimulated migration, eNOS Ser-1177 phosphorylation and tubulogenesis 
under conditions of hypoxia in endothelial cells (Nagata et al., 2003). Under normoxic 
conditions however, the dominant negative AMPK adenovirus was without effect (Nagata 
et al., 2003). In the present study, VEGF was found to stimulate phosphorylation of eNOS 
at Ser-1177 in a time- (Figure 3.2) and dose- dependent manner (Figure 3.3), concomitant 
with AMPK activation (Figure 3.1), suggesting that this phosphorylation may be mediated 
by AMPK in HAEC. Indeed, infection of HAEC with Ad.DN or pre-treatment with the 
CaMKK  inhibitor  STO-609  significantly  inhibited  VEGF-stimulated  eNOS 
phosphorylation (Figures 3.4 and 3.5 respectively), and moreover Ad.DN infection resulted 
in  a  significant  (~40  %)  reduction  in  NO  production  (Figure  3.7).  In  the  presence  of 
wortmannin, infection with Ad.DN significantly reduced VEGF-stimulated NO production 
to basal levels (Figure 3.7). Together these data, unlike those reported by (Nagata et al., 
2003), demonstrate both PKB and AMPK, in HAEC at least; mediate VEGF-stimulated 
phosphorylation of eNOS at Ser-1177 and NO production under normoxic conditions.  
A number of recent reports have also provided evidence which supports the finding that 
AMPK and PKB are both important molecules which regulate VEGF-stimulated eNOS 
activation.  Youn  and  coworkers  have  demonstrated  that  inhibition  of  AMPK  using 
compound C completely attenuates VEGF-stimulated NO production, while wortmannin 
elicits  a  similarly  potent  effect,  suggesting,  in  BAEC  at  least,  there  is  some  crosstalk 
between  these  pathways  (Youn  et  al.,  2008).  Another  study  also  conducted  in  BAEC 
suggests Rac1 may act as a molecular link between AMPK and PKB (Levine et al., 2007). 
In the present study as incubation of HAEC with wortmannin completely inhibits PKB 
phosphorylation  (Figure  3.6)  without  altering  AMPK  activity  (Figure  4.1),  AMPK 
activation is not downstream of PI3K in response to VEGF in HAEC. It remains possible 
that  AMPK  lies  upstream  of  PKB  in  VEGF-stimulated  eNOS  phosphorylation,  as  is 
reported  in  BAEC  (Levine  et  al.,  2007),  but  this  seems  unlikely  as  previous  work 
conducted in HAEC reported infection with dominant negative AMPK adenoviruses did 
not alter PKB phosphorylation (Morrow et al.,  2003).  Interestingly, a  recent study has 
demonstrated  that  PKB  and  AMPK  act  as  two  mutually  independent  kinases  which 
regulate ghrelin-mediated eNOS signalling (Xu et al., 2008). It may be the case that a 
similar mechanism underlies VEGF-eNOS/NO signalling in HAEC.  James A Reihill, 2009    Chapter 3, 137 
SU1498  has  been  reported  as  a  specific  inhibitor  of  VEGF-R2.  Surprisingly,  pre-
incubation of HAEC with the VEGF-R2 inhibitor SU1498 stimulated AMPK activity even 
in  the  absence  of  VEGF  treatment  (Figure  3.8).  Stimulation  with  VEGF  did  not 
significantly increase AMPK activity in the presence of SU1498 (Figure 3.8). SU1498 has 
previously  been  shown  to  inhibit  VEGF-stimulated  migration  and  tubulogenesis  of 
HUVEC (Boguslawski et al., 2004). However it was found that SU1498 also inhibited 
tubulogenesis of HUVEC in response to spingosine 1-phosphate, basic fibroblastic growth 
factor  and  hepatocyte  growth  factor  (Boguslawski  et  al.,  2004).  In  addition  SU1498 
stimulated  the  accumulation  of  phosphorylated  forms  of  ERK1/2  but  blocked  ERK1/2 
activity in the presence of VEGF (Boguslawski et al., 2004). These data and the finding 
that SU1498 increases AMPK activity in the present investigation challenge the specificity 
of SU1498 as a VEGF-R2 inhibitor.  
Further experiments were undertaken to determine the role of VEGF-R1 and VEGF-R2 in 
VEGF-mediated AMPK activation. Although not statistically significant (p>0.05), even in 
the absence of VEGF treatment there seemed to be a substantial increase in basal ACC 
phosphorylation in HeLa cells transfected with both VEGF-R1  and VEGF-R2 (Figures 
3.10B and C). It is well documented that tumour cell lines, including HeLa, produce VEGF 
(Asano et al., 1999; Kondo et al., 1993).  Indeed, VEGF was first described as a factor 
secreted by a hepatocarcinoma cell line that increased dye extravasation into the skin of 
guinea pigs (Senger et al., 1983). Therefore it is perhaps not surprising that VEGF receptor 
transfection resulted in increased ACC phosphorylation even in the absence of exogenous 
VEGF application. VEGF treatment increased phosphorylation of ACC at Ser-80 in mock 
transfected  cells  (Figure  3.10C)  suggesting  an  endogenous  expression  of  VEGF 
receptor(s). It has been reported previously that HeLa cells express cell surface VEGF 
receptors  (Neufeld  et  al.,  1994).  The  VEGF  receptor  subtype(s)  responsible  for  this 
endogenous activation was undetermined in the present study. Neither VEGF-R1 (data not 
shown) nor VEGF-R2 was detected in HeLa lysates when probed with the appropriate 
receptor specific antibodies (Figure 3.10A). The VEGF-R2 antibody did detect the receptor 
in HeLaVEGF-R2 and in a HAEC lysate. Notably, the VEGF-R1 antibody failed to detect the 
receptor in HeLa cells, HeLaVEGF-R2 and in lysates made from various endothelial cell lines 
(data not shown). It remains possible that VEGF receptors are expressed in HeLa cells 
below the detection level of the antibodies used.  Perhaps more suitable antibodies or an 
alternative approach such as RT-PCR to confirm VEGF receptor expression may be of 
value.  James A Reihill, 2009    Chapter 3, 138 
A third VEGF receptor subtype, VEGF-R3, which although primarily expressed in the 
lymphatic endothelium, has been reported in HUVEC, HDMEC and vascular endothelial 
cells in vivo (Makinen et al., 2001). This receptor subtype has also been demonstrated in 
HeLa cells (Shi et al., 2007). As VEGF activates the VEGF-R1 and VEGF-R2 (Neufeld et 
al., 1999), but not the VEGF-R3, subtype which is specifically activated by VEGF-C and 
VEGF-D (Neufeld et al., 1999), it is unlikely that any effects seen in response to VEGF in 
this  study  can  be  attributed  to  this  receptor.  It  was  further  observed  that  in  both  the 
presence  and  absence  of  VEGF  treatment  there  was  an  increase  in  ACC-Ser-80 
phosphorylation in HeLaVEGF-R1 and HeLaVEGF-R2 (Figure 3.10C), and  furthermore, in  a 
preliminary  experiment  the  VEGF-R1  and  VEGF-R2  specific  ligands,  VEGF-B  and 
VEGF-E respectively, had the ability to stimulate AMPK (Figure 3.9). Although the latter 
data represents a preliminary experiment, together these data may indicate a possible role 
for both VEGF receptor subtypes in the regulation of VEGF-stimulated AMPK activity, 
and as such warrant further investigation.   
It has previously been shown that in both native and transfected endothelial cells VEGF-
R2-mediated autophosphorylation leads to downstream eNOS activation (He et al., 1999; 
Feng et al., 1999; Wu et al., 1999; Kroll and Waltenberger, 1999; Thuringer et al., 2002). 
Conversely, another report has documented that VEGF-mediated NO synthesis is driven 
through VEGR-R1 in HUVEC, whereas specific activation of VEGF-R2 was unable to 
induce NO release (Bussolati et al., 2001). The addition of a neutralizing anti-VEGF-R1 
antibody has been shown to significantly inhibit VEGF-induced NO release in HUVEC 
(Ahmed  et  al.,  1997),  and  specific  activation  of  VEGF-R1  using  VEGF-B  has  been 
demonstrated to increase phosphorylation of eNOS at Ser-1177 and PKB at Ser-473, and 
furthermore to promote angiogenesis (Silvestre et al., 2003). It therefore remains unclear as 
to which receptor mediates the effect of VEGF on eNOS/NO production with different 
studies  implicating  both  endothelial  VEGF  receptor  subtypes.  CYP  epoxygenases 
metabolise  arachidonic  acid  to  EETs,  which  activate  several  signalling  pathways  to 
promote  endothelial  cell proliferation,  migration  and  angiogenesis.  A  recent  report has 
shown VEGF increases CYP 2C promoter activity and that a dominant negative AMPK 
mutant prevented the VEGF-induced increase in CYP 2C RNA and protein expression in 
human endothelial cells (Webler et al., 2008). It was observed that VEGF was able to 
increase the activity of the CYP 2C9 promoter in cells expressing both VEGF-R1 and 
VEGF-R2 (Webler et al., 2008). VEGF-R2
 siRNA was reported to abrogate AMPK and 
ACC phosphorylation in
 response to VEGF in BAEC (Levine et al., 2007). The findings of 
the present investigation suggest VEGF-R1, in addition to VEGF-R2, may mediate the James A Reihill, 2009    Chapter 3, 139 
effects of VEGF on AMPK activation. Activation of the VEGF-R2 receptor by VEGF in 
cells devoid of
 VEGF-R1 results in a mitogenic response, while the activation
 of VEGF-R1 
by VEGF in cells lacking VEGF-R2 fails to induce
 cell proliferation (Seetharam et al., 
1995; Waltenberger et al., 1994). However, activation of VEGF-R1
 by VEGF does induce 
cell migration, a response that is also
 induced as a result of VEGF-R2 activation by VEGF 
(Barleon et al., 1996; Yoshida et al., 1996; Soker et al., 1998). These results indicate that 
the  signal  transduction  cascades
  induced  by  VEGF-R1  and  VEGF-R2  are  somewhat 
different. It is an intriguing possibility that VEGF acting through different VEGF receptors 
may confer a specific signal to AMPK which may enable the kinase to direct separate 
functional effects.      140 
4  THE MECHANISM OF VEGF-STIMULATED 
AMPK ACTIVATION James A Reihill, 2009    Chapter 4, 141 
4.1 Introduction 
The  underlying  regulatory  mechanisms  of  VEGF-stimulated  AMPK  activity  remained 
uncharacterised. The experiments discussed in this chapter were therefore undertaken to 
elucidate this signalling process. 
A number of previous studies provide evidence implicating a range of likely candidates 
perhaps involved in the regulation of VEGF-stimulated AMPK activity. PI3K, Src and 
PLC-γ are known effectors of VEGF signalling in endothelial cells. It has been suggested 
that AMPK stimulation is downstream of PI3K and Src activation in peroxynitrite- and 
metformin-treated  BAEC  (Zou  et  al.,  2004;  Zou  et  al.,  2003).  In  a  recent  study  also 
conducted  in  BAEC  an  inhibitor  of  Src  diminished  VEGF-mediated  AMPK  and  ACC 
phosphorylation (Levine et al., 2007).  In HUVEC, histamine and thrombin have been 
shown  to  stimulate  AMPK,  a  process  proposed  to  be  mediated  by  a  PLCγ-mediated 
increase  in  intracellular  Ca
2+  (Thors  et  al.,  2004).  In  this  chapter,  the  role  of  these 
signalling  effectors  in  the  regulation  of  VEGF-stimulated  AMPK  in  HAEC  was 
investigated. 
LKB1  and  CaMKK  are  AMPKKs,  either  of  which  may  potentially  regulate  VEGF-
stimulated AMPK activity. LKB1 is responsible for AMPK activation when there is an 
increase in the cellular AMP:ATP ratio whereas CaMKK stimulates AMPK in an AMP-
independent,  Ca
2+–dependent  manner.  As  mentioned  above  histamine-  and  thrombin-
stimulated AMPK activity may be mediated by a PLCγ-dependent increase in intracellular 
Ca
2+  (Thors  et  al.,  2004).  Interestingly,  thrombin  has  recently  been  demonstrated  to 
activate AMPK in endothelial cells via a pathway involving PLC and CaMKKβ (Stahmann 
et al., 2006). It therefore seemed possible that a PLC-Ca
2+-CaMKK pathway may underlie 
VEGF-stimulated AMPK activity. However, LKB1 itself may participate in the regulation 
of this process. There is reduced vascular structure and angiogenesis in LKB1
-/- mouse 
embryos and increased concentrations of VEGF, suggesting a possible link between LKB1 
and VEGF/angiogenesis (Ylikorkala et al., 2001).  In this chapter, the importance of both 
CaMKK and LKB1 in VEGF-mediated AMPK activity was also determined. 
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4.2 Results 
Inhibition of either PI3K or Src, with the inhibitors wortmannin and PP1 (described in 
table 2.5) respectively, at concentrations previously demonstrated to inhibit PI3K/Src in 
endothelial cells (Wang et al., 2005; Zeng and Quon, 1996; Klint et al., 1999), had no 
effect  on  VEGF-stimulated  AMPK  activity  in  HAEC,  suggesting  that  neither  of  these 
kinases  mediate  VEGF-stimulated  AMPK  activation.  Conversely,  VEGF-stimulated 
AMPK activity was reduced to basal levels in HAEC pre-treated with the reported PLC 
inhibitor U73122 (described in table 2.5) (Figure 4.1). However, further work conducted 
using U73122 suggests this agent may not be a specific inhibitor of PLC. AMPK activation 
stimulated by both AICAR and OAG (an agent found to stimulate AMPK activity (Figure 
4.12), likely downstream of PLC) were unexpectedly inhibited by U73122 (Figures 4.2B 
and  4.2A  respectively).  In  addition  PKB  phosphorylation  at  Ser-473  was  completely 
abolished by U73122 treatment (Figure 4.2C).      143 
 
Figure 4-1  Effect of various inhibitors on VEGF-stimulated AMPK activity 
HAEC were incubated in the presence or absence of VEGF for 5 minutes after pre-incubation with 100 nM 
wortmannin,  1  µM  PP1  or  10  µM  U73122  for  45  minutes  and  lysates  prepared.  Total  AMPK  was 
immunoprecipitated from HAEC lysates (100 µg) and assayed for AMPK activity. The results are expressed 
as the mean ± SD basal AMPK activity for four independent experiments. *p<0.01 relative to the value in the 
absence of inhibitor. These experiments were performed by Dr I. Salt. 
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Figure 4-2  The action of U73122 
HAEC were incubated in the presence or absence of (A) 100 µM OAG for 30 minutes (B) 2 mM AICAR for 
30 minutes after pre-incubation with 10 µM U73122 for 15 minutes and lysates prepared. Total AMPK was 
immunoprecipitated  from  HAEC  lysates  (100-200  µg)  and  assayed  for  AMPK  activity.  The  results  are 
expressed as the mean ± SEM basal AMPK activity for two independent experiments in each case. (C) 
HAEC were incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes after pre-treatment with 
10  µM  U73122  for  30  minutes  and  lysates  prepared.  Lysates  were  resolved  SDS–PAGE,  transferred  to 
nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-PKB and α-PKB Ser-473 
resulted in a single band at ~60 kDa in both instances. James A Reihill, 2009    Chapter 4, 145 
As preliminary work had implicated PLC in VEGF-mediated AMPK activity, and as PLC 
is known to increase intracellular Ca
2+ levels in response to VEGF treatment (Xia et al., 
1996), an intriguing possibility that VEGF stimulated AMPK was regulated by the Ca
2+ 
dependent upstream kinase CaMKK was highlighted. Using isoform-specific anti-CaMKK 
antibodies  the  expression  of both  isoforms  of  CaMKK,  α  and  β,  was  demonstrated in 
HAEC (Figure 4.3).  
AMPK activity in HAEC was responsive to increased intracellular Ca
2+ levels as treatment 
with the Ca
2+ ionophore A23187 resulted in a ~3.7-fold increase in AMPK activity (Figure 
4.4A).  Moreover,  VEGF  treatment  resulted  in  a  ~1.8-fold  increase  in  AMPK  activity 
(Figure 4.4B) in HeLa cells which express CaMKK but are LKB1-deficient (Hurley et al., 
2005).  
The  Ca
2+  chelator  BAPTA-AM  was  employed  to  further  ascertain  the  role  of  Ca
2+  in 
VEGF-stimulated  AMPK  activation.  In  HAEC  pre-treated  with  BAPTA-AM  AMPK 
activity was no longer increased in response to VEGF treatment (Figure 4.5). There was 
however  a  noticeable,  yet  non-significant  increase,  in  AMPK  activity  above  basal  in 
BAPTA-AM  treated  cells even  in  the  absence  of  VEGF  treatment  (156  ±  40 %, n=5, 
p>0.05) (Figure 4.5). Indeed, VEGF treatment in the presence BAPTA-AM resulted in an 
AMPK activity not dissimilar to VEGF treatment alone (Figure 4.5).  
The  role  of  CaMKK  in  the  regulation  of  VEGF-stimulated  AMPK  activity  was 
subsequently determined using the inhibitor STO-609. Pre-treatment of HAEC with STO-
609 reduced VEGF-stimulated AMPK activity to basal levels, without altering AICAR- 
stimulated AMPK activity (Figure 4.6). VEGF-stimulated phosphorylation of AMPK at 
Thr-172 was similarly reduced to basal levels after pre-incubation with STO-609 (Figure 
4.7).  
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Figure 4-3  CaMKK isoform expression 
HAEC lysates were resolved by SDS PAGE, transferred to nitrocellulose and probed with anti-CaMKKα 
antibodies. CaMKKβ was immunoprecipitated from HAEC lysate, subjected to Western blotting and probed 
with  anti-CaMKKβ  antibodies.  A  lysate  prepared  from  whole  rat  brain  was  used  as  a  positive  control. 
Representative immunoblots are shown. Probing of lysates with α-CaMKKα resulted in a band at ~63 kDa 
whereas probing with α-CaMKKβ resulted in a two distinct bands at ~66 kDa. 
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Figure 4-4  Activation of AMPK in HeLa and HAEC 
 (A) HAEC were treated with 2 mM AICAR for 45 minutes or 5 µM A23187 for 10 minutes and lysates 
prepared. (B) HeLa cells were treated in the presence or absence of 10 ng/ml VEGF for 5 minutes, 2 mM 
AICAR  for  45  minutes  or  5  µM  A23187  for  30  minutes  and  lysates  prepared.  Total  AMPK  was 
immunoprecipitated from HAEC lysates and assayed for AMPK activity in both cases. Data shown in A & B 
are representative of two independent experiments in each case.     148 
 
Figure 4-5  Effect of BAPTA-AM on VEGF-stimulated AMPK activity 
HAEC were incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes after pre-incubation with 
25 µm BAPTA-AM for 25 minutes and lysates prepared. Total AMPK was immunoprecipitated from HAEC 
lysates  and  assayed  for  AMPK  activity.  The  results  are  expressed  as  the  mean ± SEM  %  basal  AMPK 
activity for five independent experiments. *p< 0.01 relative to value in the absence of VEGF. 
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Figure 4-6  Effect of STO-609 on VEGF-stimulated AMPK activity 
HAEC were incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes, 2 mM AICAR for 30 
minutes or 25 µm STO-609 for 45 minutes and lysates prepared. Total AMPK was immunoprecipitated from 
HAEC lysates and assayed for AMPK activity. The results are expressed as the mean ± SEM % basal AMPK 
activity for seven independent experiments. *p <0.05 relative to value of vehicle treated control. 
#p <0.01 
relative to value in the absence of inhibitor. 
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Figure 4-7  Effect of STO-609 on VEGF-stimulated phosphorylation of AMPK at 
Thr-172 
(A) AMPK immunoprecipitates were resolved by SDS–PAGE, transferred to nitrocellulose and probed with 
the  antibodies  indicated.  Representative  immunoblots  are  shown,  repeated  with  similar  results  on  four 
different samples of lysates. Probing of lysates with α-AMPK and α-AMPK-Thr-172 resulted in a single 
band at ~62 kDa in both instances. (B) Quantification of AMPK phosphorylation from four independent 
experiments using ImageJ software. Results are expressed as the mean ± SEM % basal AMPK Thr-172 
phosphorylation. *p<0.05 relative to the value in absence of inhibitor. James A Reihill, 2009    Chapter 4, 151 
The role of LKB1 in the regulation of VEGF-stimulated AMPK activity was also assessed. 
LKB1, immunoprecipitated from lysates made from VEGF-treated HAEC, was incubated 
with recombinant AMPK and assayed for activity. VEGF treatment was found to have no 
effect on LKB1 activity in HAEC (Figure 4.8).  
As  the  action  of  LKB1  on  AMPK  activation  is  manifested  through  an  increase  in  the 
cellular  AMP:ATP  ratio  the  effect  of  VEGF  on  intracellular  adenine  nucleotide 
concentrations in HAEC was determined. Stimulation of HAEC with concentrations of 
VEGF up to 50 ng/ml has no effect on the ADP:ATP ratio, whereas treatment of cells with 
phenformin and azide, LKB1-mediated activators of AMPK, both resulted in an increase in 
this  ratio  (Figure  4.9).  The  levels  of  intracellular  AMP  proved  too  low  to  measure 
accurately in these cells.  
To further investigate the role of LKB1, the effect of VEGF on AMPK activity in HeLa 
cells stably expressing
 HeLaLKB1-KD or HeLaLKB1-WT (as described in 2.4.5) was determined 
(Sapkota et al., 2002). The expression of FLAG-epitope tagged HeLaLKB1-KD or HeLaLKB1-
WT was successfully induced by the addition of tetracycline for 24h (Figure 4.10A).  In 
both  HeLaLKB1-KD  and  HeLaLKB1-WT  cells  AMPK  activity  was  completely  unaltered  by 
VEGF treatment, yet seemed responsive to AICAR stimulation (Figure 4.10B). In addition 
there was a ~3.9-fold increase in basal AMPK activity in HeLaLKB1-WT cells (0.17 ± 0.0175 
nmol 
32P-incorporated/min/mg protein, n=3, p<0.001) in comparison with their HeLaLKB1-
KD  counterparts  (0.043  ±  0.018  nmol 
32P-incorporated/min/mg  protein,  n=3)  (Figure 
4.10B).      152 
 
Figure 4-8  Effect of VEGF treatment on LKB1 activity in HAEC 
HAEC were incubated with the indicated concentration of VEGF for 5 minutes and lysates prepared. Total 
LKB1  was  immunoprecipitated  from  HAEC  lysates  (200  µg),  incubated  with  recombinant  AMPK  and 
assayed for AMPK activity. The results are expressed as the mean ± SEM % basal AMPK activity for three 
independent experiments performed in triplicate. 
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Figure 4-9  ADP:ATP ratio in VEGF-treated HAEC 
HAEC  were pre-incubated  for 2h at 37 ºC in KRH buffer containing  test substances and incubated for 
various durations at 37ºC. Neutralised perchloric acid extracts  were prepared by Dr I. Salt as described 
previously  (Boyle  et  al.,  2008).  Nucleotides  were  subsequently  separated  by  HPLC.  This  work  is 
representative of 4 independent experiments performed by Prof. D. G. Hardie’s laboratory, University of 
Dundee. *p<0.01 relative to control value.     154 
 
 
Figure 4-10  Effect of VEGF in HeLaLKB1-KD and HeLaLKB1-WT expressing cells 
1µg/ml tetracycline was added to cells for 24h to induce the expression of LKB1-KD or LKB1-WT in HeLa 
cells.  (A)  Lysates  were  subsequently  made  from  these  cells,  subjected  to  SDS  PAGE,  transferred  to 
nitrocellulose then probed with the antibodies indicated. (B) LKB1-KD and LKB1-WT expressing HeLa 
cells were treated with the indicated concentrations of VEGF for 5 minutes or AICAR for 45 minutes. Total 
AMPK was immunoprecipitated from these cells and AMPK activity assessed. The results are expressed as 
the mean ± SEM nmol 
32P-incorporated/min/mg protein AMPK activity for three independent experiments. 
*p<0.001 relative to vehicle-treated control cells. James A Reihill, 2009    Chapter 4, 155 
Together the data presented in Figures 4.1-4.10) support a role for CaMKK, but not LKB1, 
in  the  regulation  of  VEGF-stimulated  AMPK  activity.  As  a  result  of  VEGF-mediated 
activation, PLCγ stimulates hydrolysis of PIP2 thus generating the second messengers IP3 
(inositol triphosphate) and DAG (diacylglycerol).  IP3 diffuses into the cytosol whereas 
DAG  remains  within  the  plasma  membrane,  due  to  its  hydrophobic  properties.  IP3 
stimulates the release of calcium ions from the smooth endoplasmic reticulum (Berridge, 
1995a), whereas DAG is a physiological activator of PKC. In addition DAG may also 
affect intracellular Ca
2+ concentration through a direct action on a number of non-selective 
cation channels from the TRPC channel family which promotes Ca
2+ influx across the 
plasma membrane (Hofmann et al., 1999).  
Whether either mechanism (IP3 or DAG- mediated Ca
2+ mobilisation/influx) is involved in 
VEGF-stimulated AMPK activation was subsequently assessed. VEGF-stimulated AMPK 
activity  remained  intact  (~2.7-fold)  in  HAEC  which  had been pre-treated  with  the  IP3 
receptor blocker 2-APB (Figure 4.11). 2-APB treatment alone had no effect on AMPK 
activity  (Figure  4.11).  Conversely,  in  HAEC  treated  with  a  high  K
+-containing 
extracellular solution, which prevents Ca
2+ influx through non-selective cation channels in 
endothelial cells (He and Curry, 1991), VEGF-stimulated AMPK activity was reduced to 
basal levels (Figure 4.11). The addition of the high K
+-containing solution alone had no 
effect  on  AMPK  activity  (Figure  4.11).  These  data  suggest  Ca
2+  influx,  and  not  Ca
2+ 
mobilisation  from  IP3-sensitive  intracellular  stores,  is  essential  for  VEGF-stimulated 
AMPK activity. In agreement with this finding the removal of extracellular Ca
2+ abrogated 
VEGF-stimulated AMPK activity, without affecting AICAR-stimulated AMPK activity in 
HAEC (Figure 4.12). 
Of the seven members of the TRPC channel family (TRPC1-7), TRPC3/6/7 are known to 
be activated by DAG thus promoting Ca
2+ influx across the plasma membrane (Pedersen et 
al., 2005). RT-PCR was used to assess the expression of TRPC3/6/7 in HAEC. Figure 4.13 
shows that a cDNA fragment of an appropriate size (435bp) was amplified using primers 
designed against TRPC6. TRPC3 (400bp) or TRPC7 (458bp) were not detected in this 
experiment. HAEC were then treated with a cell permeable mimetic of DAG. This agent, 
OAG (1-oleoyl 2-acetyl-sn glycerol), which stimulates TRPC3/6/7 (Pedersen et al., 2005; 
Venkatachalam et al., 2004), elicited a ~2.2-fold stimulation of AMPK activity, an effect 
sensitive to both STO-609 pre-treatment and high K
+-induced depolarisation (Figure 4.14). 
STO-609 treatment alone was found to reduce AMPK activity (Figure 4.14).      156 
Gadolinium (Gd
3+) is an agent used to block of Ca
2+ entry through non-selective cation 
channels. In HAEC Gd
3+ elicited a variable effect on AMPK activity with an overall non-
significant ~2.6-fold increase in kinase activity, an effect that was not increased further by 
VEGF application (Figure 4.15).     157 
 
 
Figure 4-11  Effect of high K
+-containing KRH on VEGF-stimulated AMPK activity  
HAEC were treated in the presence or absence of VEGF (10 ng/ml, 5 minutes) after pre-treatment with the 
IP3 receptor antagonist 2-APB (100 µM, 20 minutes) or with a high-K
+ solution to depolarise endothelial 
cells (made as described in section 2.2.1) and lysates prepared. Total AMPK was immunoprecipitated from 
HAEC lysates and assayed  for AMPK activity. The results are expressed as the  means ± SEM % basal 
AMPK activity for five independent experiments. *p < 0.05 relative to the value in the absence of high K
+-
containing extracellular solution. 
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Figure 4-12  Effect of extracellular Ca
2+ on VEGF-stimulated AMPK activity 
HAEC were bathed in either normal KRH (2.5 mM Ca
2+) or KRH without Ca
2+ + 1 mM EGTA for 30 
minutes then treated in the presence or absence of the indicated concentrations of VEGF for 5 minutes or 
AICAR for 45 minutes. Lysates were subsequently prepared, total AMPK immunoprecipitated from these 
lysates  and  assayed  for  AMPK  activity.  The  results  are  expressed  as  the  mean ± SEM  %  basal  AMPK 
activity for three independent experiments. *p < 0.05 relative to value in KRH containing 2.5 mM Ca
2+. 
 
 
 
 
.  
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Figure 4-13  RT-PCR of TRPC channels 
Equal volumes of HAEC cDNA (as described in section 2.3.5.3) were mixed with a PCR mastermix (as 
described  in  section  2.3.5.2),  and  gene-specific  primers  to  the  transcript  of  interest  were  added.  PCR 
reactions were carried out in a gradient thermocycler under the conditions described in section (2.3.5.3). PCR 
products  were  resolved  in  ethidium  bromide-stained  agarose  gel  and  visualised  on  a  UVT-28  MP 
transilluminator. Targeted products were as follows: 400bp for TRPC3 (C3), 435bp for TRPC6 (C6), 458bp 
for TRPC7 (C7), 250bp for 18s RNA (18s). 
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Figure 4-14  OAG-stimulated AMPK activity 
HAEC were treated in the presence or absence of OAG (100 µM, 20 minutes) after pre-treatment with STO-
609 (25 µM, 15 minutes) or with a high K
+-containing KRH solution and lysates prepared. Total AMPK was 
immunoprecipitated from HAEC lysates and assayed for AMPK activity. The results are expressed as the 
mean ± SEM % basal AMPK activity for five independent experiments. *p< 0.05 relative to value in absence 
of OAG. **p<0.05 relative to value in absence of STO-609 or high K
+-induced depolarisation. 
#p<0.001 
relative to value in absence of inhibitor. 
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Figure 4-15  Effect of Gd
3+ on VEGF-stimulated AMPK activity 
HAEC were incubated in the presence or absence of 10 ng/ml VEGF for 5 minutes after pre-incubation with 
100 µm Gd
3+ for 15 minutes and lysates prepared. Total AMPK was immunoprecipitated from HAEC lysates 
and assayed for AMPK activity. The results are expressed as the mean ± SEM % basal AMPK activity for 
four independent experiments.  James A Reihill, 2009    Chapter 4, 162 
4.3 Discussion 
Previous studies have suggested that AMPK stimulation is downstream of PI3K and Src 
activation in peroxynitrite- and metformin-treated BAEC (Zou  et al., 2004; Zou et  al., 
2003). Another study, also conducted in BAEC, has reported that inhibition of Src prevents 
VEGF-induced AMPK and ACC phosphorylation (Levine et al., 2007), whereas it has also 
been proposed that VEGF stimulates complex formation of VEGF-R2 with Src and that 
Src activation is required for VEGF induction of PLCγ1 activation and subsequent eNOS 
stimulation (He et al., 1999). As eNOS has been shown to be activated downstream of 
VEGF-stimulated  AMPK  activation  (Figures  3.3  and  3.4B)  these  mediators  were  of 
particular interest in the regulation of this process. However, in the current investigation, 
inhibition  of  Src  had  no  effect  on  VEGF-stimulated  AMPK  activity  (Figure  4.1), 
suggesting  neither  Src  nor  PLC-dependent  Src  activation  mediates  VEGF-stimulated 
AMPK activation in HAEC. Additionally, pre-treatment of HAEC with wortmannin, at a 
concentration shown to completely inhibit VEGF-stimulated PKB phosphorylation (Figure 
3.6) was without effect on VEGF-stimulated AMPK activity suggesting PI3K is not an 
essential component of this signalling cascade. In contrast, pre-treatment of HAEC with 
the  PLC  inhibitor  U73122  reduced  VEGF-stimulated  AMPK  activity  to  basal  levels. 
Interestingly, histamine has previously been reported to activate AMPK in HUVEC in a 
PI3K-independent, PLC dependent manner (Thors et al., 2004), suggesting histamine and 
VEGF may share a common mechanism by which they stimulate AMPK. 
However, a number of additional experiments (Figure 4.2) conducted using the ‘specific’ 
PLC inhibitor U73122 (Thompson et al., 1991; Yule and Williams, 1992; Stam et al., 
1998) indicate this agent may have a number of off-target effects. VEGF stimulates PKB 
via  PI3K  (Papapetropoulos  et  al.,  1997;  Xia  et  al.,  1996),  whereas  AICAR  directly 
activates AMPK through the action of the upstream kinase LKB1. In HAEC pre-treated 
with  U73122  VEGF-stimulated  phosphorylation  of  PKB  at  Ser-473  (Figure  4.2C)  and 
AICAR-stimulated AMPK activity (Figure 4.2B) were completely abolished. The TRPC 
family of non-selective cation channels act downstream of PLCβ or PLCγ when activated 
by GPCRs or RTKs respectively (Xia et al., 1996). TRP channels allow the flux of cations 
down  their  electrochemical  gradient,  raising  intracellular  Ca
2+  and  Na
+.  It  is  widely 
accepted that of the seven members of the ‘canonical’ family (TRPC1-7), TRPC3/6/7 are 
DAG- (or the mimetic OAG)- activated channels (Pedersen et al., 2005). OAG was found 
to stimulate AMPK activity in HAEC (Figure 4.14), an effect also unexpectedly inhibited 
by U73122 pre-treatment (Figure 4.2A). Despite these observations it has recently been James A Reihill, 2009    Chapter 4, 163 
shown that VEGF-mediated elevated intracellular Ca
2+ and angiogenesis are inhibited by 
dominant negative TRPC6 in HMEC (Hamdollah Zadeh et al., 2008), and Ca
2+ entry via 
TRPC channels is necessary for thrombin-induced AMPK activation in endothelial cells 
(Bair et al., 2008). These data, and the finding that OAG can stimulate AMPK activity in 
HAEC (Figure 4.14), suggest PLC-TRPC signalling may be an important component of the 
VEGF-AMPK signalling cascade in these cells. 
A  key  finding  of  the  current  investigation  is  the  identification  of  CaMKK  as  the 
responsible  upstream  kinase  which  mediates  VEGF-stimulated  AMPK  activity  (Figure 
4.6).  In  agreement  with  this  observation,  a  more  recent  study  has  similarly  identified 
CaMKK as the AMPKK necessary for VEGF-stimulated AMPK activity in BAEC (Levine 
et al., 2007). An increasing number of studies have confirmed that CaMKK, especially the 
β isoform, can act as an alternate upstream kinase to LKB1 that activates AMPK in a Ca
2+-
dependent and AMP-independent manner in a range of tissues and cell types (Hardie et al., 
2006;  Hawley  et  al.,  2005;  Woods  et  al.,  2005;  Birnbaum,  2005).  Although  initially 
characterised and isolated from neuronal tissue, both CaMKKα and CaMKKβ have a wide 
expression in rodent tissues (Edelman et al., 1996; Anderson et al., 1998; Vinet et al., 
2003). Using isoform-specific anti-CaMKK antibodies, expression of both CaMKKα and 
CaMKKβ  was  confirmed  in  HAEC  for  the  first  time  (Figure  4.3).    Moreover,  pre-
incubation of HAEC with the CaMKK inhibitor STO-609 completely abolished VEGF-
stimulated  AMPK  Thr-172  phosphorylation  and  AMPK  activity  (Figures  4.6  and  4.5 
respectively). STO-609 is a selective, but not specific inhibitor, of both CaMKK isoforms, 
which at sufficient concentrations can inhibit other kinases including AMPK (Bain et al., 
2007).  Importantly,  in  the  present  investigation,  CaMKK-independent  stimulation  of 
AMPK,  induced  by  AICAR,  was  unaffected  by  STO-609  pre-treatment  (Figure  4.6). 
Additional lines of evidence also support CaMKK as the responsible upstream kinase in 
the  regulation  of  VEGF-stimulated  AMPK  activity.  Treatment  of  HeLa  cells,  which 
express CaMKK but are LKB1-deficient (Hurley et al., 2005), with VEGF resulted in an 
increase in AMPK activity (Figure 4.4B). Incubation of HAEC with the Ca
2+ ionophore 
A23187 also elicited a large stimulation of AMPK activity in both HAEC and HeLa cells 
(Figures  4.4A  and  B  respectively),  whilst  Ca
2+  influx  across  the  plasma  membrane  in 
response  to  VEGF  was  shown  to be  essential  in  the  maintenance  of  VEGF-stimulated 
AMPK activity in HAEC (Figures 4.11 and 4.12, discussed in detail below). In HAEC pre-
treated with the Ca
2+ chelator BAPTA-AM, VEGF treatment failed to increase AMPK 
activity  in  comparison  to  BAPTA-AM-treated  controls  (Figure  4.5).  Of  note  however, 
although of no statistical significance, BAPTA-AM treatment alone did increase AMPK James A Reihill, 2009    Chapter 4, 164 
activity. Additional work such as siRNA targeted knockdown of CaMKK in HAEC to 
further corroborate the finding CaMKK is the upstream kinase which mediates VEGF-
stimulated AMPK may be of benefit. Moreover, this would also allow specific targeting of 
the individual CaMKKα and CaMKKβ isoforms, both of which are expressed in HAEC 
(Figure 4.3). CaMKKβ is has been shown to play a role in the regulation of AMPK activity 
in both neuronal tissue  (Hawley et al., 2005) and T cells (Tamas et al., 2006). In addition, 
the aforementioned kinase appears to be the major isoform in endothelial cells regulating 
AMPK activity in response to a range of agonists (Stahmann et al., 2006; Levine et al., 
2007; Xu et al., 2008). Conversely, CaMKKα appears to be the major isoform in skeletal 
muscle cells (Witczak et al., 2007; Jensen et al., 2007), where the expression of CaMKKβ 
is  controversial (Kitani  et  al.,  1997;  Jensen  et al.,  2007;  Shen  et  al.,  2007). CaMKKα 
activation is responsible for AMPK activation by α-lipoic acid in C2C12 myotubes (Shen 
et al., 2007), and has also been implicated in the regulation of skeletal muscle glucose 
uptake, though this effect occurred independently of AMPK and PKB activation (Witczak 
et al., 2007). Although CaMKKβ is likely the principal isoform which regulates endothelial 
AMPK  activation  in  response  to  VEGF  in  HAEC  it  may  be  of  additional  interest  to 
determine the role of CaMKKα.  
The current investigation also sought to determine the contribution of LKB1 to VEGF-
stimulated  AMPK  signalling.  LKB1  activity  is  unchanged  under  many  conditions  that 
stimulate AMPK phosphorylation, including phenformin, AICAR, muscle contraction and 
extreme ischemia in a variety of tissues (Lizcano et al., 2004; Sakamoto et al., 2004).  
Consistent with these findings, in the present study, there was no alteration in recombinant 
AMPK  activity  upon  incubation  with  LKB1  immunoprecipitated  from  VEGF-treated 
HAEC (Figure 4.8). In vitro, purified recombinant LKB1 directly phosphorylates AMPK at 
Thr-172, leading to activation. In LKB1-deficient cells, such as HeLa, activation of AMPK 
in  response  to  stimuli  that  increase  the  AMP:ATP  ratio  or  with  AICAR,  is  abolished 
(Hawley et al., 2003). This suggests that LKB1 is required for the activation of AMPK in 
response to elevated AMP (or the AMP mimetic, ZMP). However, AMP does not directly 
activate LKB1. Indeed, the kinase is constitutively active and does not therefore require 
stimulation  (Hawley  et  al.,  2003).  Current  evidence  suggests  the  action  of  AMP  is 
manifested through an inhibition of AMPK dephosphorylation by protein phosphatases 
(Sanders et al., 2007b;  Suter et al., 2006; Davies et al., 1995).  Indeed the majority of 
AMPK stimuli have been shown to raise the intracellular AMP:ATP ratio. However, in the 
present investigation treatment of HAEC with VEGF had no effect on the ADP:ATP ratio 
which is indicative of the AMP:ATP ratio (Figure 4.9). Both phenformin and azide which James A Reihill, 2009    Chapter 4, 165 
are known to stimulate AMPK through an increase in the AMP:ATP ratio  resulted in a 
significantly increased ADP:ATP ratio in these experiments (Figure 4.9).  
Interestingly, it has been reported that there is reduced vascular structure and angiogenesis 
in LKB1
-/- mouse embryos (Ylikorkala et al., 2001). These phenotypes were associated 
with a tissue-specific deregulation of VEGF expression, including a marked increase in the 
amount of VEGF mRNA. These findings provide an intriguing link between the LKB1 and 
VEGF signalling pathways. Other studies have assessed the role of LKB1 in endothelial 
cells  using  siRNA  targeted  to  the  kinase.  However  complete  knockdown  of  LKB1  is 
difficult to achieve (Zhang et al., 2008; Zou et al., 2002; Hattori et al., 2008). In an attempt 
to definitively assess the role of LKB1, the effect of VEGF on AMPK activity in HeLa 
cells stably expressing
 HeLaLKB1-KD or HeLaLKB1-WT was determined (Sapkota et al., 2002). 
HeLaLKB1-KD or HeLaLKB1-WT FLAG-epitope tagged LKB1 was induced in these cell lines 
by the addition of tetracycline (Figure 4.10A). In both HeLaLKB1-KD and HeLaLKB1-WT cells 
AMPK  activity  was  completely  unaltered by  VEGF  treatment.   This  complete  lack  of 
effect  was  somewhat  surprising  as  in  earlier  work  VEGF  had been  shown  to  increase 
AMPK activity in HeLa cells (Figure 4.4). A number of observations suggest that the 
HeLaLKB1-KD and HeLaLKB1-WT cells are indeed functional. Consistent with the view that 
LKB1 is a constitutively active kinase, induction of HeLaLKB1-WT resulted in an increase in 
the  basal  activity  of  AMPK  compared  to  that  found  in  HeLaLKB1-KD  controls  (Figure 
4.10B).  LKB1-mediated  AMPK  activation  stimulated  using  AICAR  caused  a  ~2-fold, 
albeit non-significant, increase in AMPK activity in HeLaLKB1-WT compared to HeLaLKB1-
KD cells in which it was without effect (Figure 4.10B). Moreover, other work conducted in 
our  laboratory  using  these  cell  lines  demonstrated  that  rosiglitazone-stimulated  AMPK 
activity  is  dependent  on  LKB1  (Boyle  et  al.,  2008).  As  CaMKK-dependent  VEGF-
stimulated AMPK activity is seemingly compromised in the HeLaLKB1KD/WT cell lines, the 
contribution,  if  any,  of  LKB1  could  not  be  determined.  At  present  the  underlying 
mechanism  of  these  seemingly  disparate  effects  elicited  in the  various HeLa cell  lines 
remains unknown. 
As initial experiments conducted in the present study (Figure 4.1) suggested PLC mediated 
VEGF-stimulated  AMPK  activation;  and  histamine  and  thrombin  had  previously  been 
reported to activate AMPK in HUVEC in a PLC-dependent manner (Thors et al., 2004; 
Thors et al., 2004) the role of PLC signalling was further characterised. Indeed, as a Ca
2+-
dependent AMPKK mediates VEGF-stimulated AMPK activation (Figures 4.6 and 4.7), 
and PLC increases intracellular Ca
2+ levels in response to VEGF in endothelial cells (Xia James A Reihill, 2009    Chapter 4, 166 
et al., 1996; McLaughlin and De Vries, 2001), experiments were conducted to determine 
whether PLC-mediated elevated intracellular Ca
2+ levels are responsible for the stimulation 
of CaMKK-AMPK signalling. IP3 is produced subsequent to PLCγ activation by VEGF. 
IP3 mobilises Ca
2+ from intracellular stores (Berridge, 1995b), which may then stimulate 
Ca
2+ influx by a capacitative entry pathway (Maruyama et al., 1997). However in HAEC 
pre-treated  with  the  IP3  receptor  blocker  2-APB  VEGF-stimulated  AMPK  activity 
remained completely intact (Figure 4.11).  
Since its discovery 2-APB has been a widely used tool to inhibit IP3-mediated Ca
2+ release 
(Maruyama et al., 1997; Gysembergh et al., 1999; Ascher-Landsberg et al., 1999; Sergeant 
et al., 2001; Dyachok and Gylfe, 2001; Bishara et al., 2002), and is an effective modulator 
of the IP3 receptor in many cell types including endothelial cells  where the agent has been 
shown  to  inhibit  Ca
2+  release  and  subsequent  capacitative  Ca
2+  entry  induced  by  the 
agonists  ATP,  bradykinin,  VEGF  and  receptor-independent  Ca
2+  mobilisation  via 
ionomycin or thapsigargin (Bishara et al., 2002; Erdogan et al., 2005). However, emerging 
data suggest that in some cell types the specific action of 2-APB is on SOC entry rather 
than initial Ca
2+ release (Ma et al., 2001; Broad et al., 2001). The best evidence for 2-APB 
inhibiting SOC through a mechanism not involving IP3 is that it is still effective in some 
cell types that do not express IP3 receptors (Gafni et al., 1997).  In the present study 2-APB 
had no effect on VEGF-stimulated AMPK activity suggesting IP3-mediated store release 
may not be involved. Indeed, if 2-APB had any effect on the subsequent entry of Ca
2+ 
through SOC then this would additionally imply this mechanism may not play a role either. 
Although 2-APB was used at a concentration demonstrated to inhibit IP3-mediated Ca
2+ 
release in endothelial and other cell types (Bair et al., 2008; Bishara et al., 2002; Peppiatt et 
al., 2003), the present investigation provides no direct evidence demonstrating Ca
2+ release 
was  effectively  blocked  upon  2-APB  addition.  The  membrane  permeable  fluorescent 
calcium probe FLUO-3-AM was utilised in an attempt to directly determine whether 2-
APB  sufficiently  inhibits  IP3-mediated  Ca
2+  release  from  intracellular  stores  under  the 
conditions of the present study. Unexpectedly however, addition of this indicator proved 
toxic when added to HAEC, even when used at concentrations below that successfully 
utilised in other studies also conducted in endothelial cells (data not shown). Additional 
experiments are therefore required to fully determine the role, or lack thereof, of IP3–
mediated Ca
2+ release in the regulation of VEGF-stimulated AMPK activity in HAEC. In 
addition to 2-APB there are a limited number of alternative IP3 modulators which may be 
used to assess the involvement of IP3-mediated Ca
2+ release.  Xestospongins were first James A Reihill, 2009    Chapter 4, 167 
described  as  membrane-permeant  IP3  receptor  antagonists  (Bootman  et  al.,  2002). 
However  xestospongins  are  expensive,  slow  to  act  and  have  exhibited  variable  results 
between laboratories (Taylor and Broad, 1998). Alternatively heparin is another commonly 
used IP3 receptor antagonist. However this agent is not cell permeable and has been shown 
to have multiple actions such as the activation of ryanodine receptors (Adams et al., 1989; 
Cannell and Sage, 1989; Takeda and Klepper, 1990).  
DAG, also produced upon PLC activation, increases intracellular Ca
2+ levels through non-
selective cation channels in the endothelium (Pocock et al., 2004). Experiments on cultured 
endothelial cells show a relative lack of functional voltage-gated Ca
2+ channels (Colden-
Stanfield et al., 1987; Brauneis et al., 1992; Groschner et al., 1994; Popp and Gogelein, 
1992; Zhang et al., 1994). Indeed evidence suggests non-selective cation channels are the 
principal  mechanism  which  account  for  agonist-induced  Ca
2+ entry  in  the  endothelium 
(Tran et al., 2000). Thrombin, bradykinin, serotonin, ATP and endothelin-1 have all been 
shown  to  activate  endothelial  non-selective  cation  channels  (Adams  et  al.,  1989; 
Bregestovski  et  al.,  1988;  Jacob,  1990;  Sauve  et  al.,  1988;  Schilling,  1989).  Unlike 
excitable  cells,  where  depolarisation  stimulates  Ca
2+  influx,  depolarisation  reduces  the 
driving force for Ca
2+ entry through non-selective cation channels in the endothelium (He 
and Curry, 1991; Curry, 1992). High potassium solutions have been shown to depolarise 
the  membranes  of  endothelial  cells  in  a  number  of  studies  (Adams  et  al.,  1989; 
Bregestovski et al., 1988; Jacob, 1990; Sauve et al., 1988; Schilling, 1989). In the present 
investigation a high K
+-containing KRH solution was prepared by replacing 59.5 mM Na
+ 
with KCl to give a final K
+ concentration of 64.3mM (described in detail in section 2.2.1). 
Similar  K
+-containing  solutions  have  previously  been  shown  to  inhibit  elevated 
intracellular Ca
2+ levels induced by Ca
2+ ionophores in endothelial cells and microvessels 
(He and Curry, 1991; Curry, 1992). The removal of extracellular Ca
2+ (Figure 4.12) and 
high  K
+-induced  depolarisation  (Figure  4.11)  completely  prevented  VEGF-stimulated 
AMPK activity, indicating Ca
2+ entry through non-selective cation channels may underlie 
this  process.  There  are  now  numerous  reports  which  show  the  non-selective  cation 
channels TRPC3/6/7 can be activated by DAG, and their role as DAG-activated channels is 
widely accepted. HAEC were subsequent treated with the DAG mimetic, OAG, which was 
found  to  significantly  increase  AMPK  activity,  an  effect  sensitive  to  STO-609  pre-
treatment and high K
+-induced depolarisation (Figure 4.14).  
DAG kinase catalyses the conversion of DAG to phosphatic acid, whereas DAG lipase 
catalyses the hydrolysis of DAG, releasing free fatty acid and monoacylglycerol. TRPC6 James A Reihill, 2009    Chapter 4, 168 
has been identified as an important channel which participates in bradykinin-induced non-
capacitive Ca
2+ entry in endothelial cells. In addition to OAG, the action of bradykinin has 
been shown to be mimicked by the DAG lipase inhibitor RHC-80267 (Leung et al., 2006). 
RHC-80267  and  the  DAG  kinase  inhibitor  R-59949  have  also  been  shown  to  cause  a 
transient  increase  in  a  TRPC-like  channel  cation  channel  activity  in  rabbit  ear  artery 
myocytes  (Albert  et  al.,  2005).  RHC-80267  and  R-59949  were  used  in  HAEC  to 
investigate whether inhibition of DAG metabolism could activate AMPK via an increase in 
endogenous DAG levels. However, neither RHC-80267 nor R-59949, when added alone to 
HAEC, had any effect on AMPK activity (data not shown). The effect of these agents in 
combination  has,  as  yet,  not  been  determined.  This  may  be  of  value  as  sufficient 
metabolism  of  DAG  may  occur  through  the  non-inhibited  pathway,  thus  preventing  a 
meaningful increase in endogenous DAG levels. In addition, the basal activity of DAG 
lipase  and  DAG  kinase may  be  of  importance.  For  example, it  is  known  that  in non-
stimulated  cells  DAG  kinase  activity  is  low  enabling  DAG  to  be  used  in 
glycerophospholipid biosynthesis. Therefore, inhibition of this DAG kinase may have little 
effect  on  overall  DAG  levels.  However,  it  may  be  the  case  that  inhibition  of  DAG 
metabolism  would  greatly  augment  VEGF-stimulated  AMPK  activity.  Further  work  is 
required to test this hypothesis.   
Gd
3+, a small lanthanide, is a well recognized blocker of many types of mechanosensitive 
cation channels. At submillimolar concentrations, Gd
3+ blocks the non-selective mechano-
gated  channels  (Hamill  and  McBride,  Jr.,  1996)  and  various  Ca
2+  permeable  channels 
(Beedle et al., 2002; Biagi and Enyeart, 1990; Lansman, 1990; Mlinar and Enyeart, 1993). 
In addition Gd
3+ has been used to inhibit members of the TRPC channel subfamily (Minke 
and Cook, 2002; Cheng et al., 2006). In experiments conducted in the present investigation 
Gd
3+ elicited a highly variable effect on AMPK activity (Figure 4.15). In hindsight, this 
may not be of great surprise as dual effects of lanthanides, potentiating and blocking, have 
been  reported  in  members  of  the  mammalian  TRP  channel  superfamily.  The  currents 
carried through TRPC4 and TRPC5 have been shown to be potentiated by submillimolar 
concentrations  of  La
3+  or  Gd
3+,  whereas  millimolar  concentrations  were  inhibitory.  In 
addition Gd
3+ has previously been shown to inhibit TRPC3 and TRPC6 without affecting 
TRPC7 (Cheng et al., 2006).  
Other modulators have been used to investigate the involvement of non-selective cation 
channels such as nickel and flufenamic acid. Nickel ions have previously been shown to 
attenuate Ca
2+ influx in endothelial cells (He and Curry, 1991; Jacob, 1990). However, in James A Reihill, 2009    Chapter 4, 169 
the present study the addition of nickel to endothelial cells proved highly toxic (data not 
shown).  Flufenamic  is  another  molecule  often  used  to  investigate  the  role  of  TRPC 
channels. However again this agent is not ideal as it is known to enhance TRPC6 whilst 
inhibiting TRPC3 currents (Pocock et al., 2004). 
 In  general  TRPC  channels  are  almost  ubiquitously  expressed  and  most  have  splice 
variants.  Primary  endothelial  cells  in  culture  express  multiple  TRPC  isoforms  with 
different expression patterns occurring between endothelial cells from different species and 
vascular beds (Tiruppathi et al., 2006). For example, HUVEC express all of the DAG-
activated TRPC isoforms, whereas RPAEC do not express any (Tiruppathi et al., 2006). Of 
the  DAG-activated  TRPC  channels  RT-PCR  confirmed  TRPC6  expression  in  HAEC 
(Figure 4.13). Neither TRPC3 nor TRPC7 were detected. However, a positive control such 
as HUVEC or any other TRPC3/7 expressing tissue would need to be included in order to 
rule out these isoforms. In addition isoform specific antibodies against TRPC channels are 
now commercially available and may be utilised to ascertain the TRPC expression profile 
in HAEC.  
A  number  of  other  studies  have  implicated  TRPC  channels  as  components  of  various 
VEGF-signalling  pathways.  VEGF  was  initially  shown  to  increase  microvascular 
permeability in vivo trough a mechanism that is dependent on PLC (Pocock et al., 2004). 
Subsequent work has shown DAG-mediated Ca
2+ entry through TRPCs is essential for this 
increase in permeability (Pocock et al., 2004). A very recent report has implicated TRPC6 
in the VEGF-mediated angiogenic pathway in human endothelial cells (Hamdollah Zadeh 
et al., 2008), and it has previously been shown that that co-transfection of HEK cells with 
VEGF-R2
 and TRPC6 enables the cells to respond to VEGF by increasing
 intracellular 
Ca
2+ (Pocock et al., 2004). Also of particular interest is the recent identification of EETs as 
a component of the VEGF-AMPK signalling cascade leading to angiogenesis (Webler et 
al.,  2008).  It  has  been  proposed  that  EETs  regulate  intracellular  Ca
2+  by  inducing  the 
translocation of TRPC6 channel proteins to caveolin-1 rich areas of the endothelial cell 
membrane (Fleming et al., 2007). Together, these reports and the findings of the present 
study  suggest  TRPCs  (likely  TRPC6)  may  be  involved  in  the  regulation  of  VEGF-
stimulated AMPK activity in HAEC. In endothelial cells K
+ channel activation results in a 
hyperpolarisation of the cell membrane building an electrochemical gradient for prolonged 
Ca
2+ influx (Vaca et al., 1996; Luckhoff and Busse, 1990). In HUVEC VEGF has been 
demonstrated  to  cause  a  dose-dependent  hyperpolarisation  of  the  endothelial  cell 
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production (Erdogan et al., 2005). These effects are sensitive to the potassium channel 
(Kv1.3) blocker  margotoxin  and  100 µM  2-APB.  It  would be  interesting  to determine 
whether this mechanism is involved in the regulation of VEGF-stimulated AMPK activity. 
The sensitivity of this signalling mechanism to the same concentration of 2-APB found to 
be without effect on VEGF-stimulated AMPK activity in the present study suggests this 
may not be the case. Even so, it is important to note high K
+-induced depolarisation and 
the removal of extracellular Ca
2+, which were found to prevent VEGF stimulated AMPK 
activity in the current investigation, (Figures 4.11 and 4.12 respectively) would also likely 
prevent  increased  Ca
2+  influx  resultant  from  hyperpolarisation  of  the  endothelial  cell 
membrane. Indeed although OAG-stimulated AMPK activity is suggestive of a role for 
DAG  in  the  regulation  of  AMPK  it  does  not  directly  implicate  DAG,  nor  the  TRPC 
channels upon which it acts. Therefore further work is necessary to directly determine 
whether  TRPCs  are  a  component  of  the  VEGF-AMPK  signalling  cascade  in  HAEC. 
Notably, TRPC1 was recently shown to be a necessary component of thrombin-induced 
AMPK activation through CaMKKβ in endothelial cells (Bair et al., 2008), demonstrating 
these channels can modulate AMPK signalling.  
PKC represents a family of serine/threonine kinases activated by signals which increase 
DAG concentration. As the mimetic OAG stimulates AMPK in a manner similar to that of 
VEGF the role of PKC is also of interest. Indeed, work by Zou’s group has suggested that 
PKCζ may regulate AMPK by promoting the association of LKB1 with AMPK (Xie et al., 
2006). Furthermore, it has been reported that stimulation of BAEC with the PKC activator 
PMA  activates  AMPK  (Xie  et  al.,  2006).  Whether  PKC  contributes  to  VEGF-AMPK 
signalling remains unknown. VEGF-induced vascular permeability has been demonstrated 
to be dependent on DAG-mediated Ca
2+ influx, but is unaffected by inhibition of PKC 
(Pocock and Bates, 2001; Pocock et al., 2004). Therefore, it may be the case that a similar 
DAG-dependent,  PKC-independent  mechanism  mediates  VEGF-stimulated  AMPK 
activity in HAEC. However, further work is necessary to determine whether this is the 
case. 
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5  AMPK: A  COMPONENT OF  THE VEGF-
STIMULATED ANGIOGENIC RESPONSE        James A Reihill, 2009    Chapter 5, 172 
5.1 Introduction 
Angiogenesis, the physiological process involving the growth of blood vessels from pre-
existing ones, is essential for embryonic development, growth, formation of the corpus 
luteum  and  endometrium,  regeneration  and  wound  healing  (Ferrara,  2002b;  Munoz-
Chapuli et al., 2004). Abnormal angiogenesis is associated with a number of pathologies; 
including cancer, diabetic retinopathy and arthritis (Ferrara, 2004a; Munoz-Chapuli et al., 
2004).  
One of the earliest intracellular signalling events described for VEGF was an increase in 
the intracellular Ca
2+ concentration of endothelial cells (Criscuolo et al., 1989; Brock et al., 
1991). It is now clear that an increase in intracellular Ca
2+ plays a key role in the mitogenic 
and secretory effects of growth factors (Soltoff and Cantley, 1988; Nilius et al., 1997), and 
is required for most of the downstream functions of VEGF including angiogenesis (Kohn 
et al., 1995; Erdogan et al., 2005; Hamdollah Zadeh et al., 2008; Faehling et al., 2002). In 
addition NO is a key regulator of the angiogenesis (Papapetropoulos et al., 1997; Yu et al., 
2005).  As  VEGF-stimulates  the  activation  of  AMPK,  an  effect  mediated  by  a  Ca
2+-
dependent  upstream  kinase,  leading  to  an  increase  in  NO  production  the  intriguing 
possibility that AMPK may also be involved in the angiogenic process was highlighted. 
Interestingly  some  previous  studies  have  demonstrated  that  AMPK  may  mediate 
angiogenesis in response to both adiponectin (Ouchi et al., 2004; Shibata et al., 2004) and 
hypoxia (Nagata et al., 2003). These studies, like many others, used a range of in vitro and 
in vivo models to assess the angiogenic response in their systems. Angiogenesis involves 
the escape of endothelial cells from their stable location through the basement membrane, 
with  subsequent  migration  toward  an  angiogenic  stimulus  such  as  VEGF.  Behind  this 
migrating front endothelial cells must proliferate thus providing the requisite number of 
cells  for  a  new  blood  vessel.  Subsequent  to  this  proliferation  the  new  outgrowth  of 
endothelial cells needs to reorganise into a 3D structure capable of carrying blood. Each of 
these elements, basement membrane disruption, cell migration, cell proliferation and tube 
formation are processes routinely assessed by investigators using various in vitro models 
designed  to  assess  these  individual  angiogenic  processes.  In  addition  to  these  in  vitro 
methods there are also a number of organ culture assays, namely the aortic ring assay and 
the chick aortic arch assay, which in addition to endothelial cells, include the surrounding 
mural cells also regarded as important in angiogenesis (Karamysheva, 2008). However, 
perhaps the best approach to determine angiogenesis is an in vivo model, of which the James A Reihill, 2009     Chapter 5, 173 
chick chorioallantoic membrane (CaM) assay or the in vivo Matrigel plug assay are the 
most widely used.  
The present study utilised an in vitro approach to initially determine whether AMPK may 
be involved in the VEGF-stimulated angiogenic response in HAEC. As endothelial cell 
migration  and  proliferation  are  key  processes  of  the  angiogenic  response  both  were 
assessed as described in the following chapter. 
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5.2 Results 
HAEC  proliferation  was  determined  using  a  colorimetric  method  for  determining  the 
number  of  viable  cells  in  proliferation  assays  (described  in  detail  in  section  2.6.6). 
Treatment of HAEC with serum (Figure 5.1A) or VEGF (Figure 5.1B) elicited a dose-
dependent  increase  in  HAEC  proliferation.  Throughout  the  course  of  the  current 
investigation HAEC were routinely cultured in endothelial cell media containing 2 % (v/v) 
serum (formulation described in detail in section 2.1.6). However, serum contains a range 
of  mitogens  therefore,  in  order  to  assess  the  specific  role  of  a  given  physiological 
concentration  of  VEGF  on  HAEC  proliferation  and  migration,  a  low-serum-containing 
media formulation (0.2 % (v/v) serum) was utilised.  
In HAEC incubated in this low-serum formulation, cells remained healthy and responsive 
to VEGF which was found to stimulate HAEC proliferation in a dose-dependent manner 
(10 ng/ml VEGF, 116 ± 3 %, n=5, p<0.01; 20 ng/ml VEGF, 122 ± 2 %, n=5, p<0.001 
versus control cells) (Figure 5.1B). 
The AMPK inhibitor compound C was used to determine whether AMPK is involved in 
VEGF-stimulated proliferation. Pre-treatment of HAEC with this agent prevented AICAR-
stimulated  ACC-Ser-80  phosphorylation  (Figure  5.2A),  and  moreover  was  found  to 
attenuate VEGF-stimulated proliferation (Figure 5.2B). Treatment of HAEC with 10 µM 
compound C resulted in an increase in proliferation even in the absence of VEGF treatment 
suggesting a role for AMPK in the regulation of basal proliferation. 
The effect of the CaMKK inhibitor STO-609 on HAEC proliferation was also determined. 
VEGF (20 ng/ml) treatment was found to stimulate HAEC proliferation (125 ± 5 %, n=3 
p<0.05 versus vehicle-treated cells), an effect abolished in cells treated with STO-609 (5 
µM STO-609, 108 ± 3 %, n=3, p<0.05; 10 µM STO-609, 106 ± 2 %, n=3, p<0.05 in 
comparison to 20 ng/ml VEGF-treated cells) (Figure 5.3).      175 
 
 
 
Figure 5-1  VEGF- and serum-mediated HAEC proliferation 
 (A) HAEC were serum starved for 2h then incubated in basal endothelial cell media containing 0.2-4 % (v/v) 
serum in the presence or absence of 20 ng/ml VEGF and proliferation assessed. The results are expressed as 
the mean ± SEM % basal absorbance measured at 488 nm for two independent experiments conducted in 
triplicate. (B) HAEC were serum starved for 2h then treated with the indicated concentrations of VEGF for 
24h in basal endothelial cell media containing 0.2 % (v/v) serum (a formulation used in all subsequent 
experiments unless otherwise indicated) and proliferation assessed. The results are expressed as the mean ± 
SEM % basal absorbance measured at 488 nm for five independent experiments conducted on 3-6 replicates 
in each case. *p<0.01 or **p<0.001 relative to the value in the absence of VEGF treatment.       176 
 
 
 
 
Figure 5-2  Effect of compound C on VEGF-stimulated HAEC proliferation 
 (A) HAEC were incubated with the indicated concentrations of compound C for 24h, treated in the presence 
or absence of AICAR (2 mM, 45 minutes) and lysates prepared. Lysates were resolved by SDS PAGE, 
transferred to nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-ACC-Ser-80 
resulted in a single band at ~280 kDa whereas as probing with α-GAPDH resulted in a band at ~ 35 kDa. (B) 
HAEC were treated with the indicated concentrations of compound C and/or VEGF for 24h and proliferation 
assessed. The results are expressed as a mean ± SEM % basal absorbance at 488 nm for three independent 
experiments conducted in triplicate. *p<0.05 relative to value in the absence of VEGF. 
#p<0.05 relative to 
value in the absence of compound C.      177 
 
Figure 5-3  Effect of STO-609 on VEGF-stimulated HAEC proliferation 
HAEC were treated with the indicated concentrations of STO-609 and/or VEGF for 24h and proliferation 
assessed. The results are expressed as a mean ± SEM % basal absorbance at 488 nm for three independent 
experiments conducted in triplicate.*p<0.05 relative to the value in the absence of VEGF treatment, 
#p<0.05 
relative to the value in the absence of STO-609. James A Reihill, 2009    Chapter 5, 178 
Ad.DN was also used to further characterise the involvement of AMPK in the VEGF-
mediated proliferative response. The Western blots shown in Figures 5.4A and B show 
Ad.DN potently inhibited AICAR-induced ACC Ser-80 phosphorylation; an effect which 
remained  intact  in  control-infected  HAEC.  VEGF-treatment  (20  ng/ml)  was  found  to 
increase HAEC proliferation in control-infected cells (Figure 5.4C). However, in HAEC 
infected with Ad.DN cell proliferation evoked by 20 ng/ml VEGF treatment was abolished 
(Figure  5.4C).  Incubation  of  HAEC  with  10  ng/ml  VEGF,  a  concentration  previously 
shown to stimulate proliferation (Figure 5.1B), was found to be without effect in this set of 
experiments (Figure 5.4C). This observation may suggest virally infected HAEC have a 
reduced sensitivity to VEGF treatment. Infection of HAEC with Ad.DN also seemed to 
result in a reduction in the basal proliferative rate (86 ± 6 %, n=6, p=0.053) (Figure 5.4C). 
It may be the case that cell proliferation is altered in the absence of AMPK.  Indeed, in 
HAEC  treated  with  10  ng/ml  VEGF,  a  concentration  which  did  not  stimulate  cell 
proliferation, Ad.DN infection reduced proliferation in comparison to control-infected cells 
(Figure 5.4C). 
The  use  of  Ad.DN  was  also  employed  to  determine  whether  AMPK  mediates  VEGF-
stimulated migration. Migration of HAEC toward VEGF was increased ~3-fold in control-
infected HAEC (Figure 5.5). In contrast, when HAEC were infected with Ad.DN VEGF-
stimulated migration was abolished (Figure 5.5).  
A constitutively active mutant AMPK (Ad.CA) (Woods et al., 2000) was also expressed in 
HAEC,  by  adenovirus-mediated  gene  transfer,  and  the  subsequent  effect  on  HAEC 
migration  assessed.  This  constitutively  active  mutant  consists  of  a  truncated  AMPKα1 
(residues 1-312) where Thr-172 is mutated to an aspartic acid. Truncation of AMPKα1 at 
residue 312 yields a polypeptide that no longer associates with the β and γ subunits, yet 
retains significant kinase activity (Crute et al., 1998). Mutation of Thr-172, the major site 
of phosphorylation by AMPK kinase (Hawley et al., 1996), to an aspartic acid,  prevents its 
inactivation by protein phosphatases (Stein et al., 2000). As demonstrated in Figure 5.5 
infection of cells with Ad.CA, which potently stimulates phosphorylation of ACC at Ser-
80 (Figure 5.6), increased HAEC migration even in the absence of VEGF treatment (~7-
fold). There was no additional increase in migration of Ad.CA-infected HAEC in response 
to VEGF (Figure 5.5). 
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Figure 5-4  Effect of Ad.DN on VEGF-stimulated HAEC proliferation 
 (A and B) HAEC were infected with 0-50 pfu/cell Ad.Null or Ad.DN as indicated for 24h then incubated in 
the  presence  or  absence  AICAR  (2  mM,  45  minutes).  Lysates  were  prepared,  resolved  by  SDS  PAGE, 
transferred to nitrocellulose and probed with the antibodies indicated. (C) HAEC  were infected  with 25 
pfu/cell adenovirus as indicated for 24h and subsequently treated in the presence or absence of the indicated 
concentrations of VEGF and proliferation assessed. The results are expressed as the mean ± SEM % basal 
absorbance at 488 nm for six independent experiments conducted in triplicate. *p<0.01 relative to the value 
in  the  absence  of  VEGF, 
#p<0.01  relative  to  the  value  in  control-infected  cells  treated  with  the  same 
concentration of VEGF. 
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Figure 5-5  Effect of Ad.DN on VEGF-stimulated HAEC migration 
HAEC were infected with Ad.Null, Ad.DN or Ad.CA adenovirus for 24h. HAEC migration in response to 10 
ng/ml VEGF was subsequently assessed using a Boyden chamber (described in detail in section 2.6.7). The 
results are expressed as the mean ± SEM % VEGF-stimulated migration based on 12-24 replicates for each 
condition. *p<0.001 relative to value in absence of VEGF.  
#p<0.001 relative to value in control-infected 
cells.  **p<0.001  relative  to  value  in  control-infected  cells  treated  with  VEGF.  These  experiments  were 
performed by Dr. Marie-Ann Ewart. James A Reihill, 2009    Chapter 5, 182 
Experiments were also conducted in order to determine the effect of AMPK activation on 
HAEC  proliferation.  Treatment  of  HAEC  with  Ad.CA  resulted  in  an  increase  in 
phosphorylation of ACC at Ser-80 (Figure 5.6A), and furthermore elicited a decrease in 
cell proliferation (Figure 5.6B). Similarly, treatment of HAEC with AICAR resulted in a 
dose-dependent decrease in HAEC proliferation (Figure 5.7).  
In addition the newly identified AMPK activator A-769662 (a generous gift provided by 
Professor D.G Hardie, University of Dundee) was also used to investigate the effect of 
AMPK activation on HAEC proliferation. Treatment of HAEC with this agent resulted in a 
dose-dependent  increase  in  phosphorylation  of  ACC  at  Ser-80  (Figure  5.8A)  and 
furthermore resulted in a trend whereby proliferation was decreased in a dose-dependent 
fashion (Figure 5.8B).  
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Figure 5-6  Effect of Ad.CA on HAEC proliferation 
 (A) HAEC were infected with Ad.Null or Ad.DN and lysates prepared. Lysates were also prepared from 
uninfected HAEC (control). Lysates were resolved by SDS PAGE, transferred to nitrocellulose and probed 
with the antibodies indicated.  (B) HAEC were infected with Ad.Null or Ad.CA and proliferation assessed. 
The results are expressed as a mean ± SEM % basal absorbance at 488 nm for three independent experiments 
conducted in triplicate. *p<0.01 relative to the value of control-infected cells.      184 
 
Figure 5-7  Effect of AICAR on HAEC proliferation 
HAEC were treated with the indicated concentrations of AICAR for 45 minutes, serum starved for 2h and 
proliferation assessed as normal. The results are expressed as a mean ± SEM % basal absorbance at 488 nm 
based on 12 replicates. *p<0.05, **p<0.001 relative to value in absence of AICAR. These experiments were 
performed by Dr Marie-Ann Ewart.  
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Figure 5-8  Effect of A-769662 on HAEC proliferation 
 (A) HAEC were incubated with the indicated concentrations of A-769662 for 24h and lysates prepared. 
Lysates  were  subsequently  resolved  by  SDS  PAGE,  transferred  to  nitrocellulose  and  probed  with  the 
antibodies indicated. Probing of lysates with α-ACC-Ser-80 resulted in a single band at ~280 kDa whereas as 
probing  with  α-GAPDH  resulted  in  a  band  at  ~  35  kDa  (B)  HAEC  were  treated  with  the  indicated 
concentrations of A-769662 for 24h and proliferation assessed. The results are expressed as a mean ± SEM % 
basal absorbance at 488 nm for three independent experiments conducted in triplicate. *p<0.05 relative to 
value in absence of A-769662. James A Reihill, 2009    Chapter 5, 186 
5.3 Discussion 
Compound C and STO-609 have been used in a number of studies on endothelial cells to 
inhibit AMPK and CaMKK respectively (Kim et al., 2007; Youn et al., 2008; Levine et al., 
2007; Stahmann et al., 2006; Hattori et al., 2008; Levine et al., 2007). Treatment of HAEC 
with compound C attenuated VEGF-stimulated phosphorylation of ACC on Ser-80 (Figure 
5.2A) and VEGF-stimulated proliferation (Figure 5.2B). Similarly STO-609 was found to 
abrogate  VEGF-stimulated  HAEC  proliferation  (Figure  5.3).  Although  these  initial 
observations indicate a role for AMPK in the regulation of VEGF-mediated proliferation it 
is important to note that both STO-609 and compound C have multiple off-target effects. 
Indeed when tested against a panel of protein kinases STO-609, also inhibited, in addition 
to  CaMKKα/β,  ERK8,  MAPK  integrating  protein  kinase  1  (MNK1),  casein  kinase  2, 
AMPK,  provirus  integration  site  for  Moloney  murine  leukaemia  virus  2  and  3,  dual-
specificity  tyrosine-phosphorylated  and  regulated  kinase  (DYRK)  2  and  3,  and 
homeodomain interacting protein kinase 2 (HIPK2) (Bain et al., 2007). Similarly, in the 
same study, the AMPK inhibitor compound C proved to be a potent inhibitor of other 
kinases including ERK8, MNK1, phosphorylase kinase, maternal embryonic leucine zipper 
kinase,  DYRK  isoforms,  HIPK2,  Src, lymphocyte-cell  specific protein  tyrosine kinase, 
Yes, FGF receptor 1 and ephrin A2 receptor (Bain et al., 2007). Another report has also 
shown that compound C inhibits the hypoxic activation of HIF-1 independent of AMPK in 
MEFs (Emerling et al., 2007). A lack of effect in response to STO-609 or compound C 
treatment may provide some evidence precluding the involvement of CaMKK and AMPK 
respectively  in  a  given  physiological  event.  However,  due  to  their  relative  lack  of 
specificity, any attenuated response as a result of their use does not necessarily establish 
the  involvement  of  CaMKK  or  AMPK.  Therefore,  in  order  to  confirm  AMPK  as  a 
mediator  of  VEGF-stimulated  proliferation,  and  also  migration,  a  dominant  negative 
AMPK adenovirus was utilised. Both VEGF-stimulated HAEC proliferation and migration 
were abrogated in HAEC in which AMPK had been ablated by infection with Ad.DN 
(Figures 5.4C and 5.5 respectively). In contrast, VEGF evoked a significant stimulation of 
proliferation and migration in control-infected HAEC (Figures 5.4C and 5.5 respectively). 
It was additionally found that infection of HAEC with Ad.CA, even in the absence of 
chemoattractant i.e. VEGF, resulted in a significant increase in cell migration, indicative of 
the induction of chemokinesis in these cells (Figure 5.5). 
Together these observations establish AMPK as a mediator of key physiological functions 
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consistent  with  a  number  of  other  reports  implicating  AMPK  as  a  mediator  of  the 
angiogenic response. Calpain, a cytosolic cysteine protease that translocates to membrane 
when activated, is a key regulator of  the cytoskeletal organisation of endothelial cells 
(Deroanne et al., 2001; Kulkarni et al., 2002); a process essential for angiogenesis. Calpain 
acts  through  a  range  of  substrates  to  mediate  effects  on  endothelial  cell  migration, 
differentiation and proliferation (Goll et al., 2003; Cuevas et al., 2003; Kulkarni et al., 
1999;  Hajimohammadreza  et  al.,  1997).  Calpain,  shown  to  mediate  VEGF-stimulated 
angiogenesis in human microvascular endothelial cells  (Su et al., 2006), has recently been 
reported to be an upstream mediator of AMPK upon VEGF stimulation of BAEC (Youn et 
al., 2008). Calpain has additionally been shown to act upstream of Rac1 and RhoA to 
regulate  the  formation  of  focal  adhesions  and  Rac-  and  Rho-induced  cytoskeletal 
organisation in BAEC (Kulkarni et al., 1999). Rac1, acting downstream of the VEGF-
AMPK  signalling  cascade  in  BAEC,  has  been  identified  as  a  mediator  of  both  tube 
formation  and  BAEC  migration  (Levine  et  al.,  2007).  Other  work  conducted  using 
transgenic mice overexpressing the calpain inhibitor calpastatin has suggested AMPK is a 
substrate for calpain in skeletal muscle (Otani et al., 2006).  
A number of other AMPK activators have also been shown to participate in the regulation 
of  the  angiogenic  response.  Statins  have  been  shown  to  regulate  endothelial  cell 
angiogenesis in vitro and in vivo, mediated through NO (Kureishi et al., 2000). Shyy and 
colleagues  have  demonstrated  in  HUVEC  that  statin-induced  tube  formation  is 
significantly  attenuated  by  infection  of  a  dominant  negative  AMPK  adenovirus  or 
compound  C  treatment  (Sun  et  al.,  2006).  Adiponectin  has  been  shown  to  stimulate 
HUVEC migration and differentiation into capillary-like structures in vitro (Ouchi et al., 
2004) and angiogenesis in response to tissue ischemia in vivo (Shibata et al., 2004), in an 
AMPK-mediated manner.  
AMPK  signalling  has  also  been  reported  as  essential  for  angiogenesis  in  response  to 
hypoxic stress (Nagata et al., 2003).  However, in contrast to data presented in the current 
investigation  (Figure  5.5),  Walsh  and  co-workers  reported  suppression  of  AMPK 
signalling was without effect on VEGF-stimulated migration under normoxic conditions 
(Nagata et al., 2003). Similar to the findings of the present study, in normoxic conditions, 
caffeine, at least in part, and adiponectin, have been shown to mediate endothelial cell 
migration in an AMPK-dependent manner  (Spyridopoulos et al., 2008; Ouchi et al., 2004). 
Hypoxia  has  been  reported  to  upregulate  CYP  epoxygenases  (Michaelis  et  al.,  2005), 
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proliferation,  migration  and  angiogenesis  (Chen  et  al.,  1998;  Fleming  et  al.,  2001b; 
Medhora et al., 2003; Michaelis et al., 2005; Zhang and Harder, 2002) Whilst CYP 2C 
protein expression has been demonstrated in native endothelial cells; mRNA and protein 
levels rapidly decrease after cell isolation, so that in passaged cultured endothelial cells 
mRNA  can  only  be  detected  using  RT–PCR  (Fisslthaler  et  al.,  2000).  Endothelial
  cell 
migration and tube formation are inhibited by a CYP 2C inhibitor and by downregulation 
of CYP 2C8/9
 expression using antisense oligonucleotides (Michaelis et al., 2005). As it 
has been reported that CYP 2C-derived EETs act as second messengers in the angiogenic 
response evoked by VEGF in endothelial cells (Webler et al., 2008) it may be the case that 
the CYP isozyme expression level may play a role in VEGF-stimulated endothelial cell 
signalling. This may provide a possible explanation for the disparate results observed in the 
present study and by (Nagata et al., 2003) where sufficient levels of CYP may only have 
been  present  under  hypoxic  conditions  in  the  endothelial  cells  used  by  Nagata  and 
coworkers. 
It is also worth noting that Nagata and colleagues used a dominant negative AMPKα2 
construct whereas the present study utilised a dominant negative AMPKα1 version. Both 
α1- and α2-AMPK subunits are expressed in endothelial cells (Davis et al., 2006), though 
the predominant isoform is α1 (Zou et al., 2004; Davis et al., 2006), with AMPKα2 barely 
detectable in these cells. Thus, it remains possible that AMPKα1 (and not AMPKα2) is 
responsible  for  mediating  VEGF-stimulated  angiogenesis  under  normoxic  conditions, 
whereas the AMPKα2 isoform may be of importance under hypoxic conditions. Further 
work is necessary to determine whether this is the case. 
CaMKK is the upstream kinase for VEGF-stimulated AMPK activation (chapter 3) and 
(Levine et al., 2007). This is of particular interest considering the number of reports that 
have demonstrated the critical nature of transmemebrane Ca
2+ entry in relation to processes 
associated  with  angiogenesis  (Faehling  et  al.,  2002;  Erdogan  et  al.,  2005;  Hamdollah 
Zadeh et al., 2008).  Preliminary work conducted in the present study (discussed in detail 
in chapter 4) and a recent report (Hamdollah Zadeh et al., 2008) suggest TRPC channels 
may underlie the Ca
2+ signal which is a key component of the VEGF-AMPK signalling 
cascade leading to angiogenesis. EETs, which have recently been implicated in VEGF-
mediated AMPK signalling (Webler et al., 2008) and activate several signalling pathways 
to  promote  endothelial  cell  proliferation,  migration  and  angiogenesis,  have  also  been 
demonstrated  to  regulate  Ca
2+  influx  in  response  to  bradykinin  by  a  mechanism  that 
involve translocation of TRP channels in endothelial cells (Fleming et al., 2007). If indeed James A Reihill, 2009     Chapter 5, 189 
TRPC channels are involved in the regulation of VEGF-stimulated AMPK activation in 
HAEC it would be of additional interest to characterise their involvement, and that of 
CaMKK, in any subsequent downstream effects, such as proliferation and migration. In T 
lympocytes triggering of the TCR has been shown to stimulate CaMKK-AMPK signalling 
(Tamas  et  al.,  2006).  It  has  been  proposed  that  AMPK  activation  by  TCR  may  be  a 
mechanism to stimulate the conservation and production of ATP in anticipation of the 
demand  for  ATP  initiated  by  Ca
2+-mediated  signalling  pathways;  in  this  instance  the 
energy demands of an immune response (Tamas et al., 2006). CaMKK-mediated activation 
of AMPK in the endothelium may underlie a similar mechanism to regulate events such as 
angiogenesis.  It  is  also  worth  noting  that  in  response  to  VEGF,  a  variety  of  parallel 
signalling pathways, in addition to AMPK, are also stimulated which are necessary for a 
proliferative response. For example, VEGF activated MAPKs, which are key components 
of  the  VEGF-induced  signalling  cascade  leading  to  endothelial  cell  proliferation 
(Waltenberger  et  al.,  1996;  Ziche  et  al.,  1997;  Kroll  and  Waltenberger,  1997),  are 
necessary for VEGF-induced proliferation, but are not sufficient to induce proliferation 
when activated alone (Faehling et al., 2002). Thus it is clear a multitude of pathways are 
necessary  for  a  proliferative  response.  NO,  a  key  regulator  of  this  response 
(Papapetropoulos  et  al.,  1997;  Yu  et  al.,  2005),  which  is  produced,  at  least  in  part, 
downstream of VEGF-mediated AMPK activation may be responsible for the proliferative 
effects  mediated  by  AMPK  in  HAEC;  which  acts  in  concert  with  Ca
2+-independent 
pathways such as MAPK to regulate proliferation. 
Whilst the data presented in the  current study demonstrate that AMPK  is required for 
VEGF-mediated  proliferation  a  wide  range  of  experimental  evidence  has  additionally 
shown activation of AMPK mediates a number of pathways (summarised in Figure 5.9) 
which result in the suppression of proliferation. These pathways, briefly described below, 
are reviewed in (Motoshima et al., 2006). 
Up-regulation of the p53-p21 axis by AMPK has been shown to cause G1 cell cycle arrest 
due to the accumulation of the tumour suppressor p53, which in turn up regulates the 
CDKI protein p21
CIP (Imamura et al., 2001; Jones et al., 2005; Igata et al., 2005). AMPK- 
mediated  activation  of  mTOR,  a  serine/threonine  kinase  known  to  regulate  protein 
translation and synthesis, suppresses mTOR signalling by growth factors and amino acids 
(Kimura et al., 2003; Krause et al., 2002; Bolster et al., 2002). FAS, ACC and HMGR are 
AMPK substrates for AMPK which regulate fatty acid and cholesterol synthesis. Many 
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rosiglitazone-induced AMPK activation has been demonstrated to reduce the expression of 
FAS and ACC resulting in the suppression of prostate cancer cell proliferation (Xiang et 
al., 2004). 
In the current study, activation of AMPK, using AICAR, was also found to result in a 
suppression of proliferation (Figure 5.7). This is consistent with the findings of several 
other studies. AICAR-induced AMPK activation causes cycle arrest in hepatoma HepG2 
cells (Imamura et al., 2001), MEFs (Jones et al., 2005), human aortic smooth muscle cells 
and rabbit aortic strips (Igata et al., 2005). Activation of AMPK has also been shown to 
facilitate  apoptosis  of  lung  cancer  cells,  gastric  cancer  cells,  pancreatic  cancer  cells, 
hepatic carcinoma cells, and prostate cancer cells (Rattan et al., 2005). However, although 
widely used as an activator of AMPK AICAR does not directly
 activate the kinase in cell-
free assays. AICAR, a pro-drug taken up into cells by
 adenosine transporters (Gadalla et 
al., 2004), is converted to its active component (ZMP, an AMP analogue) inside the cell, 
which acts as a mimetic of AMP thus activating AMPK (Corton et al., 1995). ZMP, in 
addition to AMPK, is known to regulate other AMP-sensitive enzymes such as fructose-
1,6-bisphosphatase (Vincent  et  al.,  1996) and  glycogen phosphorylase (Longnus  et  al., 
2003). Accumulation  of  adenosine  outside
  cells,  with  consequent binding  to  adenosine 
receptors can have effects in some in vitro systems (Gadalla et al., 2004). Notably AICAR 
has also been shown to inhibit proliferation in embryonic fibroblasts
 from both wild-type 
and LKB1 knock-out mice, suggesting
 AICAR itself may have a role in the inhibition of 
cancer
 cell growth (Rattan et al., 2005). It is therefore clear AICAR is not a model tool to 
determine the effect of AMPK activation on proliferation.  
A-769662,  which  is  described  in  detail  in  section  1.2.6.4,  is  a  newly  identified  direct 
activator of AMPK (Cool et al., 2006; Sanders et al., 2007a; Goransson et al., 2007),. 
Figure  5.8A  demonstrates  that  treatment  of  HAEC  with  A-769662  resulted  in  a  dose-
dependent  stimulation  of  phosphorylation  of  the  major  AMPK  substrate  ACC  Ser-80. 
Moreover, incubation of HAEC with A-769662 resulted in a dose-dependent decrease in 
proliferation (Figure 5.8B). In further agreement with this observation, infection of HAEC 
with Ad.CA similarly resulted in a reduction in HAEC proliferation (Figure 5.6B). 
So, on one hand, while AMPK has been demonstrated to underlie the VEGF-stimulated 
proliferative  response,  activation  of  the  kinase,  in  this  study  and  others,  has  been 
demonstrated to suppress proliferation. In vivo angiogenic endothelial cells must not only 
proliferate but produce molecules able to degrade the extracellular matrix, change their James A Reihill, 2009     Chapter 5, 191 
adhesive properties, migrate, avoid apoptosis and differentiate into vascular tubes in order 
to carry blood (Munoz-Chapuli et al., 2004). As stated above, in response to VEGF, a 
variety of parallel signalling pathways, in addition to AMPK, are also stimulated which are 
required for this complex angiogenic response. Thus, the selective stimulation of AMPK 
may suppress proliferation, as in the absence of the overall signalling network necessary 
for the angiogenic response; its activation may merely represent a waste of energy. It may 
be the case that in the absence of CaMKK-mediated AMPK activation, such as that evoked 
by VEGF, the tumour suppressor LKB1 is the dominant upstream kinase which may confer 
an anti-angiogenic signal on AMPK.  
Indeed the degree to which CaMKK/LKB1 contributes to AMPK activation may confer a 
pro- or anti-angiogenic signal. Mammalian cell proliferation is wholly dependent on the 
cell  cycle  machinery.  Cell  cycle  progression  is  positively  regulated  by  CDKs  and 
negatively regulated by CDKIs and tumour suppressor genes (Motoshima et al., 2006). The 
various  pathways  activated  by  growth  factors  such  as  VEGF  ultimately  converge  on 
common downstream regulators of the cell cycle such as CDKIs, tumour suppressors and 
CDKs, the balance of which regulates the progression of the cell cycle (Grana and Reddy, 
1995). AMPK may be an important mechanism which contributes to this overall balance in 
a pro- or anti-angiogenic manner dependent on its mode of activation. 
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Figure 5-9  AMPK-regulated pathways which may modulate cell proliferation 
AMPK activation may regulate cell proliferation not only by activation of p53–p21 axis and inhibition of 
mTOR  signalling,  but  also  by  suppression  of  the  mevalonate  synthesis  pathway  and  de  novo  fatty  acid 
synthesis. When AMPK is activated, various pathways indicated by dashed arrows are suppressed. (Figure 
adapted from (Motoshima et al., 2006)). 
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6  VEGF AND ENDOTHELIAL CELL FATTY ACID 
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6.1 Introduction 
The storage of body fat acts as an essential energy reserve for times of starvation, but also 
substantially increases the risk of diabetes and heart disease (Bays et al., 2008). Thus, a 
suitable balance between fat utilisation and storage is imperative. ACC1, ACC2 and CPT1 
are important molecules which regulate this balance. ACC, of which there are two distinct 
isoforms, ACC1 and ACC2, are crucial enzymes which regulate this balance of fatty acid 
synthesis and oxidation through the catalysis of acetyl-CoA to malonyl-CoA (Brownsey et 
al., 2006). The malonyl-CoA generated within the cell by ACC1 and ACC2 is in distinct 
pools  (Wakil  and  Abu-Elheiga,  2008).  The  ACC1  isoform,  present  in  the  cytosol,  is 
primarily responsible for fatty acid synthesis (as discussed in section 1.3.1.3), and while 
generally expressed in most tissues is found in high abundance in lipogenic tissues such as 
liver, adipose and lactating mammary gland (Iverson et al., 1990). ACC2, localised to the 
mitochondria, is an important regulator of fatty acid oxidation (as discussed in section 
1.3.1.3), and is the predominant isoform expressed in heart, muscle and to a lesser extent 
liver (Abu-Elheiga et al., 2000).  
The excess accumulation of triglyceride in tissues such as liver and muscle is associated 
with insulin resistance (Petersen and Shulman, 2006). At the level of the endothelium, 
exposure  to  excessive  free  fatty  acids  is  associated  with  endothelial  dysfunction, 
characterised  by  increased  superoxide  production,  impaired  nitric  oxide  activity  and  a 
reduction  in  endothelium-dependent  vasodilation  (McCarty,  2005).  An  excess  of  fatty 
acids in endothelial cells leads to an increase in the production of DAG with consequent 
activation of PKC (Lee et al., 1989; Inoguchi et al., 2000). Activation of PKC results in 
enhanced endothelial superoxide production via NADPH oxidase (Inoguchi et al., 2000), 
reduced NO synthase activity (Michell et al., 2001), impaired endothelial responsiveness to 
insulin  (Ruderman  et  al.,  2003)  and  the  promotion  of  a  pro-inflammatory  phenotype 
through the activation of NF-κB (Pieper and Riaz, 1997; Sugiyama et al., 1998; Park et al., 
2003).  
AMPK phosphorylates ACC resulting in a reduction in the activity of both isoforms with a 
consequent increase in fatty acid oxidation and reduction in fatty acid synthesis (Hardie 
and  Pan,  2002;  Hardie,  2008).  A  number  of  reports  have  demonstrated  that  AMPK 
activation in response to AICAR, glucose deprivation and bradykinin stimulates fatty acid 
oxidation in endothelial cells (Dagher et al., 2001; Dagher et al., 1999; Mount et al., 2008). 
Activation of the AMPK-ACC system is therefore an attractive therapeutic target which James A Reihill, 2009     Chapter 6, 195 
may ameliorate the adverse effects of excessive free fatty acids on the endothelium. In 
addition to the increased oxidation of fatty acids activation of AMPK in the endothelium 
likely  confers  some  additional  effects  on  lipid  metabolism.  PKC  activation  inhibits 
glycerol-3-phosphate  acyltransferase,  required  for  de  novo  synthesis  of  DAG.  AMPK- 
mediated activation of eNOS  may oppose the adverse impact of PKC on the enzyme 
(Chen et al., 1999; Morrow et al., 2003) and furthermore, it has been reported that AICAR-
induced  activation  of  AMPK  prevents  against  the  adverse  effects  of  palmitate  or 
hyperglycemia on endothelial superoxide production and inflammatory NF-κB activation 
(Ruderman et al., 2003). 
In light of the benefits associated with AMPK activation, the effect of the endothelial- 
specific AMPK activator, namely VEGF, on ACC phosphorylation and fatty acid oxidation 
was  determined  in  HAEC.  Intriguingly,  increased  fatty  acid  oxidation  in  response  to 
bradykinin  has  recently  been  demonstrated  in  BAEC;  an  effect  mediated  by  the  same 
AMPKK (CaMKK)  responsible for VEGF-stimulated AMPK activation (Mount et al., 
2008). 
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6.2 Results 
There  are  two  major  ACC  isoforms  expressed  in  mammals  with  potentially  distinct 
functions. Using isoform-specific anti-ACC antibodies the expression of both isoforms of 
ACC, 1 and 2, was demonstrated in HAEC (Figure 6.1). 
The Ser-80 site in ACC1 is conserved in ACC2 (Hardie and Pan, 2002). As well as the 
serine  residue,  some  of  the  surrounding  residues  that  are  positive  determinants  for 
recognition by AMPK (Scott et al., 2002) are also conserved in ACC2 (Hardie and Pan, 
2002). Because of the N-terminal extension in ACC2, the serine residue equivalent to Ser-
80 on ACC1 is Ser-220 on ACC2. The effect of VEGF treatment on ACC phosphorylation 
was used using an antibody (section 2.1.7) that recognizes both phosphorylated species 
(referred to as Ser-80).  
VEGF stimulated a transient phosphorylation of ACC (Figure 6.2). The effect reached a 
maximal ~2.2-fold stimulation of ACC at Ser-80 after 5 minutes and rapidly returned to 
basal levels within 30 minutes (Figure 6.2). Phosphorylation of ACC at Ser-80 was dose-
dependent, such that phosphorylation of this residue was stimulated maximally (~5-fold) 
by 50 ng/ml VEGF (Figure 6.3).  
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Figure 6-1  ACC isoform expression in HAEC 
HAEC  lysates  (~200  µg)  were  precipitated  with  streptavidin-immobilised  agarose  beads.  Samples  were 
resolved by SDS PAGE, transferred to nitrocellulose and probed with the antibodies indicated. 
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Figure 6-2  Time course: VEGF-stimulated phosphorylation of ACC at Ser-80 
HAEC lysates were prepared from cells incubated with 10 ng/ml VEGF for the indicated durations. Lysates 
were resolved by SDS PAGE, transferred to nitrocellulose and probed with the antibodies indicated. Probing 
of lysates  with α-ACC and α-ACC Ser-80 resulted in a  single band at ~280 kDa in both instances (A) 
Representative immunoblots are shown, repeated with similar results on 3 different samples of lysates. (B) 
Quantification of ACC Ser-80 phosphorylation from 3 independent experiments.*p<0.01 relative to value in 
absence of VEGF. 
#p<0.05 relative to value in absence of VEGF.  
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Figure 6-3  Dose-response: VEGF-stimulated phosphorylation of ACC at Ser-80 
 (A) HAEC lysates were prepared from cells incubated with the indicated concentrations of VEGF for 5 
minutes and lysates prepared. Lysates were resolved by SDS PAGE, transferred to nitrocellulose and probed 
with the antibodies indicated. Probing of lysates with α-ACC and α-ACC Ser-80 resulted in a single band at 
~280 kDa in both instances. (A) Representative immunoblots are shown, repeated with similar results on 3 
different  samples  of  lysates.  (B)  Quantification  of  ACC  Ser-80  phosphorylation  from  3  independent 
experiments. * p<0.01 relative to value in absence of VEGF.  
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The involvement of AMPK in VEGF-stimulated ACC phosphorylation was subsequently 
determined.  The  CaMKK  inhibitor  STO-609  abrogated  VEGF-stimulated  ACC 
phosphorylation  at  Ser-80  (Figure  6.4)  implicating  a  role  for  CaMKK-AMPK  in  this 
process.  
However,  as  discussed  previously  (section  5.3)  STO-609  is  not  ideal  candidate  to 
determine the effect AMPK on downstream substrates. Consequently, HAEC were infected 
with  Ad.DN  and  VEGF-stimulated  ACC  phosphorylation  on  Ser-80  phosphorylation 
determined. Ablation of AMPK by infection of HAEC with Ad.DN completely inhibited 
VEGF-stimulated  ACC  Ser-80  phosphorylation  further  indicating  the  involvement  of 
AMPK in this process (Figure 6.5).      201 
 
 
Figure 6-4  Effect  of  STO-609  on  VEGF-stimulated  phosphorylation  of  ACC  on 
Ser-80 
HAEC lysates were prepared from cells incubated with 10 ng/ml VEGF for 5 minutes after pre-treatment 
with 25 µM STO-609 for 20 minutes. Lysates were resolved by SDS PAGE, transferred to nitrocellulose and 
probed with the antibodies indicated. Probing of lysates with α-ACC and α-ACC Ser-80 resulted in a single 
band at ~280 kDa in both instances. (A) Representative immunoblots are shown, repeated with similar results 
on 4 different samples of lysates. (B) Quantification of ACC Ser-80 phosphorylation from 4 independent 
experiments using ImageJ Software. *p<0.05 relative to value in absence of STO-609. 
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Figure 6-5  Effect of Ad.DN on VEGF-stimulated phosphorylation of ACC on Ser-
80 
HAEC were infected with Ad.DN or control-adenoviruses then lysates were subsequently prepared from 
cells  incubated  in  the  presence  or  absence  of  10  ng/ml  VEGF.  Lysates  were  resolved  by  SDS  PAGE, 
transferred to nitrocellulose and probed with the antibodies indicated. Probing of lysates with α-ACC and α-
ACC-Ser-80 resulted in a single band at ~280 kDa in both instances. (A) Representative immunoblots are 
shown, repeated with similar results on 4 different samples of lysates. (B) Quantification of ACC-Ser-80 
phosphorylation from 4 independent experiments. *p<0.01 relative to value in control virus-infected cells.   James A Reihill, 2009    Chapter 6, 203 
Inhibition  of  phosphorylation  at  Ser-80  of  ACC  by  AMPK  has  been  demonstrated  to 
decrease fatty acid synthesis in adipose and liver whilst stimulating fatty acid oxidation in 
heart and skeletal muscle (Carling, 2004). In endothelial cells activation of AMPK has 
been reported to stimulate fatty acid oxidation (Dagher et al., 2001; Mount et al., 2008). 
This highlighted the possibility that VEGF stimulates the oxidation of fatty acids due to 
AMPK-mediated phosphorylation of ACC. Similar to the findings reported by (Dagher et 
al., 2001) incubation of HAEC with AICAR resulted in a ~2.3-fold increase in fatty acid 
oxidation in comparison to control cells (238 ± 60 %, n=3, p=0.15) (Figure 6.6). However, 
treatment of HAEC with VEGF did not alter fatty acid oxidation (103 ± 10 % versus 
control cells) (Figure 6.6). 
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Figure 6-6  Effect of VEGF on HAEC fatty acid oxidation 
Fatty acid oxidation was measured in HAEC over 2h on the basis of 
3H2O production from 
3H-palmitate 
(described in detail in section 2.6.5) in HAEC treated with the indicated concentrations of VEGF or AICAR. 
Values are mean ± SEM % basal fatty acid oxidation for 3 independent experiments conducted in triplicate. James A Reihill    Chapter 6, 205 
6.3 Discussion 
VEGF stimulated ACC Ser-80 phosphorylation  in a time- and dose dependent manner 
(Figures 6.2 and 6.3 respectively). Moreover, pre-treatment of HAEC with STO-609 or 
infection with Ad.DN abrogated VEGF-stimulated ACC Ser-80 phosphorylation (Figures 
6.4 and 6.5 respectively), supporting a role for AMPK in this process. This is consistent 
with  a  number  of  studies  which  observed  activation  of  AMPK  causes  inhibitory 
phosphorylation of ACC in endothelial cells (Zou et al., 2002; Zou et al., 2004; da Silva et 
al., 2006; Stahmann et al., 2006; Sun et al., 2006; Zou et al., 2003; Mount et al., 2008). In 
HUVEC and BAEC, activation of AMPK by  AICAR  and bradykinin  respectively, has 
been shown to increase fatty acid oxidation (Dagher et al., 2001; Mount et al., 2008). In 
contrast however, in the present investigation, the AMPK activator VEGF was without 
effect on HAEC fatty acid oxidation. AICAR, similar to the effects reported by (Dagher et 
al., 2001), elicited a ~2.4-fold increase in fatty acid oxidation in comparison to control 
cells  (Figure  6.6).  Although  not  of  statistical  significance  this  observation  indicates  a 
suitable assay was used to assess fatty acid oxidation in this study.  
In comparison to VEGF AICAR is a more potent (Figure 4.6) and sustained activator of 
AMPK. In the study by Dagher and colleagues AICAR mediated AMPK and ACC activity 
maximally after 30 minutes, an effect sustained for at least 2h (Dagher et al., 1999). VEGF 
stimulated AMPK and ACC maximally after 5 minutes; an effect which returned to basal 
levels  within  30  minutes  (Figures  3.1A  and  6.2).  This  VEGF-induced  response  is 
consistent  with  the  effects  elicited  by  other  CaMKK-dependent  AMPK  activators 
(Stahmann et al., 2006; Tamas et al., 2006). This raises the possibility that the activation of 
ACC by VEGF, and other transient activators, may not be sufficient, unlike AICAR, to 
measurably increase fatty acid oxidation over the time period measured. Interestingly, a 
recent  report  conducted  in  BAEC  has  demonstrated  bradykinin  stimulates  fatty  acid 
oxidation  in  a  CaMKK-dependent  manner  (Mount  et  al.,  2008).  Bradykinin  rapidly 
induced phosphorylation of ACC on Ser-80 within 30 seconds and reached a maximum 
after 5 minutes, yet unlike the response elicited by VEGF, the response to bradykinin still 
remained intact after 30 minutes (Mount et al., 2008). The effect of bradykinin after 30 
minutes incubation was not reported in this study (Mount et al., 2008). Thus, it remains 
possible that VEGF  elicited a transient increase in fatty acid oxidation which  was not 
detected in the present study. Indeed any transient effect may have been masked by the 
basal oxidation of fatty acids occurring throughout the 2h time period measured. However 
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or prior exercise (Oakes et al., 1997),  both of which transiently increase AMPK activity, 
cause sustained decreases in malonyl-CoA and increased insulin-stimulated glucose uptake 
in muscle 24h later. Thus a transient activation of AMPK may be sufficient to mediate 
fatty acid oxidation in the longer term. Therefore it may be appropriate to determine the 
effect  of  VEGF-treatment  on  malonyl-CoA  levels  and  subsequently  assess  fatty  acid 
oxidation over the relevant time period.  
VEGF-stimulated  fatty  acid  oxidation  was  assessed  in  HAEC  incubated  in  Earle’s 
balanced  salt  solution  (for  formulation  see  section  2.2.1)  containing  5.5  mM  glucose. 
Although recent reports have demonstrated that under certain conditions fatty acids may be 
a substantial fuel source for the endothelial cell (Dagher et al., 2001; Mount et al., 2008) it 
was originally believed these cells derive most of their metabolic energy from glycolysis 
(Spahr et al., 1989; Krutzfeldt et al., 1990). It may be the case that glycolytic breakdown of 
glucose is sufficient to cope with the energy requirements of HAEC under the conditions 
of  this  study.  In  times  of  necessity  the  oxidation  of  fatty  acids  may  become  more 
prominent. 
The main actions of VEGF, as discussed in detail above, are to promote survival, induce 
proliferation  and  enhance  migration  and  invasion  of  endothelial  cells  leading  to 
angiogenesis.  Contact  inhibited  endothelial  cells  have  a  reduced  response  to  specific 
growth factor signals when they reach confluence (Fagotto and Gumbiner, 1996; Vinals 
and Pouyssegur, 1999), and intracellular contacts transfer a negative signal reducing the 
responsiveness  of  cells  to  proliferative  signals  with  pro-survival  signalling  pathways 
becoming dominant.  As confluent HAEC were used to assess VEGF-stimulated fatty acid 
oxidation  it  seems  feasible  that  ATP-consuming  pathways,  mediating  effects  such  as 
proliferation and migration, were not activated in response to VEGF, as would be the case 
in  sub-confluent  cells.  Therefore  it  may  also  be  worthwhile  determining  the  effect  of 
VEGF-treatment on fatty acid oxidation using sub-confluent (proliferative) HAEC. 
Finally, whilst this study provides no evidence indicating that VEGF-stimulated AMPK 
activation  mediates  fatty  acid  oxidation  in  HAEC,  isoform-specific  ACC  antibodies 
indicate the presence of both ACC1 and ACC2 in these cells (Figure 6.1). The phospho-
ACC antibody used in this study detected ACC as a single band (Figures 6.2-6.5), and as 
such it is indistinguishable whether the band is the ACC1 or ACC2 isoform. Therefore it 
remains possible inhibition of ACC1 mediated by VEGF-stimulated AMPK activation may James A Reihill, 2009     Chapter 6, 207 
inhibit fatty acid synthesis in these cells. Further work however is necessary to determine 
whether this is indeed the case.     208 
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7.1 Summary of findings and future work 
This project aimed to characterise the role of AMPK in human vascular endothelial cell 
function  in  response  to  VEGF  exposure.  VEGF  and  AMPK  are  important  signalling 
molecules in the endothelium, both of which have been shown to promote NO production, 
a key molecule which maintains cardiovascular homeostasis and protects the endothelium 
against the development of atherosclerosis. At the beginning of this work VEGF had been 
demonstrated to stimulate NO production, proposed to be a result of phosphorylation and 
activation eNOS at Ser-1177 (Fulton et al., 1999), a residue also phosphorylated upon 
AMPK activation in cultured endothelial cells (Morrow et al., 2003). However, prior to the 
present  study,  the  role  of  AMPK  in  VEGF-simulated  NO  production  remained 
undetermined. As outlined in chapter 3 physiological concentrations of VEGF were found 
to transiently stimulate AMPK in a time- and dose-dependent manner, and furthermore 
AMPK was shown to partly mediate VEGF-stimulated eNOS phosphorylation at eNOS-
Ser-1177 and NO production. More recent studies have further confirmed the finding that 
AMPK  is  a  component  of  VEGF  signalling  in  endothelial  cells  (Levine  et  al.,  2007; 
Webler et al., 2008; Youn et al., 2008) that underlies eNOS activation (Levine et al., 2007; 
Youn et al., 2008). A similar mechanism has also been reported in endothelial progenitor 
cells (EPCs) (Li et al., 2008). 
The present study then sought to determine the molecular mechanisms underlying VEGF-
stimulated AMPK activation. As there is reduced vascular structure and angiogenesis in 
LKB1
-/- mouse embryos, and increased concentrations of VEGF, it seemed possible there 
was a link between LKB1 and VEGF/angiogenesis (Ylikorkala et al., 2001). However, a 
number of observations outlined in chapter 4 indicate LKB1 is not involved in VEGF-
mediated AMPK activation in HAEC. In contrast, the alternate upstream kinase for AMPK 
CaMKK was found to be essential for VEGF-stimulated AMPK activity. In a study by 
Levine  and  coworkers  a  genetic  approach  indicated  the  β  isoform  of  CaMKK  is 
responsible for VEGF-stimulated AMPK activation in bovine endothelial cells (Levine et 
al., 2007), again supporting the finding that CaMKK underlies VEGF-mediated AMPK 
activation. In addition to VEGF, an increasing number of groups have also identified that a 
range of other agonists including extracellular nucleotides, thrombin, bradykinin, ghrelin 
and NO also stimulate endothelial AMPK in a CaMKK-dependent manner (da Silva et al., 
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CaMKK-mediated  activation  of  AMPK  is  rapid  and  transient  (Stahmann  et  al.,  2006; 
Mount et al., 2008; Xu et al., 2008; da, X et al., 2000). It has been suggested that AMPK 
activation, mediated by CaMKK, may act as a mechanism to anticipate energy expenditure 
(Tamas et al., 2006). It makes sense that AMPK can anticipate energy expenditure, perhaps 
an  inevitable  outcome  upon  the  initiation  of  Ca
2+  signalling,  in  addition  to  acting 
retrospectively to compromised energy status (via LKB1). Together CaMKK and LKB1 
may work to maintain energy balance in the short and longer term. 
Chronic dysfunction of the endothelium, characterised by reduced NO bioavailability, is 
implicated  in  the  pathophysiology  of  several  cardiovascular  disorders,  including 
atherosclerosis,  hypertension,  diabetic  vasculopathy  and  heart  failure  (Harrison  et  al., 
2003). Therefore the role of AMPK in VEGF-stimulated NO production is of particular 
interest. However, VEGF only elicits a transient activation of eNOS at Ser-1177, thus one 
could reasonably argue that increased NO by this mechanism would need to be over a 
more sustained period for any beneficial effect in the context of cardiovascular disease. 
Interestingly, however, NO has been reported to act as an endogenous
 activator of AMPK 
in  endothelial  cells  through  a  pathway  involving  CaMKKβ  (Zhang  et  al.,  2008).  This 
observation, and the findings of the present study, would indicate that a positive feedback 
mechanism  may  exist  whereby  NO  produced  by  VEGF-AMPK  may  in  turn  activate 
AMPK thus enabling an increase in NO production in the longer term. It has been further 
reported  that  NO  up-regulates  VEGF  expression  which  may  also  contribute  to  this 
mechanism (Hood et al., 1998; Dembinska-Kiec et al., 1997). 
Phosphorylation of eNOS at Ser-633 increases NO independent of increased intracellular 
Ca
2+ concentration (Boo et al., 2003), and in response to several stimuli, including VEGF 
(Michell  et  al.,  2002),  the  onset  of eNOS Ser-633 phosphorylation  is  slower than that 
observed for Ser-1177 (Boo et al., 2002a). Thus, it may be the case that stimulation of 
eNOS Ser-633 phosphorylation is important in maintaining eNOS activation after initial 
activation by Ca
2+ flux and/or Ser-1177 phosphorylation. A very recent report by Chen and 
coworkers  has  shown  phosphorylation  of  eNOS  Ser-633  in  response  to  shear  stress, 
atorvastatin, and adiponectin is AMPK-dependent. In light of this finding further work to 
characterise the role of AMPK in response to VEGF, at Ser-633, or the other known eNOS 
phosphorylation sites (Ser-114, Thr-495 and Ser-615), may be of interest.  
Data outlined in chapter 4 suggest Ca
2+ influx across the plasma membrane is essential for 
VEGF-stimulated CaMKK-AMPK activation. The TRPC family of non-selective cation James A Reihill, 2009     Chapter 7, 211 
channels  represents  an  attractive  candidate  which  may  underlie  this  observation.  Very 
recent  reports  have  shown  that  TRPC6  is  required  for  VEGF-stimulated  angiogenesis 
(Hamdollah Zadeh et al., 2008), and thrombin-induced AMPK activation (Bair et al., 2008) 
in endothelial cells. However, as yet, the role of these channels has not yet been directly 
determined in relation to VEGF-induced AMPK activation. Therefore the role of TRPC 
channels in relation to AMPK function represents an area of study which would advance 
the present investigation. 
Another  attractive  candidate  for  future  study  is  PLC  and  its  role  in  VEGF-stimulated 
AMPK activation. PLC has been shown to underlie thrombin-induced AMPK activation 
(Stahmann et al., 2006), and moreover this signalling molecule represents a component of 
the RTK-induced activation of TRPC channels. Although attempts were made to determine 
the role of PLC in VEGF-mediated AMPK activity in this investigation, further work is 
necessary to elucidate its role.  
VEGF  is  a  critical  regulator  of  angiogenesis,  the  physiological  process  involving  the 
growth  of  new  blood  vessels  from  pre-existing  ones.  NO  has  been  characterised  as  a 
critical regulator of VEGF-induced angiogenesis (Papapetropoulos et al., 1997; Yu et al., 
2005; Fukumura et al., 2001). As the present study identified AMPK as a component of the 
VEGF-eNOS signalling cascade it seemed possible that AMPK may be involved in the 
VEGF-mediated angiogenic response. In addition, as Ca
2+ signalling is a critical regulator 
of angiogenesis (Kohn et al., 1995; Faehling et al., 2002; Hamdollah Zadeh et al., 2008), it 
was  interesting  that  the  activation  of  AMPK  was  Ca
2+  dependent.  Angiogenesis  is  a 
complex process, two key features of which are endothelial cell migration and proliferation 
(Ferrara, 2004b).  As outlined in chapter 5, ablation of AMPK prevented both VEGF-
stimulated  proliferation  and  migration,  demonstrating  a  key  role  for  the  kinase.  These 
observations  are  consistent  with  a  number  of  other  studies.  In  a  Matrigel
  plug  assay 
conducted  in  mice,  endothelial  cells  were  recruited  into  VEGF-impregnated
  plugs;  an 
effect that was sensitive to the inclusion
 of siRNA directed against AMPK (Webler et al., 
2008). Furthermore, in addition to VEGF; hypoxia, adiponectin and statins have also been 
shown  to  mediate  angiogenesis  in  an  AMPK-dependent  manner  (Ouchi  et  al.,  2004; 
Shibata et al., 2004; Nagata et al., 2003; Sun et al., 2006). While it seems highly likely that 
AMPK-stimulated  NO  production  underpins  the  importance  of  AMPK  in  the  VEGF-
mediated angiogenic response it is worth noting that this was not determined in the present 
study.  Thus,  further  experiments  to  confirm  this  hypothesis  may  be  worthwhile.  For James A Reihill, 2009     Chapter 7, 212 
example,  does  a  NO  donor  rescue  the  effect  of  AMPK  ablation  on  VEGF-stimulated 
proliferation and migration? 
A large body of evidence indicates that VEGF-R2 is largely responsible for mediating the 
effects of VEGF including proliferation and migration, whereas it has often been suggested 
that VEGF-R1 signalling is of limited relevance in comparison. However, a number of 
reports  suggest  VEGF-R1  may  also  contribute  to  a  number  of  important physiological 
processes.  VEGF-R1-blocking  antibodies  have  been  demonstrated  to  prevent  the 
migration, but not proliferation, of HUVEC in response to VEGF (Kanno et al., 2000) and 
one study has reported that VEGF-mediated NO synthesis is driven through VEGR-R1 in 
HUVEC,  whereas  specific  activation  of  VEGF-R2  was  unable  to  induce  NO  release 
(Bussolati et al., 2001). Furthermore, specific activation of VEGF-R1 using VEGF-B has 
been  demonstrated  to  increase  eNOS  Ser-1177  phosphorylation,  PKB  Ser-473 
phosphorylation and angiogenesis (Silvestre et al., 2003). VERF-R1-mediated signalling 
appears to preferentially modulate the reorganization of actin via MAPK, whereas VEGF-
R2 contributes to the re-organization of the cytoskeleton by phosphorylating FAK and 
paxillin,  suggesting  a  different  contribution  of  the  two  receptors  to  the  chemotactic 
response.  As  initial  studies  in  this  study  indicated  VEGF-R1  and  VEGF-R2  may 
potentially  mediate  AMPK  activation  in  response  to  VEGF,  it would be  of interest to 
determine  whether  a  kinase  such  as  AMPK  can  mediate  distinct  functional  effects 
depending on the activating VEGF receptor. For example does VEGF-R1 or VEGF-R2 
have a particular importance in regards to the effects on proliferation and migration seen in 
the present investigation? Also, it may be interest to determine whether the neuropilins, 
identified as VEGF co-receptors (Soker et al., 1998; Soker et al., 2002), are involved in 
VEGF-stimulated AMPK activation and any subsequent functional effects.  
In addition to VEGF, a range of molecules serve as positive regulators of angiogenesis 
such as fibroblast growth factors, transforming growth factors, hepatocyte growth factor, 
TNFα, oestrogen, angiogenin, IL-8 and angiopoietins, often acting in synergistic fashion 
with VEGF (Goto et al., 1993; Yoshiji et al., 2005; Stannard et al., 2007; Xiao et al., 2004). 
In  addition,  cytokines,  growth  factors,  and  gonadotropins  that  do  not  stimulate
 
angiogenesis  directly  can  modulate  angiogenesis  by  modulating
  VEGF  expression 
(Deroanne et al., 1997; Finkenzeller et al., 1997; Ryuto et al., 1996; Pertovaara et al., 1994; 
Frank et al., 1995; Goad et al., 1996; Li et al., 1995; Cohen et al., 1996; Matsumoto et al., 
1997).  In  the  experiments  outlined  in  chapter  5  endothelial  cell  proliferation  was 
determined in response to VEGF which was added to a low serum-containing medium (0.2 James A Reihill, 2009     Chapter 7, 213 
% FCS). This was done in order to assess the role of a given concentration of VEGF on 
endothelial  cell  proliferation,  and  subsequently  the  role  of  AMPK  in  this  process. 
However, the role of AMPK in regards to endothelial cell proliferation should also be 
determined in response to the physiological battery of growth factors.  
While  the  proliferation  and  migration  assays  conducted  in  the  present  study  provide 
valuable initial information it is also clear that they are limited by the fact that they are in 
vitro experiments, which differ from the in vivo setting in a number of ways. Importantly, 
for example, in the established vasculature of a normal adult it is estimated that only 0.01 
% of cells are dividing at any given moment (Hobson and Denekamp, 1984). Clearly, the 
cultured endothelial cells used in a laboratory setting are different in nature. Additionally, 
it is also important to note that the angiogenic process, not only involves endothelial cells, 
but is also influenced by surrounding mural cells (Karamysheva, 2008). Short of an in vivo 
study, the rat aortic ring assay is a widely used in vitro study that more closely mirror the 
in vivo environment (West and Burbridge, 2009; Nicosia and Ottinetti, 1990). This assay 
includes
 the surrounding non-endothelial cells, and in addition the endothelial
 cells have 
not been pre-selected by passaging (and thus are not
 in a proliferative state at the time of 
explantation).  However,  it  is  also  worth  noting  that  angiogenesis  is  primarily  a 
microvascular event, thus the aorta is not an ideal choice in this regard. This is relevant to 
the present study where aortic endothelial cells were used as a model. Therefore, it may be 
of additional benefit to determine the role of AMPK in response to
 VEGF in endothelial 
cells derived from the microvasculature. In addition, possible in vivo assay systems that 
may also be used to advance the current study include the chick chorioallantoic membrane 
assay, an in
 vivo Matrigel plug assay, and a group of assays that use implants
 of sponges 
containing test cells or substances. 
7.2 Relevance of VEGF/AMPK signalling 
As  NO  is  pivotal  in  the  regulation  of  vascular  tone;  and  furthermore  exerts  anti-
inflammatory and  anti-thrombotic effects on the vascular wall, the finding that AMPK 
underlies its production in response to the endothelial-specific factor VEGF is an important 
finding. Further understanding of AMPK-signalling in the endothelium may provide some 
insight into possible therapeutic targets for the treatment of cardiovascular disorders. Proof 
of concept may be derived from the finding that the widely used treatment for type 2 
diabetes,  metformin,  a  known  activator  of  AMPK,  in  contrast  to  other  anti-diabetic 
therapies  (e.g.  insulin  or  sulphonylureas),  diminishes  the  incidence  of  cardiovascular James A Reihill, 2009     Chapter 7, 214 
disease when used as a monothereapy in obese patients with type 2 diabetes, despite the 
fact  each of these modalities has similar effects on  glycaemia control  (UKPDS 1998). 
Metformin  is  proposed  to  indirectly  activate  AMPK  by  inhibiting  complex  I  of  the 
mitochondrial respiratory chain, a mechanism which may underlie some of the undesirable 
side effects of the drug. Thus, it seems likely that more specific activators of AMPK may 
act  as  better  tolerated  therapies.  Intriguingly,  the  finding  that  the  AMPK  activator  A-
769662  only  stimulates  β1-containing,  and  not  β2-containing,  AMPK  complexes, 
highlights  the  possibility  that  isoform  specific  AMPK  activators  may  be  obtainable 
enabling the tissue specific manipulation of AMPK. 
AMPK has been described as the fuel gauge of the mammalian cell (Hardie and Carling, 
1997), that also operates to regulate whole body energy balance (Hardie, 2008). As the 
delivery of nutrients and oxygen to the tissues requires an intact vasculature it makes sense 
that AMPK also affects vascular growth and function. AMPK acting as a component of 
VEGF-signalling  may  influence physiological  processes  including  vasodilatation  of  the 
vasculature  and  mediate  angiogenesis,  thus  regulating  tissue  perfusion  and  therefore 
metabolism. As VEGF signalling is largely regulated by hypoxia AMPK may be part of a 
mechanism  that  targets  specific  tissues  which  may  otherwise  become  metabolically 
compromised.  Clearly  this  action  is  of  benefit  to  the  metabolic  status  of  the  overall 
organism. 
Therapeutic angiogenesis involves the promotion of new blood vessels to treat ischemic 
disorders. The angiogenic properties of VEGF have been exploited
 to stimulate in vivo 
angiogenesis as a potential treatment for ischemic disease (Baumgartner et al., 1998; Isner 
et al., 1996; Magovern et al., 1997; Tsurumi et al., 1997; Asahara et al., 1995). However, 
although promising results were initially reported, a number of placebo-controlled trials 
have been less than convincing (Lederman et al., 2002; Henry et al., 2003). Transplantation 
of stem and progenitor cells represents a new strategy for vascular regeneration (Rafii and 
Lyden,  2003).  EPCs,  first  described by (Asahara  et  al.,  1997)  are  one  such candidate. 
While the role of EPCs remain incompletely understood, increasing evidence suggests they 
enhance re-endothelialisation in injured or diseased arteries (Shi et al., 1998; Xu et al., 
2003) and improve endothelial function (Wassmann et al., 2006). In models of arterial 
injury EPCs have been shown to enhance the restoration of the endothelial monolayer and 
reduce neo-intimal hyperplasia (Werner et al., 2002; Griese et al., 2003; Kong et al., 2004). 
Interestingly,  a  VEGF-AMPK-NO  signalling  pathway,  similar  to  that  described  in  the 
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differentiation, is mediated at least in part by AMPK (Li et al., 2008). Thus, the mechanism 
underlying  VEGF-AMPK  signalling  is  important  in  regards  to  the  generation  of  new 
vessels from EPCs and may be of relevance for the development of clinical therapies for 
ischemic heart disease. 
VEGF-AMPK signalling may also be of importance in regards to the aetiology of diseases 
that  are  characterized
  by  deregulated  angiogenesis.  Angiogenesis  is  required  for  the 
development  of  primary  tumours  and  metastases  (Folkman,  1995;  Ferrara  and  Kerbel, 
2005). Without the onset of angiogenesis, most tumours cannot grow beyond 1 to 2 mm 
because of diffusion limitations and thus may remain dormant (Gimbrone, Jr. et al., 1972). 
Therefore, the production
 of angiogenic factors, such as VEGF, by tumourigenic cells is 
essential for
 the development of solid tumours (Folkman, 1990). In addition to the finding 
of the present study that VEGF regulates AMPK activity, it has also been reported that 
AMPK regulates VEGF mRNA expression in response to exercise (Zwetsloot et al., 2008), 
and furthermore activation of AMPK stimulates VEGF expression and  angiogenesis in 
skeletal muscle (Ouchi et al., 2005). It has been shown that prolonged hypoxia promotes 
the expression and functional activation of AMPKα2 and VEGF production in glioma cell 
lines  and  glioblastoma  multiform  tumours,  thus  contributing  to  tumour  survival  and 
angiogenesis in high grade human gliomas (Neurath et al., 2006), and glucose deprivation 
leads to a significant increase in the mRNA level of a number of genes, including VEGF, 
in several cancer cells dependent on AMPK (Yun et al., 2005). In addition exposure of 
humans  to  both  metals  and  metalloid  species  exacerbates  the  risk  of  human  diseases, 
particularly cancers. It has been suggested that AMPK is a critical regulatory component in 
metal-induced  VEGF  expression,  implying  a  role  for  AMPK/VEGF  in  metal-induced 
carcinogenesis  (Lee  et  al.,  2006).  Together,  the  finding  that  VEGF  stimulates  AMPK 
activation, and the observation that AMPK may increase VEGF expression in a number of 
pathophysiological  settings,  indicates  the  potential  for  a  positive  feedback  mechanism 
between VEGF-AMPK, which would act to exacerbate the pathological angiogenesis seen 
in tumour development. 
Efforts  to  inhibit  VEGF-induced
  tumour  angiogenesis  include  the  development  of 
humanized neutralizing
 anti-VEGF monoclonal antibodies (Presta et al., 1997), inhibitory 
soluble VEGF
 receptors (Ferrara et al., 1998; Kendall and Thomas, 1993; Lin et al., 1998), 
antisense  VEGF  mRNA  expressing  constructs  (Cheng  et  al.,  1996),  VEGF-toxin 
conjugates  (Ramakrishnan  et  al.,  1996),  antagonistic  VEGF  mutants  (Siemeister  et  al., 
1998) and inhibitors of VEGF receptor function (Skobe et al., 1997; Strawn et al., 1996).
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While inhibition of VEGF via these strategies yields some promise it is likely that a better 
understanding of VEGF signalling may offer new therapeutic targets with a reduction in 
the undesirable side-effects. Bevacizumab, in combination with chemotherapy, has been 
shown to an effective treatment for patients with metastatic colorectal cancer  (Hurwitz et 
al., 2004). However, hypertension requiring medical intervention developed in 11 % of 
bevacizumab-treated patients and is now recognized as a classic effect of VEGF blockers 
(Ferrara et al., 2007). It is tempting to speculate that this may be a result of reduced NO 
bioavailability.  Thus  in  this  context,  the  signalling  molecules,  such  as  AMPK,  which 
underlie VEGF-stimulated NO production are of particular interest. 
Retinal neovascularisation is a hallmark of proliferative diabetic retinopathy, an important 
risk factor for severe vision loss in patients with type 2 diabetes (Abdallah and Fawzi, 
2009).  VEGF,  a  key  regulator  of  neovascularisation  (Miller  et  al.,  1994),  is  directly 
correlated  with  the  severity  of  proliferative  diabetic  retinopathy  (Aiello  et  al.,  1994). 
Inhibition of VEGF can prevent iris neovascularisation in primates (Adamis et al., 1996), 
and  studies  in  humans  have  indicated  the  potential  for  anti-VEGF  therapy  in  retinal 
vascular disease (associated with pathological angiogenesis) (Adamis et al., 1994). The 
survival of endothelial cells is critical for the maintenance of microvascular integrity. It has 
been reported that retinal endothelial cells die prematurely and undergo apoptosis in both 
human  and  experimental  diabetes  (Mizutani  et  al.,  1996).  Kim  and  coworkers  have 
reported that AMPK activation, in response to the hypolipidemic drug fenofibrate, prevents 
apoptotic cell death induced by serum deprivation in human retinal endothelial cells (Kim 
et  al.,  2007).  Thus,  AMPK  activation  may  have  a  novel  therapeutic  property  that  can 
control unwanted cell death found in diabetic retinopathy.  However, AMPK activation 
was also reported to increase VEGF mRNA (Kim et al., 2007). While VEGF may be of 
benefit in the early stage of diabetic retinopathy, maintaining vascular integrity, the excess 
production of VEGF is believed to be responsible for the proliferative and exudative stages 
of  diabetic  retinopathy  (Witmer  et  al.,  2003);  and  thus  may  be  maladaptive  with  the 
progression of the disease. Therefore further characterisation of VEGF/AMPK signalling 
may be appropriate in relation to the development of treatments for vascular disease of the 
retina. 
7.3 Summary 
VEGF-stimulated NO production regulates a range of functional effects in the endothelium 
and is regarded as an important “protective” mechanism for the tissue which offsets the James A Reihill, 2009     Chapter 7, 217 
development of arthrosclerosis. Therefore, the finding of the present study that AMPK acts 
as an important intermediate in VEGF-stimulated NO production is of importance. The 
current  investigation  also  provides  evidence  suggesting  AMPK  is  necessary  for  the 
angiogenic  response  evoked  by  VEGF.  As  resistance  to  anti-angiogenic  therapy  is 
emerging (Kerbel and Folkman, 2002), a better understanding of pathways which mediate 
pathological angiogenesis in various circumstances is required. VEGF-AMPK signalling is 
of relevance in regards to tumour progression and diabetic retinopathy and furthermore 
may be of relevance in the context of therapeutic angiogenesis which is seen as a potential 
mechanism to treat ischemic disease. As the role of VEGF-AMPK signalling in relation to 
these pathologies remains incompletely understood the underlying molecular mechanisms 
warrant further investigation. 
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